

PUBLIC SPENDING ON HEALTH AND LONG-TERM CARE: A NEW SET OF PROJECTIONS

Christine de la Maisonneuve and Joaquim Oliveira Martins

(OECD Economics Department, forthcoming)

Preliminary Version not for citation

TABLE OF CONTENTS

PUBLIC SPENDING ON HEALTH AND LONG-TERM CARE: A NEW SET OF PROJECTIONS	4
Executive Summary	4
1. Introduction.....	5
2. Health care	6
2.1 Projection framework.....	6
2.1.1 Demographic drivers	8
2.1.2 Non-demographic drivers	10
2.1.3 Summing up.....	13
2.2 Projection results: public health expenditures, 2010-2060.....	13
2.2.1 Demographic and income effects	13
2.2.2 The cost-pressure scenario.....	16
2.2.3 The cost-containment scenario	17
2.2.4 Sensitivity analysis	17
3. Long-term care.....	19
3.1. Projection framework.....	20
3.1.1 Demographic drivers of expenditure	21
3.1.2 Non-demographic drivers of expenditure.....	23
3.2 Projection results: long-term care 2010-2060	26
3.2.1 The cost-pressure scenario.....	27
3.2.2 The cost-containment scenario	28
3.3 Sensitivity analysis.....	28
4. Summary of results and comparison with previous projections	30
4.1 Cross-country projection results: an overview	30
4.2 Comparison with OECD (2006) projections	32
APPENDIX 1. THE HEALTH PROJECTION FRAMEWORK.....	34
APPENDIX 2: INCOME ELASTICITY: REVIEW OF LITERATURE	38
APPENDIX 3. ESTIMATIONS TO CALIBRATE THE LTC FRAMEWORK.....	42
APPENDIX 4. DETAILED SCENARIO RESULTS FOR HEALTH AND LONG-TERM CARE.....	43
REFERENCES	59

Tables

2.1. Decomposing growth in public health spending (1995-2009).....	11
2.2. Assumptions underlying the alternative projection scenarios: public health care	15
2.3. Projection scenarios for public health expenditure	16
2.4. Sensitivity analysis on public health care projections.....	18
3.1. Assumptions underlying the alternative projection scenarios: public long-term care	26
3.2. Projection scenarios for public long-term care expenditure	27
3.3. Sensitivity analysis on public long-term care projections.....	29
4.1. Projection scenarios for public health and long-term care spending	31
4.2. Public health and long-term care spending: comparison with previous projections.....	32

Figures

1.1. Evolution of public health and long-term care expenditure.....	6
2.1. Public health care expenditure by age groups.....	8
2.2. Shifts in expenditure profiles, ageing and non-ageing effects	14
3.1. Public long-term care expenditure per beneficiary as a % of GDP per capita.....	20
3.2. Dependency ratios by age	22
3.3. Long-term care expenditure and GDP per capita.....	25
4.1. Percentage point increase in total public health and long-term care spending, 2010-2060	30

Boxes

Box 1. Projecting GDP and population.....	7
Box 2. Healthy ageing hypothesis	9
Box 3. Explaining health care expenditure growth that is unrelated to demographics and income	12
Box 4. Dependency ratio estimates.....	23
Box 5. Estimations to calibrate the LTC framework	25

Appendix tables

A1.1. Real public health expenditure per capita: econometric estimates	35
A2.1. Survey of income elasticity estimates of health care expenditures (or utilisation) by level of observation	37
A2.2. Selected recent income elasticity estimates of health care expenditures	40
A3.1. Dependency ratio: econometric estimates	41
A3.2. LTC expenditure: econometric estimates	41
A4.1. Breakdown of the projections of public health expenditure for each driver	43
A4.2. Breakdown of the projections of public health care expenditure for each driver	44
A4.3. Breakdown of the projections of public health care expenditure by each driver	45
A4.4. Breakdown of the projections of public health care expenditure for each driver	46
A4.5. Breakdown of the projections of public health care expenditure for each driver	47
A4.6. Breakdown of the projections of public health care expenditure for each driver	48
A4.7. Breakdown of the projections of public health care expenditure for each driver	49
A4.8. Breakdown of the projections of public health care expenditure for each driver	50
A4.9. Breakdown of the projections of total long-term care expenditure for each driver	51
A4.10. Breakdown of the projections of total long-term care expenditure for each driver	52
A4.11. Breakdown of the projections of total long-term care expenditure for each driver	53
A4.12. Breakdown of the projections of total long-term care expenditure for each driver	54
A4.13. Breakdown of the projections of total long-term care expenditure for each driver	55
A4.14. Breakdown of the projections of total long-term care expenditure for each driver	56
A4.15. Breakdown of the projections of total long-term care expenditure for each driver	57

PUBLIC SPENDING ON HEALTH AND LONG-TERM CARE: A NEW SET OF PROJECTIONS¹

Executive Summary

Updated, refined and extended projections of public spending on health and long-term care for OECD countries and the BRIICS suggest a rapidly rising trend over the next 50 years. Starting from around 6% of GDP in 2006-10, the combined public health and long-term care expenditure for OECD countries is projected to reach 9.5% in 2060 in a *cost containment* scenario assuming that policies act more strongly than in the past to rein in some of the expenditure growth. In a *cost-pressure* scenario, which assumes no stepped-up policy action spending could reach 14% of GDP. Projected increases are even steeper for some of the BRIICS going on average from the current 2.5% to 5.3% and 9.8% of GDP depending on the scenario.

Significant differences in health and long-term care spending emerge across OECD countries reflecting factors such as demographic trends and the initial starting point concerning income and the informal long-term care supply. Korea, Chile, Turkey and Mexico, for example, are projected to experience above average increases in public health expenditures. By contrast, the Nordic countries, as well as the United States and the United Kingdom, display lower than average growth over the next 50 years.

In all countries, both health and long-term care will be driving up public spending. Focusing on the cost-containment scenario, for OECD countries average public health care expenditure is projected to increase from 5.5% of GDP in 2010 to 8% in 2060; whereas public long-term care expenditure is projected to increase from 0.8% to 1.6% of GDP in 2060. For the BRIICS, average public health care expenditure is projected to increase from 2.4% of GDP in 2010 to more than 4% in 2060; while public long-term care expenditure is projected to increase from 0.1% to 0.9% of GDP in 2060.

The drivers of expenditure increases will differ between spending categories: health care spending will be pushed up mostly by the combined effect of technology, relative prices and exogenous factors (such as institutions and policies), while pressures on long-term care costs will originate mostly from weaker productivity gains than in the economy as a whole. Under reasonable assumptions about improving health conditions of the elderly in ageing societies (the so-called “healthy ageing” hypothesis) and the response of health spending to rising incomes, pure demographics and income effects will play only a minor role in the projected increase of public health and long-term care expenditures.

Given the competing pressures from other social spending programmes, these projected trends in public health and long-term care spending are likely to be a major source of concern for most governments. Upside risks related to extension of the typical pre-death period of ill health as longevity increases, higher than expected costs as technical progress makes it possible to meet new demands and increased dependency due to obesity trends or dementia suggest that the projected path of expenditures provides a lower bound in the absence of more ambitious cost containment policies.

These new public health and long-term care spending projections corroborate, at the aggregate level, those published in OECD (2006). The new set of projections suggests a more important increase in health

¹ The present version of this paper has been discussed by the OECD Working Party No1 and will be revised in light of comments received from that group as well as comments received at the conference. The authors would like to thank Jørgen Elmeskov, Fabrice Murtin, Giuseppe Nicoletti and Jean-Luc Schneider for their valuable comments. The views expressed in this paper are those of the authors and do not necessarily reflect those of the OECD and its member Countries.

expenditure than in the 2006 exercise, which is partly offset by a less important projected increase in long-term care.

1. Introduction

1. Spending on health and long-term care (henceforth LTC) is a first-order policy issue for most governments in OECD countries. These expenditures are putting pressure on public budgets, adding to that arising from other social spending programmes and, once interest rates normalise, servicing of higher debt levels than in the past. Over the past four decades, combined health and LTC expenditure roughly doubled to reach around 6% of GDP. Looking towards the future, the OECD (2006) public health and LTC spending projections highlighted the growing pressures over the next 50 years. In an upside “cost-pressure” scenario, average health and LTC expenditure was projected to almost double again, to reach approximately 13% of GDP by 2050. But, even in the so-called “cost-containment” scenario, spending was still projected to rise to approximately 10% of GDP on average across OECD countries over the next 40 years. Comparing the 2006 projections with actual data up to 2010 (Figure 1.1), the observed increase in the ratio of public health and LTC to GDP was above even the pessimistic “cost-pressure scenario”. Nonetheless, it should be noted that GDP developments have fallen short of those expected and, thus, the deviations come more from GDP than from health expenditure alone.


2. The projections in this paper update and refine the OECD (2006) analysis by extending the country coverage and improving the method of estimating future developments in health and LTC expenditure. In addition to the 34 OECD countries, health and LTC expenditure is also projected for Brazil, China, India, Indonesia, Russia and South Africa (henceforth BRIICS). Concerning the methodology, as in 2006, the new projections separate health and LTC and, within each type of expenditure, demographic from non-demographic drivers. For health care, the main difference concerns the non-demographic drivers, with an attempt to better understand the residual expenditure growth by determining which share can be explained by the evolution of health prices and technology effects. Regarding LTC, a more precise estimation of the determinants of the number of dependants (people needing help in their daily life activities) is provided. In particular, the current set of projections treats health expenditure itself as a determinant of the dependency ratios (number of dependent people in total population) by age groups. Finally, the new projections extend to 2060.

3. The projections are provided for public expenditure only. Nonetheless, the cross-country differences in treatment of tax expenditures², which can be large in some cases, may introduce serious bias. Indeed, countries interpret differently the OECD manual on the System of Health accounts on how to deal with tax expenditures. Australia and Germany, for instance, deduct tax expenditures from private insurance expenditures and report it as public expenditure. But, in the United States, tax expenditures are not considered as public expenditure (OECD, 2010).

4. The paper is set out as follows. In Section 2, the main demographic and non-demographic drivers of public health expenditure are analysed and projected over the next half century. Cost-containment (with policy actions) and cost-pressure (without implicit policy actions) scenarios are presented, followed by a discussion of the sensitivity of the results to key assumptions. In Section 3, the same sequence applies to public LTC expenditures. In Section 4, different health and LTC expenditure scenarios are combined in order to provide a range of estimates for total expenditure. These are compared with previous estimates and some policy implications are drawn.

² Tax expenditure can be of different kinds, *e.g.* exclusion from workers’ taxable income of employers’ health insurance contributions in the United States, tax credits for medical expenses in Canada or income tax deductions for health care services in Portugal.

Figure 1.1 Evolution of public health and long-term care expenditure¹



1. Unweighted average of available OECD countries. As a % of trend GDP.

Source: OECD Health Database (2011), OECD (2006).

2. Health care

2.1 Projection framework

5. The framework used to project public health expenditure combines both demographic and non-demographic drivers. The evolution of each driver is first projected separately, and subsequently combined to compute the future growth of total health expenditure (for details see Appendix 1). The share of health care spending in GDP (denoted by $HE/P_Y \cdot Y$) is related to a demographic effect ($Demo$), real income per capita (Y/N , where N is total population), and a residual (Res). The precise data sources and definitions of the variables used in the public health care projections will be described below, but the simplified logarithmic growth equation used to project the evolution of spending ratios can be denoted as follows:

$$\Delta \log \left(\frac{HE}{P_Y \cdot Y} \right) = \Delta \log(Demo) + (\varepsilon - 1) \cdot \Delta \log \left(\frac{Y}{N} \right) + \Delta \log(Res) \quad (1)$$

where P_Y is a GDP deflator, which is subsequently assumed to remain constant during the projection period. $Demo$ is a combination of three demographic-related factors described in Section 2.2 (death-related costs, pure age effects and a healthy-ageing effect); ε is the income elasticity of health expenditures (it can take the value of 0.8 or 1 depending on the scenario, see Appendix 1); and Res is a (composite) residual growth factor. In contrast with OECD (2006), an effort was made to investigate the determinants of this residual in the past. As suggested by the econometric estimates (Appendix 1), around one-third of this residual can be explained by the evolution of the relative price of health-care services and improvements in the quality of these services due to technological advances. While these variables are not projected separately, understanding their past evolution and the role they have played in pushing up health care spending makes it possible to better interpret assumptions on the future evolution of the residual spending under different scenarios (see Box 3 below).

6. The growth rates in spending ratios are first projected for each country and they are then adjusted to allow for a certain convergence across countries towards a common target (Appendix 1). *Ceteris paribus*, countries having a below average initial level of health expenditure to GDP ratios were projected

to experience higher growth rates than those close to the average. This makes the projections more comparable across countries, as the effects of the different mechanisms at work during the projection period are isolated from the impact of the initial conditions. In order to smooth out the impact of the recent crisis on expenditure, the base year spending ratios are computed as the average shares of public health care spending in GDP over 2006-2010.

7. This framework is used to project health expenditures over the period 2010-60. The spending projections in turn rely on the GDP projections published in the *OECD Economic Outlook*, No. 91, as well as population projections drawn from different sources. Box 1 provides detailed information about the underlying GDP and population projections.

Box 1. Projecting GDP and population

Health spending projections depend on expected developments in GDP and demographics. The population projections are sourced from Eurostat for European OECD countries, while for non-European countries projections are from the United Nations Population Database. These projections assume that in the long term total fertility will approach the replacement-level of 2.1, without necessarily reaching it. Gains in life expectancy are projected to be smaller than those observed recently in both data sets, while differences in life expectancy across gender are assumed to narrow. Finally, the future path of international migration is such that projected levels of net migration are generally kept constant over the next decades in both datasets, although after 2050 it is assumed that net migration will gradually decline.

GDP projections, published in the *OECD Economic Outlook*, No. 91, are based on a standard aggregate Cobb-Douglas production function with constant returns to scale featuring physical capital, human capital, labour and Harrod-neutral technical progress, which can be expressed as:

$$Y_{it} = (K_{it} / Y_{it})^{\alpha/(1-\alpha)} A_{it} h_{it} L_{it} \quad (2)$$

where Y, K, A, h and L denote output, physical capital, technical progress, human capital per worker, employment, respectively, and subscripts t and i denote year and country, respectively. The share of capital α is set equal to 1/3.

Employment is further decomposed into trend population (POP), trend labour force participation rate (LFPR) and trend unemployment rate (u) according to:

$$L_{it} = POP_{it} * LFPR_{it} * (1 - u_{it}) \quad (3)$$

Starting from a base year, these components of the production function are projected to 2060 in order to construct measures of potential GDP measured in terms of constant 2005 USD purchasing power parities (PPPs).


The vision of growth underlying the GDP projections is one in which each country would be expected to converge to its own steady-state trajectory of GDP per capita determined by the interface between global technological development and country-specific structural conditions and policies (so-called conditional convergence). In the long-run, all countries are expected to grow at the rate determined by the worldwide rate of technical progress, but cross-country GDP per capita gaps would remain, mainly reflecting differences in technology levels, capital intensity and human capital. For more details see Duval and de la Maisonneuve (2010), and Johansson *et al.* (2012). A similar approach has been followed by Fouré *et al.* (2010)

2.1.1 Demographic drivers

8. The base information used to construct the health expenditure projection framework is the average health expenditure profile by age group (Figure 2.1).³ Average health expenditures are relatively high for young children; they decrease and remain stable for most of the prime-age period, and then start to increase rapidly in older age, the health care cost of people aged 90 and over being six times that of young people. Until the age of 65, health expenditure profiles are rather similar across countries, but from 65 onwards they display a large heterogeneity. The standard deviation by age group increases from 1.8% for the 65-69 age group to more than 5% for people aged 90 and over.

9. From Figure 2.1 it could be expected *a priori* that an ageing population would be associated with increasing aggregate *per capita* health care expenditures: the fact that the share of older people in the population is growing faster than that of any other age group, both as a result of longer lives and a lower birth rate, should generate an automatic increase in the average. Nonetheless, the effect of population ageing on health and health care is far from straightforward (Breyer *et al.*, 2011) and difficult to extrapolate: while the effect of ageing is likely to increase public health expenditures per capita in the future, it has been weak in the past.⁴ Zweifel *et al.* (1999) even defined as a “red herring” the idea that ageing has a significant impact on health expenditure.

Figure 2.1 Public health care expenditure by age groups¹



1. The graph shows the dispersion of health care expenditure across countries by age groups. The diamonds represent the median. The boxes are the 2nd and 3rd quartiles of the distribution of expenditure across countries. The whiskers are the 1st and 4th quartiles. The circles are outliers.

Source: European Commission, 2009 Ageing Report: Economic and budgetary projections for the EU-27 Member States (2008-2060).

3. These cost curves have been provided by the European Commission for European countries and have been drawn from national statistics for the other countries.

4. See Culyer (1990), Gerdtham *et al.*, (1992), Hitiris and Posnett (1992), Zweifel *et al.*, (1999), Richardson and Roberston (1999), Moise and Jacobzone (2003), Jönsson and Eckerlund (2003).

10. Consistent with a large number of previous studies (Felder *et al.*, (2000), Seshamani and Gray (2004); Breyer and Felder (2006); and Werblow *et al.*, (2007), etc.), this paper assumes that what matters for health spending is not ageing but rather the proximity to death: or the so-called "death-related costs" (DRC) hypothesis. This interpretation is consistent with the observed facts that health-care expenditure tends to increase in a disproportionate way when individuals are close to death, and mortality rates are obviously higher for older people. When the projected increase in life expectancy is accompanied by an equivalent gain in the number of years spent in good health, the health care spending is only driven by the proximity to death and not by an increase in the average age of the population. In other words, it is not ageing *per se* that pushes up average health expenditures, but rather the fact that mortality rates increase with age. The death-related costs hypothesis is, therefore, consistent with a so-called *healthy-ageing* regime, where longevity gains are all translated into years in good health (Box 2).

11. To account for the dominance of death-related costs and the healthy-ageing regime, the expenditure curve by age group needs to be split for each period into two segments of the population: *survivors* and *non-survivors*. The *non-survivors'* expenditure curve can be estimated by multiplying the estimated costs of death by age group by the number of deaths per age group. The cost of death was proxied here by the health expenditure per capita for the oldest age group (95+) multiplied by a factor that captures the tendency for the costs of death to be higher at younger ages. This factor is kept constant at 4 for people aged between 0 and 59 years and declines linearly (towards unity) afterwards.⁵

12. In principle, the *survivors'* expenditure curve for each country could be derived from the difference between the total cost curve and that of the non-survivor (see OECD (2006) for more details). However, given the uncertainties surrounding these data, it seemed preferable to estimate an average expenditure curve for survivors, to be then used for all countries. In this way, the projections are less sensitive to initial conditions and to country-specific data idiosyncrasies. This expenditure curve for *survivors* was estimated econometrically as a non-linear function of age (see Appendix 1). Each country-specific curve is then calibrated in order to fit the base year of the projections.

Box 2. Healthy ageing hypothesis

To take into account the "healthy ageing" hypothesis, the survivor expenditure curve is allowed to shift rightwards according to longevity gains, progressively postponing the age-related increases in expenditure. First, the curve by five-year age groups is interpolated in order to derive a yearly age profile. In this way, the expenditure curve can be shifted smoothly over time, in line with life expectancy gains.

Subsequently an "effective age" can be calculated by subtracting the increase in life expectancy at birth according to national projections from current age. For example, a 70-year old person in Germany is projected to have an effective age of 67 by 2025 and 64 by 2050.

By contrast, in a "pure demographic" scenario, the expenditure curves would not shift rightwards with ageing, reflecting the implicit assumption of unchanged health status at any given age. When these curves stay put in the presence of longevity gains, the share of life lived in 'bad health' increases with life expectancy.

The population projections used in the analysis are pre-determined and do not take into account the effect of health spending on health status and longevity. Making population projections dependent on the level of health spending is beyond the scope of this project and could be the object of further research.

⁵ While the probability of dying increases with age, the costs of death tend to decline steadily after young and prime age (Aprile, 2004).

13. As regards *non-survivors*, two different demographic effects are at play. On the one hand, the number of deaths is set to rise due to the *transitory* effect of the post-War baby-boom. On the other hand, if mortality falls over time due to an ongoing increase in longevity, fewer will be at the very end of life in each given year, thus mitigating health care costs.⁶ The total effect on public health care expenditures will depend on the relative size of these effects.

2.1.2 Non-demographic drivers

14. Demographic drivers explain relatively little of past developments in health spending, even assuming that the expenditures curve by age remains constant (or abstracting from “healthy ageing” effects). Between 1995 and 2009 (Table 2.1), public health spending grew on average and in real terms (adjusted for overall inflation) by 4.3% per year in OECD countries, of which only 0.5 percentage point can be attributed to ‘pure demographic’ developments. As already mentioned, other determinants of spending are income growth, technical progress, relative health prices as well as the underlying health policies and institutions.

15. The effect of real income growth on public health expenditures has been the subject of a vast debate, but the precise value of the income elasticity is still uncertain. Empirical estimates tend to increase with the degree of income aggregation, implying that health care could be “an individual necessity and a national luxury” (Getzen, 2000). However, a high aggregate income elasticity (above unity) often found in macro studies may result from biases in estimates originating from a number of sources, such as failure to appropriately control for true price effects and account for the peculiar statistical properties of some of the variables (see Appendix 2 for more details). Based on the most recent findings from this literature (*e.g.* Acemoglu *et al.*, 2009), as well as estimations carried out for this paper (see Appendices 1 and 2), a real income elasticity equal to 0.8 has been used and the sensitivity of the projections to this assumption was subsequently tested (by contrast, OECD (2006) assumed a unitary income elasticity throughout).

16. The combination of demographic and income effects (whether the assumed elasticity is 0.8 or unity) fails to explain a large part of the total growth in public health-care expenditure in the past. For example, assuming an income elasticity equal to 0.8, income effects add only 1.7 percentage points of growth on top of the 0.5 percentage points attributable to demographics.⁷ Therefore, a residual (unexplained) growth can be estimated at around 2 percentage points per year on average across OECD countries, with the BRIICS experiencing even more important residual growth effects. While not used directly to project this residual, an analysis has been undertaken of the extent to which its historical evolution can be accounted for by developments in, respectively, relative prices and technological progress (See Box 3 and Appendix 1).

6. See, for example Fuchs (1984), Zweifel *et al.* (1999); Jacobzone (2003); and Gray (2004).

7. This “growth accounting” of past health expenditures does not incorporate “healthy ageing” and “death-related cost” as is the case in the projections. The demographic effect would be even smaller if these hypotheses were introduced, thereby leading *ceteris paribus* to an even greater estimated residual.

Table 2.1. Decomposing growth in public health spending (1995-2009)

	Real health spending (Not adjusted for quality)	Age effect	Income effect (Income elasticity = 0.8)	Residual	<i>Memo item:</i> Residual with unitary income elasticity
	(% change)	(% contribution change)			
Australia	4.1	0.4	1.7	1.8	1.4
Austria	3.3	0.4	1.3	1.5	1.2
Belgium	4.2	0.4	1.2	2.7	2.4
Canada	2.6	0.6	1.3	0.8	0.5
Czech Republic	4.2	0.6	2.3	1.4	0.8
Denmark	3.7	0.2	0.8	2.7	2.5
Finland	4.1	0.6	2.0	1.5	1.1
France	1.6	0.5	0.9	0.3	0.0
Germany	1.7	0.6	0.8	0.2	0.0
Greece	5.9	0.6	2.1	2.5	1.8
Hungary	2.0	0.5	2.1	-0.6	-1.1
Iceland	3.1	0.4	2.0	0.9	0.4
Ireland	6.5	0.3	2.9	3.3	2.6
Italy	3.1	0.6	0.4	2.1	2.0
Japan	2.7	1.2	0.4	0.7	0.5
Korea	11.0	1.1	3.1	6.5	5.7
Luxembourg	1.9	0.1	2.0	-0.5	-1.1
Mexico	2.5	0.5	1.1	1.0	0.7
Netherlands	5.2	0.5	1.4	3.3	2.9
New Zealand	6.3	0.4	1.3	5.5	5.5
Norway	3.5	0.1	1.3	2.1	1.7
Poland	6.9	0.7	3.6	2.6	1.7
Portugal	4.6	0.6	1.2	2.4	2.0
Slovak Republic	6.3	0.6	3.4	2.1	1.3
Spain	3.4	0.5	1.5	1.4	1.0
Sweden	3.2	0.2	1.6	1.4	1.0
Switzerland	2.9	0.4	0.9	1.6	1.4
Turkey	7.7	0.5	1.8	4.5	3.9
United Kingdom	4.6	0.2	1.5	2.8	2.5
United States	3.6	0.3	1.1	2.3	2.0
Chile	7.7	0.6	1.9	4.8	4.3
Israel	1.6	0.4	1.2	-1.2	-1.7
Estonia	6.1	0.6	4.4	1.8	1.0
Slovenia	3.0	0.8	2.6	0.2	-0.3
Brazil	4.8	0.6	1.2	2.9	2.6
China	11.2	0.6	7.3	3.0	1.3
Indonesia	8.0	0.5	1.9	5.5	5.0
India	6.6	0.3	4.2	2.0	1.0
Russia	3.7	0.4	3.3	0.1	-0.6
South Africa	3.1	0.4	1.6	1.2	0.8
OECD total average	4.3	0.5	1.7	2.0	1.5
BRICS average	6.2	0.5	3.2	2.5	1.7
Total average	4.6	0.5	2.0	2.0	1.5

Box 3. Explaining health care expenditure growth that is unrelated to demographics and income

Following a large strand of research (See Fuchs (1972); Mushkin and Landefeld (1979); Newhouse (1992); KPMG Consulting (2001); Wanless (2001); Productivity Commission (2005a-b); and Dormont *et al.* (2006)), this paper explores the idea that the main factors driving the (residual) growth in health care spending that cannot be explained by demographic and income factors are likely to be technology and relative prices. Indeed, the gains in health status discussed above do not only arise from improvements in lifestyle (Sheehan, 2002; Cutler, 2001) but also from advances in medical treatment and health-care technology. The latter, however, do not come free of economic cost. Technical progress can be cost-saving and reduce the relative price of health products and services, but its impact on expenditure will depend on the price elasticity of the demand for health care. If this elasticity is high a fall in prices will induce a more than proportionate rise in demand, increasing expenditures.⁸

Health prices are not easily computable. The measure used in this paper is the value-added deflator in the health and social work sectors, taken from the OECD STAN database. It is assumed that even if the aggregate covered is broader than the health sector alone, the latter represents the lion's share of the total and the prices in both sectors follow the same path. This assumption is corroborated by the fact that the deflator is comparable to more precise price indicators available from other sources. For instance, CPI series for the health sector can be gathered from Eurostat (for European countries) and national sources (for Australia, Canada, Korea, New Zealand and the United States). The CPI series cannot, however, be used because they are available for too short a period (the HICP from Eurostat is only available from 1996 onwards) and there is also a potential lack of comparability across countries. The health price deflator is expressed as a ratio to the GDP deflator, to generate the relative price index for health services that is used to explain health care expenditures (equation A1.1 in Appendix 1).

It is also difficult to find a good measure for changes in the (technology-induced) quality of health care services. As an (admittedly heroic) assumption, a proxy indicator has, therefore, been constructed, based on a combination of patents and R&D statistics, which have proved to be good indicators of innovation. The indicator is based on the assumption that the quality of health care tends to increase everywhere with the (global) share of health patents in total patents, but the country-specific increases in quality also depend on R&D efforts of individual countries. The share of health patents in total patents calculated for the OECD as a whole is assumed to represent the technology frontier. To this end, the patents granted by the European Patent Office (EPO) have been chosen as they seem to generate substantially greater market power than their US equivalents (Bessen, 2012). To benefit from advances in this frontier, countries need to innovate and absorb foreign technology (via technology pass-through and catching up effects). While not all R&D expenditures are medical, they may advance health care technology because of externalities (Okunade and Murthy (2002)); moreover, high R&D spending is needed to *enable* the adoption of foreign technologies (the so-called absorption potential). Hence, the ratio of total R&D expenditure to GDP has been used as a proxy for the ability of a country to reach the frontier.

Using these variables and a set of econometric estimates described in Appendix 1, the overall effect of technology and relative prices is estimated to have increased health-care expenditures by 0.8% per year. In other words, the econometric model is able to explain more than one-third of the expenditure residual of 2% per year for the OECD average, displayed in Table 2.1.

17. The estimated effects of relative prices and technology capture over one-third (0.8%) of the past residual health care spending growth. Estimates suggest that the residual expenditure is also driven by other factors, such as changes in policy and institutions which can be loosely captured by a time trend (Appendix 1). These other factors account for 0.9% of the increase in health expenditure per year.

8. For example, Dormont and Huber (2005) found that in France the unit price of certain surgical treatments, such as cataract removal, decreased, whereas the frequency of the treatment increased significantly. Such effects can explain much of the recent upward shift in the health care cost curves in France.

18. Based on these estimates, the projections impose a residual expenditure growth of 1.7% per year (*i.e.* 0.8%+0.9%) as the starting point for future non-demographic, non-income pressures on spending. Starting from this initial value, residual growth over the 2010-2060 period is then assumed to change across the different projection scenarios (See Table 2.2 below for details).

2.1.3 Summing up

19. To summarise graphically the way in which demographic and non-demographic drivers contribute to health care spending (Figure 2.2), the mechanical effect of population ageing on expenditures can be displayed as moving up along the expenditure curve, assuming that the age profile of expenditures remains constant over time (Panel 1). This age factor is then adjusted by incorporating the healthy longevity hypothesis, corresponding to a rightward shift of the curve (Panel 2). This shift implies that older people still cost more than the young, but at progressively older ages. Finally, the expenditure curve may shift upwards (Panel 3) due to non-demographic drivers (income, the quality-adjusted relative health prices and other unexplained factors, such as policies and institutions).

2.2 Projection results: public health expenditures, 2010-2060

20. This section applies the analytical framework to project public health care expenditures in different scenarios over 2010-2060. The main assumptions underlying each scenario are listed in Table 2.2. The section looks first at the demographic effect on health expenditure and, subsequently, two scenarios regarding the evolution of drivers other than income and demographics (*i.e.* the residual growth) are analysed. In the 'cost pressure scenario', no policy action is undertaken to curb pressures on expenditure driven by, in particular, quality-adjusted relative prices, whereas the "cost-containment scenario" assumes some policy action to rein in these pressures on expenditures. All these scenarios assume healthy ageing and an income elasticity of 0.8. Finally, sensitivity analysis is carried out in the context of the cost-containment scenario. More specifically, sensitivity analysis is carried out regarding the value of the income elasticity, the evolution of residual spending growth (*i.e.* unrelated to income and demographics) and the "healthy ageing" hypothesis. Concerning the latter, results are obtained also in the case of no healthy ageing (*i.e.* morbidity expands with gains in longevity) and for a more optimistic hypothesis under which each year increase in life expectancy is translated into two years spent in good health.

2.2.1 Demographic and income effects

21. As discussed above, demographic effects on public health care expenditures can be decomposed into health care costs for survivors, the adjustment for "healthy ageing" and death-related costs. The pure ageing effect can be quite large in some countries, but tends to be compensated by better health status. Whereas on a per capita basis death-related costs account for the largest part of lifetime expenditures, for the population as a whole they account for only a small fraction of the increase in expenditures as a share of GDP since they concern only the non-survivors.

22. On average, the demographic effect only accounts for a small increase in expenditure. In OECD countries and on its own, it pushes spending from 5.5% of GDP on average to 6.2% in 2060. In non-OECD countries the demographic effect on its own increases spending from 2.4% of GDP to 3.4% in 2060. While the "healthy ageing" assumption may render the simulation of demographic effects relatively optimistic, this is in line with observed patterns of health status regimes in many OECD countries. It is assumed that the same pattern will apply to non-OECD countries. The effect will apply evenly before and after 2030 for both OECD and non-OECD countries.

Figure 2.2 Shifts in expenditure profiles, ageing and non-ageing effects




Table 2.2. Assumptions underlying the alternative projection scenarios: public health care

Scenarios	Health status	Income elasticity	Non-demographic, non-income drivers
<i>Demographic effect</i>	Healthy ageing: longevity gains are translated into equivalent additional years in good health	n.a	n.a
<i>Cost-pressure scenario</i>	Healthy ageing: longevity gains are translated into equivalent additional years in good health	Income elasticity = 0.8	The residual is assumed to grow at 1.7% over the projection period
<i>Cost-containment scenario</i>	Healthy ageing: longevity gains are translated into equivalent additional years in good health	Income elasticity = 0.8	The residual growth is 1.7% in the starting period and then converges to 0 in 2060
Sensitivity analysis based on the cost-containment scenario			
<i>Compression of morbidity</i>	Longevity gains are doubled into additional years in good health	Income elasticity = 0.8	The residual growth is 1.7% in the starting period and then converges to 0 in 2060
<i>Expansion of morbidity</i>	No health ageing adjustment, i.e longevity gains do not translate into additional years in good health	Income elasticity = 0.8	The residual growth is 1.7% in the starting period and then converges to 0 in 2060
<i>Country-specific quality adjusted relative prices</i>	Healthy ageing: longevity gains are translated into equivalent additional years in good health	Income elasticity = 0.8	The residual growth is country specific and converges to 0 in 2060
<i>Income elasticity = 0.6</i>	Healthy ageing: longevity gains are translated into equivalent additional years in good health	Income elasticity = 0.6	The residual growth is 1.7% in the starting period and then converges to 0 in 2060
<i>Income elasticity = 1</i>	Healthy ageing: longevity gains are translated into equivalent additional years in good health	Income elasticity = 1	The residual growth is 1.7% in the starting period and then converges to 0 in 2060

Note: The key assumption changed in each scenario is in bold

23. The total effect of demographics and income on the increase in health care expenditures by 2060 is very different across countries (Table 2.3). In OECD countries, the demographic effect ranges from 0.2 percentage points of GDP in Belgium, Iceland and the United Kingdom to more than 1.8 points in Chile, Korea and Turkey. For non-OECD countries it varies from zero in South Africa to 1.7 percentage points of GDP in Brazil and China, reflecting more rapid ageing in the latter two countries.

24. With an assumed less than unitary real income elasticity, the underlying increase in income would imply *ceteris paribus* a decrease in the health expenditure to GDP ratio. As the GDP projections are based on a convergence process (see Box 1), this downward income effect on spending ratios is more important for low-income countries. Indeed on average for OECD countries the increase will amount to -0.8 percentage point while in non-OECD countries the deviation will be -1.4 percentage point of GDP. For OECD countries, the average annual increase due to income will be about the same before and after 2030 (≈ -0.02 percentage points) whereas it will be slightly more important before 2030 (≈ -0.04 percentage points) than after (≈ -0.03 percentage points) for non-OECD countries, reflecting the underlying assumptions of catching-up for GDP projections.

Table 2.3. Projection scenarios for public health care expenditure

	Percentage point deviations from starting period in 2030					Percentage point deviations from starting period in 2060				
	Contributions of demographic and income effects			Total increase in spending ratio		Contributions of demographic and income effects			Total increase in spending ratio	
	Average 2006-2010	Demographic effect	Income effect	Cost-pressure	Cost-containment	Demographic effect	Income effect	Cost-pressure	Cost-containment	
Australia	5.6	0.4	-0.4	2.0	1.5	0.8	-0.8	6.3	2.5	
Austria	6.6	0.4	-0.2	2.1	1.7	0.6	-0.6	6.3	2.4	
Belgium	5.8	0.2	-0.3	1.8	1.4	0.2	-0.7	5.8	1.9	
Canada	5.8	0.6	-0.3	2.2	1.8	0.7	-0.7	6.3	2.5	
Chile	3.1	0.9	-0.6	2.3	1.8	1.8	-1.1	7.1	3.2	
Czech Republic	5.5	0.4	-0.5	1.9	1.4	0.7	-0.9	6.1	2.2	
Denmark	6.3	0.4	-0.2	2.1	1.6	0.3	-0.7	5.9	2.0	
Estonia	4.3	0.2	-0.5	1.6	1.1	0.6	-1.1	5.8	2.0	
Finland	5.2	0.4	-0.3	2.0	1.5	0.3	-0.7	5.9	2.0	
France	7.4	0.3	-0.3	1.9	1.4	0.3	-0.6	6.1	2.2	
Germany	7.3	0.5	-0.3	2.1	1.6	0.6	-0.7	6.2	2.3	
Greece	5.4	0.3	-0.3	1.9	1.4	0.7	-0.6	6.4	2.5	
Hungary	4.8	0.2	-0.5	1.6	1.2	0.4	-1.0	5.8	1.9	
Iceland	5.8	0.3	-0.2	2.0	1.5	0.2	-0.7	5.9	2.0	
Israel	4.0	0.3	-0.2	2.0	1.5	0.7	-0.7	6.4	2.5	
Ireland	5.5	0.3	-0.2	2.1	1.6	0.5	-0.5	6.4	2.5	
Italy	6.1	0.3	-0.2	2.1	1.6	0.7	-0.6	6.4	2.6	
Japan	6.1	0.6	-0.3	2.3	1.8	0.8	-0.8	6.3	2.5	
Korea	3.3	1.1	-0.5	2.6	2.1	2.0	-0.8	7.6	3.7	
Luxembourg	4.4	0.4	-0.1	2.2	1.7	0.7	-0.2	6.9	3.0	
Mexico	2.5	0.6	-0.5	2.1	1.6	1.6	-1.1	6.9	3.0	
Netherlands	6.4	0.6	-0.3	2.2	1.8	0.7	-0.7	6.3	2.4	
New Zealand	6.4	0.5	-0.3	2.1	1.6	0.8	-0.9	6.3	2.4	
Norway	5.1	0.3	-0.4	1.9	1.4	0.5	-0.7	6.1	2.2	
Poland	4.1	0.4	-0.5	1.9	1.4	1.0	-0.9	6.4	2.6	
Portugal	6.5	0.4	-0.2	2.0	1.6	0.8	-0.7	6.5	2.6	
Slovak Republic	5.4	0.5	-0.5	1.9	1.5	1.1	-0.9	6.5	2.6	
Slovenia	5.2	0.5	-0.3	2.1	1.7	1.0	-0.8	6.6	2.7	
Spain	5.6	0.4	-0.3	2.0	1.6	1.0	-0.6	6.7	2.8	
Sweden	6.6	0.2	-0.3	1.8	1.3	0.3	-0.7	5.9	2.0	
Switzerland	5.7	0.4	-0.3	2.1	1.6	0.9	-0.8	6.5	2.6	
Turkey	3.8	0.7	-0.6	2.0	1.5	1.8	-1.1	7.0	3.1	
United Kingdom	6.5	0.2	-0.2	1.9	1.4	0.2	-0.7	5.9	2.0	
United States	7.1	0.4	-0.3	2.0	1.5	0.5	-0.7	6.1	2.2	
OECD average¹	5.5	0.4	-0.3	2.0	1.6	0.8	-0.8	6.3	2.5	
Brazil	3.7	0.8	-0.6	2.1	1.6	1.7	-1.1	7.0	3.1	
China	1.9	0.9	-1.1	1.7	1.3	1.7	-1.7	6.4	2.5	
India	1.2	0.3	-1.0	1.3	0.8	0.9	-1.7	5.5	1.6	
Indonesia	1.2	0.6	-0.8	1.7	1.3	1.3	-1.5	6.2	2.3	
Russia	3.1	0.1	-0.6	1.5	1.0	0.2	-1.0	5.5	1.6	
South Africa	3.2	0.0	-0.6	1.4	0.9	0.0	-1.2	5.2	1.3	
Non-OECD average¹	2.4	0.5	-0.8	1.6	1.2	1.0	-1.4	5.9	2.1	
Total average¹	5.0	0.4	-0.4	2.0	1.5	0.8	-0.8	6.3	2.4	

1. Unweighted average.

2.2.2 The cost-pressure scenario

25. As mentioned earlier, in the "cost pressure scenario" it is assumed that on top of the demographic and income effects, health expenditure will grow by a residual 1.7% per year over the whole projection period. In this scenario, the OECD average health expenditure to GDP ratio is projected to increase by more than 6 percentage points, reaching close to 12% in 2060 from a starting value of 5.5% in 2010. The largest increases (above 7 percentage points of GDP) are found in Chile, Korea and Turkey, while the lowest (below 6 percentage points of GDP) are found in Belgium, Denmark, Estonia, Finland, Hungary, Iceland, Sweden and the United Kingdom. Starting from a much lower ratio of health expenditure to GDP

at 2.4%, the non-OECD countries will experience a larger increase as the ratio is set to more than triple, to reach 8.3%. The most important part of these increases is due to the residual component. For both OECD and non-OECD countries, the increase, on average, will be slightly higher in the second part of the projections period.

2.2.3 The cost-containment scenario

26. While the cost-pressure projections may be useful as a benchmark, they do not seem very plausible. It is unlikely that public health-care expenditures to GDP could continue to grow at such rates, without limit. For instance, regarding drugs the following policies can help containing the costs: a more intense use of generics, a revision of re-imburement practices for drugs with low medical service (and more stringent restrictions on exemptions to this rule), a more frequent re-evaluation of prices of new drugs (in general a more transparent and dynamic pricing of new drugs), centralised bargaining for the purchase of drugs and medical goods in public hospitals, reduction in excessive consumption of specific drugs. Regarding in-patient care, shorter length of stay, development of ambulatory hospitalisation or more user choice among health providers could help reining in the expenditure growth. Regarding out-patient care, a more stringent health monitoring of patients affected by long-term diseases in order to reduce costly complications; financial incentives set on general practitioners to reduce prescription inflation and enhance prevention could also help maintaining the health expenditure on a sustainable path.

27. Accordingly, a long-run convergence condition is considered in the cost-containment scenario. Specifically, the growth contribution of the spending residual, whose past growth was partly attributable to technology and relative price effects (Box 3), is assumed to tend to zero in 2060, implicitly representing the assumption that policies are more effective than in the past in controlling the expenditure growth driven by non-demographic non-income related factors.

28. In this scenario (Table 2.3), the health expenditure to GDP ratio for OECD countries would increase by 2.5 percentage points, to reach close to 8% on average by 2060. The largest increases (above 3 percentage points of GDP) are found in Chile, Korea, Luxembourg, Mexico and Turkey. The lowest increases (below 2 percentage points of GDP) are found in Estonia, Hungary, Sweden and the United Kingdom. The increase in non-OECD countries averages around 2 percentage points, to reach 4.5% of GDP by 2060. The effect of non-demographic non-income factors is higher before 2030 than after for all countries, as the residual growth is assumed to converge to zero over the projection period.

2.2.4 Sensitivity analysis

29. In the sensitivity analysis, a number of parameters were changed in the context of the "cost-containment scenario": the income elasticity, the residual spending growth, as well as factors underlying health status at old age (Table 2.4). Detailed results for all scenarios are provided in Appendix 4. Overall, the previous results seem relatively robust. Specifically, these alternative simulations do not change qualitatively the picture emerging from the comparison of the "cost-pressure" and "cost-containment" scenarios discussed above.

30. First, assumptions on the future evolution of the residual are necessarily arbitrary and their impact on projections was checked by computing a cost-containment scenario in line with the assumptions behind such a scenario in the previous 2006 OECD projections. In this variant, on top of the demographic and income effects, the residual component is assumed to contribute 1% per year, tending towards 0% in 2060. On average, the health expenditure to GDP ratio across OECD countries reaches 6.8% instead of 7.9% in this new exercise. For non-OECD countries, the ratio will reach 3.3% instead of 4.4%. However, the assumptions behind this scenario may be overly optimistic: the lower value of the residual growth

Table 2.4. Sensitivity analysis on public health care projections

(Performed on the cost-containment scenario)

	Income elasticity=0.6	Income elasticity=1	Country specific relative prices	Compression of morbidity	Expansion of morbidity
Percentage point deviations from cost-containment scenario in 2060					
Australia	-0.7	0.8	9.9	-0.6	0.6
Austria	-0.5	0.6	6.4	-0.7	0.9
Belgium	-0.6	0.7	0.2	-0.6	0.8
Canada	-0.6	0.7	1.0	-0.5	0.7
Chile	-0.8	1.1	0.0	-0.6	0.7
Czech Republic	-0.8	0.9	-4.0	-0.8	1.0
Denmark	-0.6	0.7	5.4	-0.7	0.8
Estonia	-0.9	1.1	0.0	-0.7	0.8
Finland	-0.6	0.7	4.0	-0.7	0.7
France	-0.5	0.6	-2.4	-0.6	0.8
Germany	-0.6	0.7	-0.7	-0.7	0.9
Greece	-0.5	0.6	2.9	-0.6	0.8
Hungary	-0.8	1.0	-1.9	-0.9	1.3
Iceland	-0.6	0.7	15.7	-0.5	0.6
Israel	-0.6	0.7	0.0	-0.5	0.7
Ireland	-0.4	0.5	0.0	-0.7	0.8
Italy	-0.5	0.6	-1.8	-0.6	0.7
Japan	-0.6	0.8	0.0	-0.6	0.7
Korea	-0.7	0.8	0.5	-0.7	0.8
Luxembourg	-0.2	0.2	-0.9	-0.7	0.9
Mexico	-0.8	1.1	0.0	-0.7	0.9
Netherlands	-0.6	0.7	-2.7	-0.6	0.8
New Zealand	-0.7	0.9	2.0	-0.6	0.6
Norway	-0.6	0.7	-1.6	-0.6	0.7
Poland	-0.7	0.9	-5.3	-1.0	1.3
Portugal	-0.6	0.7	8.7	-0.8	0.9
Slovak Republic	-0.8	0.9	-6.5	-1.0	1.4
Slovenia	-0.6	0.8	0.0	-0.7	0.7
Spain	-0.5	0.6	5.8	-0.7	0.8
Sweden	-0.6	0.7	-0.4	-0.6	0.7
Switzerland	-0.6	0.8	1.1	-0.6	0.8
Turkey	-0.8	1.1	0.0	-0.8	1.0
United Kingdom	-0.6	0.7	-2.3	-0.6	0.7
United States	-0.6	0.7	-1.6	-0.6	0.6
OECD average¹	-0.6	0.8	0.9	-0.7	0.8
Brazil	-0.9	1.1	0.0	-0.8	1.0
China	-1.1	1.7	0.0	-0.8	1.1
India	-1.1	1.7	0.0	-0.8	1.2
Indonesia	-1.0	1.5	0.0	-0.9	1.3
Russia	-0.8	1.0	0.0	-0.7	1.0
South Africa	-0.9	1.2	0.0	-0.6	1.4
Non-OECD average¹	-1.0	1.4	0.0	-0.8	1.2
Total average¹	-0.7	0.8	0.8	-0.7	0.9

contribution in the 2006 exercise reflected in part a higher income elasticity which arithmetically left less of historical spending growth to be explained by the residual. Assuming both a lower income elasticity than in the 2006 exercise and a similar residual spending component may be too much to hope for.

31. As noted above and in Appendix 2, there is considerable uncertainty concerning the income elasticity of health spending. The sensitivity analysis is carried out taking plus and minus two standard deviations from the value estimated in the benchmark regressions, corresponding to an income elasticity equal to 0.6 and 1 respectively. When the income elasticity is set to one, on average for OECD countries the health expenditure deviation from base case will be 0.8 percentage points of GDP to reach 8.7%. It is slightly higher for non-OECD countries at 1.4 percentage points of GDP. In both groups of countries, those with the largest projected GDP per capita growth are obviously the most affected by changes in the income elasticity. When the income elasticity is set to 0.6, health expenditure deviates from base case by -0.6 percentage points of GDP on average in OECD countries, to reach 7.3%. This deviation is much higher in non-OECD countries, amounting to -1 percentage point of GDP.

32. Sensitivity to alternative regimes for morbidity in old age has also been explored. In an “expansion of morbidity” scenario, the share of life spent in ill health would increase as life expectancy increases (*e.g.* an increase in the survival rates of sick people), while a “compression of morbidity” scenario would mean the opposite (*e.g.* an improvement in the health status and health behaviour of the new cohorts of old people). Under these scenarios, by 2060 average health expenditures in OECD countries range from 7.2 to 8.7% of GDP. In non-OECD countries, they range from 3.7 to 5.6%. Thus, while alternative health regimes matter for projecting future expenditure trends, their impact on projections is smaller than that of non-demographic effects.


3. Long-term care

33. Long-term care differs radically from health care. While health care services aim at changing the health condition (from unwell to well), LTC merely aims at making the current condition (unwell) more bearable. Individuals need LTC due to disability, chronic condition, trauma, or illness, which limit their ability to carry out basic self-care or personal tasks that must be performed each day. Such activities are defined as activities of daily living (ADLs), which embrace eating, dressing, bathing, getting in and out of bed, toileting and continence or instrumental activities of daily living (IADLs), which include preparing own meals, cleaning, laundry, taking medication, getting to places beyond walking distance, shopping, managing money affairs and using the telephone/Internet. A person is dependent if he or she has limitations in ADLs and IADLs.

34. It should be noted that LTC also includes a small part of health services that are thus not accounted for in health care. Indeed, total LTC spending is calculated as the sum of health care and social services for those in LTC (Colombo *et al.*, 2011)). Health-related LTC spending includes palliative care, long-term nursing care, personal care services, and health services in support of family care. Social services provided for LTC include home help (*e.g.*, domestic services) and care assistance, residential care services, and other social services. In other words, the health component of LTC spending includes episodes of care where the main need is either medical or personal care services (ADL support), while services whose dominant feature is help with IADL are considered outside the health-spending boundaries.

35. A striking difference between spending on health and LTC is that the cost of LTC per beneficiary is roughly independent of age (Figure 3.1). Indeed, the cost of helping one person in ADLs or IADLs could be more or less the same, irrespective of their age. Moreover, while potentially the entire population may benefit from health care, only dependent persons will benefit from LTC. Therefore, while the age-specific cost curve for health care was expressed per capita for each age group, that for LTC is expressed per dependant.

Figure 3.1. Public long-term care expenditure per beneficiary as a % of GDP per capita¹



1. The graph shows the dispersion of long-term care expenditure across countries by age groups. The diamonds represent the median. The boxes are the 2nd and 3rd quartiles of the distribution of expenditure across countries. The whiskers are the 1st and 4th quartiles. The circles are outliers.

Source: European Commission, 2009 Ageing Report: Economic and budgetary projections for the EU-27 Member States (2008-2060).

3.1. Projection framework

36. As for health care, the framework used to project public LTC expenditure is based on both demographic and non-demographic drivers. The evolution of each driver is projected separately. They are then combined to compute the future growth of total LTC expenditure. The basic projection equation can again be interpreted as a reduced form combining demand and supply factors that determine equilibrium LTC expenditures. Broadly speaking, these expenditures are related to the number of dependent people in the population, income developments and changes in the demand for public-financed LTC services. Income is assumed to have a direct effect via increases in living standards (GDP per capita) and an indirect effect via cost-disease (relative productivity or Baumol) effects. Given the importance of home production of LTC services, the demand for public spending on LTC is assumed to depend on developments in formal labour force participation. More details on these assumptions and the corresponding variable definitions are provided below, but adopting the same notation as in equation (1) the projection equation for LTC spending ratios is the following:

$$\Delta \log \left(\frac{LTC}{P_{Y,Y}} \right) = \Delta \log(Demo) + (\varepsilon - 1) \cdot \Delta \log \left(\frac{Y}{N} \right) + \gamma \cdot \Delta \log(Baumol) + \delta \cdot \Delta \log(Participation) \quad (4)$$

where *Demo* stands for the number of dependent people; *Baumol* stands for the cost-disease effect, with an elasticity of γ that can take the value of 1 or 0.5 depending on the scenario (0.5 or 0.25 for the BRIICS);

Participation stands for the effect of changes in the demand for public spending on LTC, with an estimated elasticity of 0.7 (see Appendix 3); and ε is the income elasticity of LTC expenditures that can take the value of 1 or 2. As for health care, the elasticities are estimated econometrically (see Box 5 and Appendix 3).

37. The total logarithmic growth rates are first projected for each country. Applying the same methodology as for health care, those growth rates are then adjusted to allow for a certain convergence across countries. Therefore, each country-specific growth rate is multiplied by the ratio of the average starting point across countries to the country-specific starting point. In order to smooth out the impact of the recent crisis on expenditure, the starting point for each country is computed as the average share of public LTC spending in GDP over 2006-2010.

3.1.1 Demographic drivers of expenditure


38. Whereas health care projections distinguished between survivors and non-survivors, the LTC projections split each age group into dependants and non-dependants. The age-specific dependency ratios have been estimated by the European Commission for 22 European countries. As can be seen, even if the shape of the dependency ratios by age differs across countries, the dispersion remains relatively limited (Figure 3.2). Thus, as a first approximation, dependency ratios (number of dependants by age group) are assumed to be broadly uniform across countries. For the purpose of projecting expenditure, this also has the advantage of eliminating current differences in the prevalence of dependency across age groups as a possible cause for future differential increases in LTC expenditures. In other words, the projections become less sensitive to initial conditions. Noteworthy, this assumption therefore abstracts from the influence of differences in policy settings on these initial conditions.

39. For the calculation of the pure demographic effect (*Demo* in equation (4)), it is assumed that the LTC spending per dependant remains constant. Thus, the variation in LTC expenditure resulting from the pure demographic effect is only driven by the increase in the number of dependants by age group. The latter is derived from the average dependency ratio (see above) multiplied by the population by age group.

40. An important driver of the prevalence of dependency is the evolution of life expectancy. As life expectancy *at birth* is increasing, dependency is assumed to diminish. Indeed, if such life expectancy gains translate into years in good health (“healthy ageing” hypothesis) the number of dependants will diminish. But, this effect can be mitigated by the amount of health expenditure, which may have the opposite impact on the prevalence of dependency. Indeed, if an increase in health expenditure translates into higher longevity at every age, and especially at older age, it may translate into an increase in the prevalence of chronic diseases in older age (Goldman *et al.*, 2005). The latter, in turn, increases the probability of dependency. This potentially creates a link between spending on health care and on LTC.

Figure 3.2. Dependency ratios by age¹

(Number of dependants as a % of population by age groups)



1. The graph shows the dispersion of dependency ratio across countries by age groups. The diamonds represent the median. The boxes are the 2nd and 3rd quartiles of the distribution of expenditure across countries. The whiskers are the 1st and 4th quartiles. The circles are outliers.

Source: European Commission, 2009 Ageing Report: Economic and Budgetary Projections for the EU-27 Member States (2008-2060).

41. In order to project the evolution of dependency until 2060 taking into account the possible link between dependency and health-care expenditures, the age-specific dependency ratios have been estimated based on historical data as a function of age, age-specific per capita health-care expenditures and life expectancy at birth (see Box 4). The healthy-ageing hypothesis implies a reduction in dependency at old age over time. Using the elasticities estimated in equation (5), the reduction of the dependency ratio by age group depends on the evolution of life expectancy and per capita public health care expenditure (as projected in the cost-containment scenario for health-care). Although health care and LTC are treated separately, having health-care expenditure as a determinant of the dependency ratio allows to account for the impact of health-care spending on dependency in the LTC projections.

Box 4. Dependency ratio estimates

In order to gauge the evolution of the dependency ratio, its past determinants have been investigated by means of panel regression techniques. Defining $Depr_{i,a}$ as the dependency ratio (number of dependent people for country i and age a), Age as the central point in each age bracket (2,7,12,...,97), $(HE/N)_{i,a}$ the public health care expenditure per capita for country i and age a and LE_i life expectancy at birth for country i ,⁹ the following equation was estimated:

$$\log(Depr_{i,a}) = \alpha + \varphi * \log(Age_i) + \beta * \log((HE/N)_{i,a}) + \gamma * \log(LE_i) + u \quad (5)$$

The equation was estimated for the population aged 52 and above, as the dependency ratio for people below 52 is small and roughly constant over time. As expected, the age variable has a highly significant, positive impact (See Table A3.1 in Appendix 3). Public health expenditure per capita also has a significant positive effect, though much smaller. Conversely, increased life expectancy *at birth* delays the prevalence of dependency.

3.1.2 Non-demographic drivers of expenditure

42. Apart from the evolution of the number of dependants in the population, non-demographic drivers also have an impact on LTC expenditure growth. The projections account for three of them: changes in the relative price of LTC, income effects and changes in the demand for public-financed LTC, which in turn depend on the availability provision of informal care.

43. One of the main non-demographic drivers of public LTC expenditure is the relative share of informal and formal care.^{10,11} Most informal care is provided by family and friends (Colombo *et al.*, 2011). Even using a narrow definition of the family care “workforce”, its size is at least twice that of the formal care workforce (*e.g.*, in Denmark), and in some cases it is estimated to be more than ten times the size of the formal-care workforce (*e.g.*, Canada, New Zealand, the United States, the Netherlands). On average, around 70% to 90% of those who provide care are family carers (Fujisawa and Colombo, 2009). Changing societal models – such as declining family size, changes in residential patterns of people with disabilities and rising female participation in the formal labour market – are likely to contribute to a decline in the availability of informal care-givers, leading to an increase in the need for paid care (Colombo *et al.*, 2011). Since there is evidence that informal elderly care is associated with lower female labour force participation (Viitanen, 2005), to project the future evolution of LTC spending informal carers have been proxied by the labour force participation of women aged 50-64 (a sensitivity check has also been carried out using their exit rate from the labour force). However, as participation rates by age and gender are not readily available

⁹ Including life expectancy *at birth* minimises the possibility that this effect could be driven by health expenditures themselves, thereby avoiding multicollinearity problems between HE and LE.

10. Formal care is provided by care assistants who are paid for providing care under some form of employment contract. It includes both care provided in institutions and care provided at home. To be considered informal, the provision of care cannot be paid for as if purchasing a service. However, an informal care-giver may still receive social transfers conditional on his/her provision of informal care and possibly, in practice, some informal payment from the person receiving care.

11. The projections do not distinguish between formal care delivered within institutions and that delivered to the patient’s home. There are fundamental differences between countries in the way they organise their formal LTC. Institutional LTC is particularly widespread in the Nordic countries (OECD, 2005b). Whether this form of organisation is adopted by other countries or whether a (cheaper) ambulatory help-at-home strategy is pursued could have important consequences for public expenditures.

for non-OECD countries, informal carers have been proxied by the overall participation rates in these countries.


44. Another important non-demographic driver of public LTC expenditure is the associated labour costs. The LTC sector is highly labour-intensive and the room for productivity gains is often seen as more limited than elsewhere in the economy. Therefore, it could be exposed to a “cost disease” or Baumol effect (Baumol, 1967, 1993). In short, this implies that the relative price of LTC *vis-à-vis* other goods and services in the economy, tends to rise as aggregate productivity and GDP per capita increase, reflecting the negative differential between productivity growth in LTC and in other sectors and equalisation of wages across sectors. With a price-inelastic demand, the share of LTC expenditure in GDP would, therefore, tend to increase over time. A possible way to capture this effect is to assume that unit costs rise in line with average earnings of care staff or a measure of wage inflation in the economy (Comas-Herrera *et al.*, 2003). In this paper, productivity growth in the total economy has been used as a proxy for the Baumol effect on public LTC expenditures.¹²

45. Finally, income is also likely to play a role in LTC expenditure. Indeed, with rising real incomes, people demand more responsive and higher quality services (Colombo *et al.*, 2011). Figure 3.3 shows the relationship between income and public LTC expenditure. It is difficult however to distinguish the income effect from the cost-disease effect, as proxied by aggregate productivity, since they are too highly correlated.

46. The influence of each of the non-demographic drivers of LTC expenditures has been adjusted to parameterise the projection equation (4) (Box 5). Given the multicollinearity between productivity and income, the two variables were tested separately.

12 The relative price effect may be limited by a growing share of immigrants among LTC workers. According to Colombo *et al.*, (2011), foreign-born workers play a significant and growing role in LTC in some countries. The average wage of the immigrant work force is lower than that of native workers and their bargaining power less important. Thus, the process of equalising the wages of foreign-born and native work forces will take time.

Figure 3.3 Long-term care expenditure and GDP per capita



Source: OECD Health database

Box 5. Estimations to calibrate the LTC framework

In order to estimate the LTC spending elasticities to productivity (Baumol effect) and to the participation rate, which are used to parameterise the projections model, the following equation was estimated over the period 1990-2009

$$\log\left(\frac{LTC}{P_Y \cdot Y}\right) = \alpha + \beta * \log(OAdep) + \gamma * \log(Prod) + \delta * \log(PR) + u \quad (6)$$

Where the share of long-term care expenditure in GDP (LTC/Y) is explained by $Prod$, the productivity in total economy capturing the Baumol effect (or alternatively the income per capita variable) and PR , the female labour force participation used as a proxy for the provision of informal care (or their exit rate from employment). In this equation $OAdep$, the ratio of people aged 80 and above to total population, is a control variable that plays no role in the projections, as a demographic effect ($Demo$) already covers the effects of ageing.

As expected, the old age dependency ratio (people above 80) is a significant determinant of LTC expenditure (Table A3.2 of Appendix 3). Nonetheless, the main determinant is the relative price effect (proxied by total economy productivity), which emerges with an elasticity of around two. Alternatively, when the income variable is introduced separately, its elasticity amounts to around 2.7. While regression estimates point to Baumol or Income elasticities higher than unity, a conservative choice has been made of a unitary elasticity for both the relative price and the income variable. Nonetheless, sensitivity analysis has been carried out where the income elasticity was fixed at two (see below). Finally all the proxies for informal care (female participation or exit rate from the labour force) also turn out to be significant.

3.2 Projection results: long-term care 2010-2060

47. As for health care, a cost-pressure scenario and a cost-containment scenario were computed. Both scenarios are based on a unitary income elasticity assumption and the "healthy ageing" hypothesis. However, in the cost-pressure scenario, for OECD countries, a full relative price effect is assumed, meaning that LTC expenditure increases fully in line with labour productivity; for non-OECD countries, excess labour supply especially in the non-tradeable sector suggests lower prospective wage pressures, and therefore the cost-pressure scenario only incorporates half the relative price effect. In the cost-containment scenario, the elasticity of LTC spending to productivity increases is supposed to be 0.5 in OECD countries, whereas in non-OECD countries the elasticity is set at 0.25, possibly reflecting policy action aimed at mitigating relative wage increases of LTC providers. For example, action to curb expenditure could be aimed at facilitating access to LTC provision by low-skilled migrants or at providing incentives to balance institutional and home-based LTC.

48. Sensitivity analysis has been carried out in the context of the cost-containment scenario, with respect to the relative price effect, the income elasticity and the implications of healthy ageing for the number of dependants. As for health care, the starting year of the projections is an average over the period 2006-2010 so as to smooth out the impact of the recent crisis. The main assumptions underlying each projection scenario are listed in Table 3.1.

Table 3.1. Assumptions underlying the alternative projection scenarios: public long-term care

Scenarios	Health status	Income effect	Baumol effect	Availability of informal care
<i>Demographic effect</i>	Healthy ageing: the prevalence of dependency per age is shifted according to the evolution of life expectancy and health expenditure	n.a	n.a	n.a
<i>Cost-pressure scenario</i>	Healthy ageing: the prevalence of dependency per age is shifted according to the evolution of life expectancy and health expenditure	Income elasticity = 1	OECD countries: Full Baumol effect (elasticity = 1) BRIICS: Half Baumol effect	OECD countries: Baseline scenario for participation rates of women aged 50-64 BRIICS: total participation rates
<i>Cost-containment scenario</i>	Healthy ageing: the prevalence of dependency per age is shifted according to the evolution of life expectancy and health expenditure	Income elasticity = 1	OECD countries: Half Baumol effect (elasticity = 0.5) BRIICS : 1/4 of Baumol effect	OECD countries: Baseline scenario for participation rates of women aged 50-64 BRIICS: total participation rates
Sensitivity analysis based on the cost-containment scenario				
<i>Income elasticity = 2</i>	Healthy ageing: the prevalence of dependency per age is shifted according to the evolution of life expectancy and health expenditure	Income elasticity = 2	OECD countries: Half Baumol effect (elasticity = 0.5) BRIICS : 1/4 of Baumol effect	OECD countries: Baseline scenario for participation rates of women aged 50-64 BRIICS: total participation rates
<i>Life expectancy plus 2 standard deviation</i>	Healthy ageing: the prevalence of dependency per age is shifted according to the evolution of life expectancy plus 2 standard deviation and health expenditure	Income elasticity = 1	OECD countries: Half Baumol effect (elasticity = 0.5) BRIICS : 1/4 of Baumol effect	OECD countries: Baseline scenario for participation rates of women aged 50-64 BRIICS: total participation rates
<i>Life expectancy minus 2 standard deviation</i>	Healthy ageing: the prevalence of dependency per age is shifted according to the evolution of life expectancy minus 2 standard deviation and health expenditure	Income elasticity = 1	OECD countries: Half Baumol effect (elasticity = 0.5) BRIICS : 1/4 of Baumol effect	OECD countries: Baseline scenario for participation rates of women aged 50-64 BRIICS: total participation rates
<i>Cost-pressure health scenario</i>	Healthy ageing: the prevalence of dependency per age is shifted according to the evolution of life expectancy and health expenditure cost pressure scenario	Income elasticity = 1	OECD countries: Half Baumol effect (elasticity = 0.5) BRIICS : 1/4 of Baumol effect	OECD countries: Baseline scenario for participation rates of women aged 50-64 BRIICS: total participation rates

49. As can be seen from Table 3.2, demographic changes are not projected to be the most important determinants of future public LTC expenditures. Indeed, as the LTC cost is independent of age, the pure age effect has only a moderate impact on spending. Moreover, this effect is mitigated by the 'healthy ageing' assumption. As with projections of public health-care spending, non-demographic drivers account for the lion's share of future expenditure increases, though with an assumed elasticity of unity, the income effect is not creating additional pressures in terms of expenditure shares to GDP. Detailed results for all scenarios are provided in Appendix 4.

Table 3.2. Projection scenarios for public long-term care expenditure

	Average 2006-2010	Percentage point deviations from starting period in 2030			Percentage point deviations from starting period in 2060		
		Demographic effect	Cost-pressure	Cost- containment	Demographic effect	Cost- pressure	Cost- containment
Australia	0.0	0.1	0.6	0.3	0.3	1.3	0.8
Austria	1.1	0.1	0.5	0.3	0.2	1.0	0.7
Belgium	1.7	0.1	0.5	0.3	0.1	1.2	0.7
Canada	1.2	0.2	0.5	0.3	0.2	1.2	0.7
Chile	0.0	0.2	0.9	0.6	0.6	2.3	1.5
Czech Republic	0.3	0.2	0.7	0.3	0.4	1.6	0.9
Denmark	2.2	0.1	0.4	0.2	0.2	1.0	0.6
Estonia	0.2	0.1	0.7	0.3	0.3	2.0	0.9
Finland	0.8	0.2	0.5	0.3	0.2	1.0	0.5
France	1.1	0.1	0.5	0.2	0.2	1.0	0.6
Germany	0.9	0.2	0.5	0.3	0.3	1.1	0.7
Greece	0.5	0.1	0.6	0.4	0.3	1.4	0.9
Hungary	0.3	0.1	0.6	0.3	0.3	1.8	1.0
Iceland	1.7	0.2	0.3	0.1	0.2	1.0	0.5
Israel	0.5	0.2	0.4	0.3	0.3	0.9	0.6
Ireland	0.4	0.1	0.5	0.4	0.2	1.0	0.7
Italy	0.7	0.1	0.5	0.3	0.2	1.2	0.8
Japan	0.7	0.2	0.5	0.3	0.3	1.4	0.8
Korea	0.3	0.4	0.8	0.5	0.8	2.0	1.3
Luxembourg	0.9	0.1	0.5	0.4	0.3	0.8	0.7
Mexico	0.0	0.2	0.7	0.5	0.6	2.2	1.5
Netherlands	2.3	0.2	0.6	0.4	0.3	1.4	0.8
New Zealand	1.3	0.2	0.5	0.3	0.3	1.4	0.8
Norway	2.1	0.1	0.4	0.2	0.2	1.0	0.5
Poland	0.4	0.2	0.7	0.3	0.5	1.8	1.0
Portugal	0.1	0.1	0.4	0.2	0.3	1.3	0.8
Slovak Republic	0.0	0.2	0.8	0.4	0.6	1.9	1.1
Slovenia	0.7	0.2	0.6	0.4	0.4	1.5	0.9
Spain	0.5	0.1	0.6	0.5	0.3	1.5	1.0
Sweden	0.7	0.1	0.4	0.1	0.1	0.9	0.5
Switzerland	1.2	0.1	0.5	0.3	0.3	1.3	0.7
Turkey	0.0	0.2	0.7	0.3	0.6	2.3	1.6
United Kingdom	0.9	0.1	0.3	0.2	0.1	0.9	0.5
United States	0.6	0.1	0.4	0.2	0.2	0.8	0.4
OECD average¹	0.8	0.1	0.5	0.3	0.3	1.4	0.8
Brazil	0.0	0.2	0.3	0.3	0.7	1.2	0.9
China	0.1	0.3	0.4	0.3	0.7	2.0	1.1
India	0.1	0.1	0.3	0.2	0.4	1.5	0.8
Indonesia	0.1	0.2	0.3	0.2	0.7	1.6	1.0
Russia	0.2	0.1	0.2	0.1	0.2	0.8	0.4
South Africa	0.2	0.1	0.2	0.2	0.3	0.7	0.5
Non-OECD average¹	0.1	0.2	0.3	0.2	0.5	1.3	0.8
Average¹	0.7	0.2	0.5	0.3	0.3	1.4	0.8

1. Unweighted average.

3.2.1 The cost-pressure scenario

50. In the cost-pressure scenario, starting from 0.8% of GDP on average for OECD countries, the ratio of public LTC expenditure to GDP is projected to increase by 1.4 percentage points to reach 2.1 % of GDP. However, some countries, like Chile, Estonia, Korea, Mexico and Turkey, will experience higher

increases (equal to or above 2 percentage points). These countries are starting from a very low level of LTC expenditure and are in the process of catching up. Conversely, Israel, Luxembourg, Sweden, the United-Kingdom and the United States are projected to experience only small increases in their LTC expenditure to GDP ratios (less than 1 percentage point). Differences in the initial level of female participation rates as well as policies in place also explain the differences across countries. For non-OECD countries, the increase in LTC spending is projected to be, on average, broadly the same as that experienced by OECD countries but starting from a much lower level (0.1%). For OECD countries, the average annual increase of public LTC expenditure will be about the same before and after 2030 (≈ 0.03 percentage points) whereas it will be slightly more important after 2030 (≈ 0.03 percentage points) than before (≈ 0.01 percentage points) for non-OECD countries.

3.2.2 The cost-containment scenario

51. In the cost-containment scenario, on average for OECD countries, the public LTC expenditure to GDP ratio increases by 0.8 percentage point from 0.8% to 1.6% of GDP. Chile, Korea, Mexico and Turkey experience the most important increases (above 1.3 percentage points), while Finland, Iceland, Norway, Sweden, the United Kingdom and the United States only have an increase lower than or equal to 0.5 percentage points. Non-OECD countries will experience on average the same increase as OECD countries (0.8 percentage points). Again for OECD countries, the average annual increase of public LTC expenditure will be about the same before and after 2030 (≈ 0.02 percentage points) whereas it will be slightly more important after 2030 (≈ 0.02 percentage points) than before (≈ 0.01 percentage points) for non-OECD countries.

3.3 Sensitivity analysis

52. Given the earlier regression results, projections assuming an income elasticity of two were performed for the cost-containment scenario for OECD countries. For non-OECD countries, in this scenario the projections assume an income elasticity of 1.5. On average, for OECD countries LTC expenditure would reach in this case 2.5% of GDP in 2060. In this scenario, Chile, Estonia, Mexico and Turkey would experience a deviation from base case of around 1.7 percentage points of GDP. Again, the assumptions underlying the GDP projections assume some catch-up for these low income countries, explaining why their LTC expenditure patterns are more affected by the higher income elasticity assumption. For non-OECD countries, the share of LTC in GDP is going to reach 1.8% of GDP. China, India and Indonesia would experience a deviation from base case of more than 1 percentage point (see Table 3.3).

53. A sensitivity analysis has also been carried out for the evolution of the number of dependants. The two drivers of the dependency ratio, life expectancy and health care spending, have been tested separately. Taking life expectancy plus (minus) two standard deviations would induce an average deviation from base case for OECD countries of 0.3 (-0.2) percentage points in the LTC expenditure to GDP ratio, which would then reach, on average, 1.9% (1.4%) of GDP. For each scenario, the expenditure for non-OECD countries will deviate from base case by the same amount as for OECD countries. Due to the very limited impact of health expenditure, alternative assumptions in this area have only a slight impact. Indeed, even under the cost-pressure health care spending scenario, the LTC expenditure to GDP ratio would only deviate from the base case by 0.1 percentage points on average for both OECD and non-OECD countries.

Table 3.3. Sensitivity analysis on public long-term care projections

(Performed on the cost-containment scenario)

	Income elasticity=2 ¹	Life expectancy plus 2 standard deviation	Life expectancy minus 2 standard deviation	Cost-pressure health-care expenditure
Percentage point deviations from cost-containment scenario in 2060				
Australia	1.0	0.2	-0.2	0.1
Austria	0.6	0.2	-0.2	0.1
Belgium	0.8	0.2	-0.2	0.1
Canada	0.8	0.2	-0.2	0.1
Chile	1.7	0.3	-0.2	0.1
Czech Republic	1.3	0.3	-0.2	0.1
Denmark	0.8	0.2	-0.2	0.1
Estonia	1.8	0.3	-0.2	0.1
Finland	0.8	0.2	-0.2	0.1
France	0.6	0.2	-0.2	0.1
Germany	0.8	0.3	-0.2	0.1
Greece	0.6	0.3	-0.2	0.1
Hungary	1.4	0.3	-0.2	0.1
Iceland	0.8	0.2	-0.2	0.1
Israel	0.7	0.2	-0.2	0.1
Ireland	0.5	0.2	-0.2	0.1
Italy	0.6	0.2	-0.2	0.1
Japan	0.9	0.3	-0.2	0.1
Korea	1.0	0.4	-0.3	0.2
Luxembourg	0.1	0.3	-0.2	0.1
Mexico	1.7	0.3	-0.3	0.1
Netherlands	0.8	0.3	-0.2	0.1
New Zealand	1.2	0.2	-0.2	0.1
Norway	0.8	0.2	-0.2	0.1
Poland	1.1	0.3	-0.2	0.1
Portugal	0.7	0.3	-0.2	0.1
Slovak Republic	1.3	0.3	-0.3	0.1
Slovenia	0.9	0.3	-0.2	0.1
Spain	0.7	0.3	-0.2	0.1
Sweden	0.9	0.2	-0.2	0.1
Switzerland	0.9	0.3	-0.2	0.1
Turkey	1.7	0.3	-0.2	0.1
United Kingdom	0.8	0.2	-0.2	0.1
United States	0.7	0.2	-0.2	0.1
OECD average²	0.9	0.3	-0.2	0.1
Brazil	0.6	0.4	-0.3	0.1
China	1.2	0.4	-0.3	0.1
India	1.3	0.2	-0.2	0.1
Indonesia	1.0	0.3	-0.3	0.1
Russia	0.5	0.2	-0.2	0.1
South Africa	0.7	0.2	-0.1	0.1
Non-OECD average²	0.9	0.3	-0.2	0.1
Average²	0.9	0.3	-0.2	0.1


4. Summary of results and comparison with previous projections

4.1 Cross-country projection results: an overview

54. Both health and LTC expenditures are projected to put sizeable pressure on public finance over the next 50 years. On average across OECD countries, the total health and LTC expenditure to GDP ratio is projected to more than double in the cost-pressure scenario, increasing from 6.2% in the starting period to 13.9% of GDP in 2060 (Table 4.1). In the cost-containment scenario the ratio would still increase by more than half, to reach 9.5%.

55. There are, however, striking differences across countries (Figure 4.1). In the cost-containment scenario, one group of countries experiences a 4 to 5 percentage point increase in total spending to GDP ratios over the period 2010-2060. It includes ageing countries (Korea and Chile), as well as those with currently low labour participation, which may face a substantial increase in the demand for *formal* long-term care (Spain and Mexico). By contrast, in the United States, the United Kingdom and the Nordic countries the projected increase is below 3 percentage points of GDP. In these countries demographic trends will be more stable. On average, non-OECD countries will experience a lower percentage point increase than OECD countries. Nonetheless, the lower initial spending to GDP ratios of these countries will more than double by 2060.

Figure 4.1 Percentage point increase in total public health and long-term care spending, 2010-2060



1. The vertical bars correspond to the range of the alternative scenarios, including sensitivity analysis. Countries are ranked by the increase of expenditures between 2010 and 2060 in the cost-containment scenario.

Table 4.1. Projection scenarios for public health and long-term care spending

In % of GDP

	Health care			Long-term care			Total		
	Average 2006-2010	2060		Average 2006-2010	2060		Average 2006-2010	2060	
		Cost- pressure	Cost- containment		Cost- pressure	Cost- containment		Cost- pressure	Cost- containment
Australia	5.6	12.0	8.1	0.0	1.4	0.8	5.7	13.3	8.9
Austria	6.6	12.9	9.1	1.1	2.2	1.8	7.8	15.1	10.8
Belgium	5.8	11.6	7.7	1.7	3.0	2.5	7.5	14.6	10.2
Canada	5.8	12.2	8.3	1.2	2.5	1.9	7.1	14.6	10.2
Chile	3.1	10.2	6.3	0.0	2.3	1.5	3.1	12.4	7.8
Czech Republic	5.5	11.6	7.7	0.3	1.9	1.1	5.8	13.5	8.9
Denmark	6.3	12.2	8.3	2.2	3.3	2.8	8.5	15.4	11.1
Estonia	4.3	10.1	6.2	0.2	2.2	1.1	4.5	12.3	7.4
Finland	5.2	11.2	7.3	0.8	1.8	1.3	6.0	13.0	8.6
France	7.4	13.5	9.6	1.1	2.1	1.7	8.5	15.5	11.3
Germany	7.3	13.5	9.6	0.9	2.1	1.6	8.2	15.5	11.2
Greece	5.4	11.8	7.9	0.5	1.9	1.5	5.9	13.7	9.3
Hungary	4.8	10.6	6.7	0.3	2.0	1.2	5.0	12.6	7.9
Iceland	5.8	11.7	7.8	1.7	2.7	2.2	7.6	14.4	10.0
Israel	4.0	10.4	6.6	0.5	1.5	1.2	4.5	11.9	7.7
Ireland	5.5	11.9	8.0	0.4	1.3	1.1	5.9	13.3	9.1
Italy	6.1	12.6	8.7	0.7	1.9	1.5	6.9	14.5	10.2
Japan	6.1	12.5	8.6	0.7	2.0	1.4	6.8	14.5	10.0
Korea	3.3	10.9	7.0	0.3	2.3	1.6	3.6	13.2	8.6
Luxembourg	4.4	11.3	7.4	0.9	1.7	1.7	5.3	13.0	9.1
Mexico	2.5	9.4	5.5	0.0	2.2	1.5	2.5	11.6	7.0
Netherlands	6.4	12.7	8.8	2.3	3.7	3.1	8.7	16.4	12.0
New Zealand	6.4	12.7	8.8	1.3	2.6	2.0	7.7	15.3	10.8
Norway	5.1	11.2	7.3	2.1	3.1	2.7	7.2	14.3	10.0
Poland	4.1	10.5	6.7	0.4	2.2	1.4	4.5	12.7	8.0
Portugal	6.5	13.0	9.1	0.1	1.4	0.9	6.6	14.3	9.9
Slovak Republic	5.4	11.9	8.0	0.0	1.9	1.1	5.4	13.9	9.2
Slovenia	5.2	11.8	7.9	0.7	2.2	1.5	5.8	14.0	9.4
Spain	5.6	12.3	8.5	0.5	2.0	1.6	6.1	14.3	10.0
Sweden	6.6	12.4	8.6	0.7	1.6	1.1	7.2	14.0	9.7
Switzerland	5.7	12.2	8.3	1.2	2.5	1.9	6.9	14.6	10.2
Turkey	3.8	10.9	7.0	0.0	2.3	1.6	3.8	13.2	8.6
United Kingdom	6.5	12.4	8.5	0.9	1.8	1.4	7.4	14.2	9.9
United States	7.1	13.2	9.3	0.6	1.3	1.0	7.6	14.5	10.3
OECD average¹	5.5	11.8	7.9	0.8	2.1	1.6	6.2	13.9	9.5
Brazil	3.7	10.7	6.8	0.0	1.3	0.9	3.7	11.9	7.7
China	1.9	8.3	4.4	0.1	2.1	1.2	2.0	10.4	5.6
India	1.2	6.7	2.8	0.1	1.6	0.9	1.3	8.3	3.7
Indonesia	1.2	7.3	3.5	0.1	1.7	1.0	1.2	9.0	4.5
Russia	3.1	8.6	4.7	0.2	1.0	0.7	3.4	9.7	5.4
South Africa	3.2	8.4	4.5	0.2	0.9	0.6	3.4	9.2	5.1
Non-OECD average¹	2.4	8.3	4.4	0.1	1.4	0.9	2.5	9.8	5.3
Total average¹	5.0	11.3	7.4	0.7	2.0	1.5	5.7	13.3	8.9

1. Unweighted average.

Source: Secretariat calculations.

4.2 Comparison with OECD (2006) projections

56. Even though comparing these new projections with those in Oliveira Martins and de la Maisonneuve (2006) is difficult (notably because the beginning and ending years are different), the two sets of results broadly deliver the same message: even in the cost-containment scenario public health care and LTC spending will put an important burden on future public finances (Table 4.2). The new set of projections suggests a more important increase in health care expenditure, both in the cost-pressure and the cost-containment scenarios. This may be explained by the assumption of a stronger non-demographic, non-income effect, reflecting a better understanding of the evolution of the underlying determinants of the unexplained residual, in particular the evolution of quality-adjusted relative prices. Conversely, regarding public LTC funding, the increase in expenditure is lower in the new set of projections than in the previous one. This may be explained by the fact that LTC costs are more appropriately treated as being independent of age in the current exercise.

Table 4.2. Public health and long-term care spending: comparison with previous projections

As a % of GDP

	Health care				Long-term care			
	New projections (Percentage point deviations from starting period in 2060)		OECD Economic Studies, 2006 (Percentage point deviations from starting period in 2050)		New projections (Percentage point deviations from starting period in 2060)		OECD Economic Studies, 2006 (Percentage point deviations from starting period in 2050)	
	Cost-pressure	Cost-containment	Cost-pressure	Cost-containment	Cost-pressure	Cost-containment	Cost-pressure	Cost-containment
Australia	6.3	2.5	4.2	2.3	1.3	0.8	2.0	1.1
Austria	6.3	2.4	3.8	2.0	1.0	0.7	2.0	1.2
Belgium	5.8	1.9	3.3	1.5	1.2	0.7	1.9	1.1
Canada	6.3	2.5	4.1	2.2	1.2	0.7	2.1	1.3
Czech Republic	6.1	2.2	4.1	2.3	1.6	0.9	1.7	1.0
Denmark	5.9	2.0	3.5	1.7	1.0	0.6	1.5	0.7
Finland	5.9	2.0	3.6	1.8	1.0	0.5	2.4	1.3
France	6.1	2.2	3.5	1.7	1.0	0.6	1.7	1.0
Germany	6.2	2.3	3.6	1.8	1.1	0.7	1.9	1.2
Greece	6.4	2.5	3.9	2.0	1.4	0.9	2.7	1.8
Hungary	5.8	1.9	3.6	1.8	1.8	1.0	2.1	0.7
Iceland	5.9	2.0	4.0	2.1	1.0	0.5	1.6	0.6
Ireland	6.4	2.5	4.0	2.2	1.0	0.7	3.8	2.4
Italy	6.4	2.6	3.8	1.9	1.2	0.8	2.9	2.2
Japan	6.3	2.5	4.3	2.5	1.4	0.8	2.2	1.5
Korea	7.6	3.7	4.9	3.0	2.0	1.3	3.8	2.8
Luxembourg	6.9	3.0	3.7	1.9	0.8	0.7	3.1	1.9
Mexico	6.9	3.0	4.5	2.7	2.2	1.5	4.1	2.9
Netherlands	6.3	2.4	3.8	2.0	1.4	0.8	2.0	1.2
New Zealand	6.3	2.4	4.2	2.3	1.4	0.8	2.0	1.2
Norway	6.1	2.2	3.4	1.6	1.0	0.5	1.7	0.9
Poland	6.4	2.6	4.1	2.3	1.8	1.0	3.2	1.3
Portugal	6.5	2.6	4.2	2.4	1.3	0.8	2.0	1.1
Slovak Republic	6.5	2.6	4.6	2.8	1.9	1.1	2.3	1.2
Spain	6.7	2.8	4.1	2.3	1.5	1.0	2.4	1.7
Sweden	5.9	2.0	3.2	1.4	0.9	0.5	1.1	0.1
Switzerland	6.5	2.6	3.5	1.6	1.3	0.7	1.4	0.7
Turkey	7.0	3.1	4.1	2.3	2.3	1.6	1.6	0.7
United Kingdom	5.9	2.0	3.6	1.7	0.9	0.5	1.9	1.1
United States	6.1	2.2	3.4	1.6	0.8	0.4	1.7	0.9
OECD average¹	6.3	2.4	3.9	2.1	1.3	0.8	2.2	1.3

1. Unweighted average.

Source: Oliveira Martins and de la Maisonneuve (2006) and Secretariat calculations.

57. Long-term spending projections are inherently uncertain and subject to upside/downside risks. While an evolution of spending more moderate than in these projections cannot be excluded (for instance if cost-saving technologies were to spread out, or if more aggressive cost-containment policies were to be implemented), these are also clear upside risks on spending. For instance, higher health spending could arise due to an extension of the pre-death period of ill health as longevity increases or because of higher than expected costs induced by technical progress. Regarding LTC, higher spending could arise from increased dependency due to obesity trends or dementia. Indeed, according to recent calculations, some 12% of those aged between 80 and 84 years, and almost one in four of those aged over 85 years, suffer from dementia (Alzheimer Europe, 2006). With ageing populations, strong increases in the prevalence of dementia may be expected (see Box 1.1 in Colombo *et al.* (2011)), though prevention and treatment may also improve in the future.

58. Even if these upside risks do not materialise, the spending projections point to important policy challenges. These challenges are reinforced by the evidence that macroeconomic cost-containment policies, which had some success in repressing spending trends over the 1980s and 1990s, have their limits. For instance, it is difficult to contain wages and at the same time, attract young and skilled workers into the health-care system. Similarly, controlling prices is not easy when technical progress is permanently creating new products and treatments, while overall constraints on supply result in unpopular waiting lists for these treatments. More generally, it is difficult to determine the appropriate supply of health and LTC services without market signals – but at the same time, health and LTC are areas where market failure is rife.

APPENDIX 1. THE HEALTH PROJECTION FRAMEWORK

I. Health Projection framework

59. The Health care projection framework is based on a (usual) non-linear demand function expressed in a *per capita* basis, as follows¹³:

$$\left(\frac{he}{N}\right) = \alpha \cdot \left(\frac{P}{P_Y}\right)^\beta \cdot Q^\gamma \cdot \left(\frac{Y}{N}\right)^\varepsilon \quad (\text{A1})$$

Where *he* denotes health care demand volumes (deflated for price and quality); *P* are health care prices; *P_Y* is the income deflator (or GDP deflator); *Q* is a quality index for health care products; *Y* real income (or real GDP); *N* is total population, and α is a constant. The expected signs for the elasticities are:

Price elasticity: $\beta < 0$
 Quality elasticity: $\gamma > 0$
 Income elasticity: $\varepsilon > 0$

60. The relation between quality-adjusted health volumes (*he*) and health expenditures (*HE*) is as follows:

$$(he) = \frac{HE}{(P/Q)} \quad (\text{A2})$$

Using (A2) to express equation (1) in terms of nominal health expenditures (*HE*) per capita, gives:

$$\left(\frac{HE}{N}\right) = \left(\frac{P}{Q}\right) \cdot \left(\frac{he}{N}\right) = \alpha \cdot \frac{P^{(1+\beta)}}{P_Y^\beta} \cdot Q^{(\gamma-1)} \cdot \left(\frac{Y}{N}\right)^\varepsilon \quad (\text{A3})$$

This nominal demand function can also be expressed as the ratio of health expenditures to GDP:

$$\frac{HE}{P_Y \cdot Y} = \alpha \cdot \left(\frac{P}{P_Y}\right)^{(1+\beta)} \cdot Q^{(\gamma-1)} \cdot \left(\frac{Y}{N}\right)^{(\varepsilon-1)} \quad (\text{A4})$$

Taking the logarithmic growth rates of equation (A4) one gets:

$$\Delta \log \left(\frac{HE}{P_Y \cdot Y}\right) = (1 + \beta) \cdot \Delta \log \left(\frac{P}{P_Y}\right) + (\gamma - 1) \cdot \Delta \log(Q) + (\varepsilon - 1) \cdot \Delta \log \left(\frac{Y}{N}\right) \quad (\text{A5})$$

¹³

To be precise, the health quality effects in equation (A1) should also appear in relative terms *vis-à-vis* the overall quality of goods and services produced in the economy. In some countries, the GDP deflator includes already hedonic prices for some goods, but not yet for health. The effect of the relative quality will be partly captured in our empirical proxy for *Q* (see below).

61. In addition, it is also assumed that health spending depends on a drift factor related to demographic factors (*demo*). In the OECD (2006) projection framework, the effects of prices and quality (technology improvements) were not disentangled and an assumption was made on their combined effect, labelled “health expenditure residual” (*Res*). This approach is also followed in the current set of projections, as the components of the health expenditure residual are difficult to extrapolate in the future. During the projection period, it is assumed that the deflator (P_Y) remains constant (*i.e.* there is no projection of economy-wide inflation), so equation (A5) becomes:

$$\Delta \log \left(\frac{HE}{Y} \right) = \Delta \log(demo) + \Delta \log(Res) + (\varepsilon - 1) \cdot \Delta \log \left(\frac{Y}{N} \right) \quad (A6)$$

This corresponds to equation (1) of the main text. To project health expenditures based on equation (A6), the values for the demographic effects, the expenditure residual and income effects need to be calibrated.

62. The calibration was done in different ways. The demographic effect is calculated using an accounting method and assumptions on the health status of the population, notably a so-called ‘healthy ageing’ regime (see Box 1 in the main text).

63. The ‘health expenditure residual’ is extrapolated as a whole. Its estimation is based on a growth accounting method, which decomposes the past average growth of health expenditures into observed age and income effects (assuming a given value for the income elasticity). This allows deriving the unexplained expenditure residual (Table 2.1 in the main text). To attempt an interpretation of this residual, an econometric equation has also been estimated, incorporating explicitly the effects of prices and a proxy for quality (see below).

64. Accordingly, the income elasticity, as well as the price and quality elasticities, were derived from a panel regression using equation (A1) above (in log terms and expressed in quality-adjusted health volumes per capita), augmented from the drift factors related to demography and exogenous policy factors captured by a time trend (*e.g.* institutional reforms increasing the coverage of the health coverage system):

$$\log \left(\frac{he}{N} \right) = \alpha_c + \theta \cdot \log(Demo) + \beta \cdot \log \left(\frac{P}{P_Y} \right) + \gamma \cdot \log(Q) + \varepsilon \cdot \log \left(\frac{Y}{N} \right) + \tau \cdot T + u \quad (A7)$$

Where α_c correspond to country fixed-effects; T to a time trend; and u a randomly distributed residual. The equation was estimated both in levels and in first differences. The demographic effect is captured by the average age of the population. The quality effect (Q) was loosely proxied by a ratio involving the relative pace of patent creation in the health sector compared with the rest of the economy for the average of OECD countries. This ratio is assumed to represent the change in the technology frontier. To capture country-specific effects related to the diffusion and adoption of technology, the ratio is multiplied by the share of R&D expenditures in GDP:

$$Q = \frac{R\&D}{GDP} \cdot \frac{\text{Total OECD Patents in the Health sector}}{\text{Total OECD patents}} \quad (A8)$$

65. The results of the econometric estimation are relatively robust, with the value of the income elasticity fluctuating from around 0.5 to close to 1, depending on the specifications (see also Appendix 2). The preferred econometric estimate (col. 8 of Table A1.1) gives an estimated elasticity of 0.42 for relative prices (β) and 0.91 for the technology/quality effect (γ). Translating these into expenditure elasticities using

equation (A5), respectively, $(\beta+1)$ and $(1-\gamma)$, and the observed growth rates of (P/P_Y) and (Q) the contribution of these variables to explaining the residual growth can be derived (see Box 3).

Table A1.1 Real public health care expenditure per capita: econometric estimates

	Pooled	Fixed effects with Time dummies	Fixed effects with Time trend	Fixed effects with Time dummies	Fixed effects with Time trend	Fixed effects with Time dummies	Fixed effects with Time dummies	Fixed effects with time trend	Income elasticity =0.8	Memo item: First differences estimates
log(gdpv per capita)	0.914*** (0.02)	0.394** (0.18)	0.495*** (0.13)	0.775*** (0.14)	0.634*** (0.14)	0.964*** (0.14)	0.749*** (0.12)	0.532*** (0.12)		
log (average age of population)	2.603*** (0.56)	3.007*** (0.59)	1.399*** (0.45)	1.396*** (0.42)	2.611*** (0.46)	2.606*** (0.42)	1.342*** (0.41)	1.471*** (0.44)	0.962** (0.43)	
timetr			0.009*** (0.00)		0.009*** (0.00)			0.009*** (0.00)	0.001 (0.00)	
log(GDP deflator)			0.453*** (0.08)	0.482*** (0.08)	0.929*** (0.06)	0.777*** (0.06)				
log(Health prices)			-0.415*** (0.07)	-0.505*** (0.06)						
lagged log(Technology)			0.908*** (0.03)	0.918*** (0.04)			0.919*** (0.04)	0.912*** (0.03)	0.930*** (0.03)	
lagged dlog(Technology)										1.027*** (0.05)
lagged log(quality adjusted health prices)					-0.788*** (0.03)	-0.755*** (0.03)				
log(Relative prices (Health prices/PGDP))							-0.503*** (0.06)	-0.415*** (0.07)	-0.492*** (0.06)	
dlog(gdpv per capita)										0.535*** (0.12)
dlog (average age of population)										1.509 (1.45)
dlog(Relative prices (Health prices/PGDP))										-0.626*** (0.06)
_cons	-11.591*** (2.08)	-7.824*** (2.19)	-3.513** (1.78)	-5.889*** (1.85)	-7.535*** (1.86)	-10.936*** (1.90)	-5.414*** (1.54)	-4.179*** (1.54)	-6.646*** (1.38)	0.006 (0.02)
N	474	474	463	463	453	453	463	463	463	447
r2	0.825	0.863	0.924	0.941	0.913	0.934	0.941	0.924	0.847	0.777
r2_a	0.824	0.845	0.918	0.933	0.906	0.925	0.933	0.918	0.837	0.746

Standard errors in parentheses

=** p<0.10

** p<0.05 *** p<0.01"

Note: Projections are based on the estimates highlighted within the box

II. Adjustment for convergence effects

66. The projection framework (equation A6 above) only projects the logarithmic growth rates of health expenditures to GDP and, as such, does not take into account possible convergence effects associated with differences in the levels of the ratio of health expenditures to GDP in the base period (2006-2010). Indeed, it seems natural that countries that display a rather low health expenditure ratio would tend to converge to OECD average levels, even if their demography, income effects and the residual growth in expenditures are the same. This is particularly important in the context of the projections that do not assume country-specific residual growth in expenditures or income elasticities (as in the baseline assumed in this paper), or for countries that have in the base year a very low level of spending, such as emerging economies.

67. Therefore, the projected (for period t) health spending ratios were adjusted as follows:

$$\left(\frac{HE}{Y}\right)_{i,t} = \left[1 + \left(\frac{(HE/Y)_{OECD,0}}{(HE/Y)_{i,0}}\right) \cdot g_i\right] \cdot \left(\frac{HE}{Y}\right)_{i,0} \quad (9)$$

Where g_i is the logarithmic growth rate of health spending for country i (from period 0 to period t) derived from equation (A6); $\left(\frac{HE}{Y}\right)_{i,0}$ is the health expenditure ratio for country i in the base period; and, $\left(\frac{HE}{Y}\right)_{OECD,0}$ is the health expenditure ratio for the OECD average in the base period.

When the spending ratio of a given country is below (or above) the OECD average for the base year this adjustment will increase (decrease) the projected growth rate of expenditures to GDP, thus allowing for convergence to take place.

III. Estimation of the survivor expenditure curve

68. An average expenditure curve for *survivors* was estimated econometrically in a panel of 23 countries and 20 age groups, using a spline function as follows:

$$\frac{he_{age\ group}}{N_{age\ group}} = -199.1 \cdot age + 14.5 \cdot age^2 - 0.41 \cdot age^3 + 0.005 \cdot age^4 - 0.00002 \cdot age^5$$

Where he is the real health expenditure by age group, N population by age group and age is the central point in each bracket (e.g., 2,7,12,...,97)

For each country, this expenditure curve by age group is multiplied by country-specific population by age group in order to obtain a total country-specific health expenditure. This expenditure is then calibrated to the OECD database total expenditure in the base year.

APPENDIX 2: INCOME ELASTICITY: REVIEW OF LITERATURE

69. Whether health care is a luxury (elasticity above one) or a necessity (elasticity below one) remains an unsettled issue. Since Newhouse (1977), a large part of the economic literature attempts to estimate this elasticity. Getzen (2000) argues that the higher the level of aggregation the higher the income elasticity of health care spending. Table A2.1 provides a summary of several studies. At the individual level the elasticity is found to be below one while at the macro level studies show elasticities greater than one. This high elasticity may result from the failure to control for true price effects.

70. Getzen (2000) argues that empirical studies often failed to distinguish between sources of variation *between* groups and *within* groups: an individual within an insured group may have little incentive to limit health expenditures, especially if the group is large and the individual's effect on the group is insignificant. Thus, an individual's health care spending is insensitive to income. By contrast, the group's total expenditure on health care is limited by its aggregate income. Total group spending will be more responsive to income than individual spending, and wider groups will be even more responsive. See OECD (2006) for a detailed review of these studies.

Table A2.1. Survey of income elasticity estimates of health care expenditures (or utilisation) by level of observation

INDIVIDUALS (micro)	Income elasticity
<i>General (insured/mixed)</i>	
Newhouse and Phelps (1976)	≤ 0.1
AMA (1978)	≈ 0
Sunshine and Dicker (1987)	≈ 0
Manning <i>et al.</i> (1987)	≈ 0
Wedig (1988)	≈ 0
Wagstaff <i>et al.</i> (1991)	≤ 0
Hahn and Lefkowitz (1992)	≤ 0
AHCPR (1997)	≤ 0
<i>Special / uninsured</i>	
Falk <i>et al.</i> (1933)	0.7
Weeks (1961)	0.3
Anderson <i>et al.</i> (1960) (1953 data)	0.4
Anderson <i>et al.</i> (1960) (1958 data)	0.2
<i>Other</i>	
USPHS (1960) (physician visits)	0.1
USPHS (1960) (dental visits)	0.8
AMA (1978) (dental expenses)	1.0-1.7
Andersen and Benham (1970) (physician expenses)	0.4
Andersen and Benham (1970) (dental expenses)	1.2
Silver (1970) (physician expenses)	0.85
Silver (1970) (dental expenses)	2.4-3.2
Newman and Anderson (1972) (dental expenses)	0.8
Feldstein (1973) (dental expenses)	1.2
Scanlon (1980) (Nursing home expenses)	2.2
Sunshine and Dicker (1987) (dental expenses)	0.7-1.5
Hahn and Lefkowitz (1992) (dental expenses)	1.0
AHCPR (1997) (dental expenses)	1.1
Parker and Wong (1997) (Mexico, total expenses)	0.9-1.6
REGIONS (intermediate)	
Feldstein (1971) (47 states, 1958-1967, \$hospital)	0.5

Fuchs and Kramer (1972) (33 states, 1966, \$physician)	0.9
Levit (1982) (50 states, 1966, 1978, \$total)	0.9
McLaughlin (1987) (25 SMSAs, 1972-1982, \$hospital)	0.7
Baker (1997) (3073 US counties, 1986-1990, \$Medicare)	0.8
Di Matteo and Di Matteo (1998) (10 Canadian provinces 1965-1991)	0.8
NATIONS (macro)	
Abel-Smith (1967) (33 countries, 1961)	1.3
Kleiman (1974) (16 countries, 1968)	1.2
Newhouse (1977) (13 countries, 1972)	1.3
Maxwell (1981) (10 countries, 1975)	1.4
Gertler and van der Gaag (1990) (25 countries, 1975)	1.3
Getzen (1990) (US, 1966-1987)	1.6
Schieber (1990) (seven countries, 1960-1987)	1.2
Gerdtham <i>et al.</i> (1992) (19 countries, 1987)	1.2
Getzen and Poullier (1992) (19 countries, 1965-1986)	1.4
Fogel (1999) (United States, long run)	1.6

Source: Getzen (2000).

71. Dormont *et al.* (2011) present new evidence on the elasticity of per capita public, private and total health care services. They argue that the income elasticity depends on the type of health care spending. Using pooled OLS estimation, they found income elasticity below or close to one in the case of per capita private health expenditures, whereas it exceeds one when considering per capita public or total health expenditures. The inclusion of a common trend or time dummies over sub-periods leads to a decrease of the latter income elasticity, though it remains largely above one.

72. These cross-sectional estimates use an implicit assumption of homogeneity across countries that seems unrealistic. To address this drawback the authors use panel estimation techniques. When controlling for individual fixed-effects, the inclusion of a common time trend significantly reduces the income elasticity to below one. This result is more robust than that of the pooled OLS. Testing a one-way error component model in the individual variables for each type of per capita health care expenditure, the authors find results that are fairly close to those of the one-way fixed effects model. Overall, results confirm that the inclusion of a common trend significantly lowers the income elasticity (below one).

Potential bias in the estimation

73. The estimation of income elasticity may be biased for several reasons. The omission of variables (for instance, technological progress) may bias the estimation upward. Similarly, a misleading specification used to estimate the parameter may also provide biased results. For instance, a vast literature stresses that the results are strongly dependent on the non-stationarity and co-integration properties of the variables. Moreover, the causal relationship between income and health is not always well defined.

74. Despite the empirical evidence suggesting a long-run relationship between health expenditure and income, there is a risk for omitted variables. Recent studies have indicated that the observed increasing health care expenditure as a share of GDP may also be due to other factors, such as technological change or insurance coverage (Hall and Jones, 2007; Okunade and Murthy, 2002; Blomqvist and Carter, 1997). Technological advances could provide an explanation for the high estimates of income elasticity found at the macro level in the literature. On the other hand, Di Matteo and Di Matteo (1998) argue that because health care is labour intensive, its cost may increase as a function of average income, so that measured income elasticity is blurred by the price effect. Since the price elasticity is presumably negative, the income coefficient is likely to be biased downward.

75. According to Acemoglu *et al.* (2009), most of the studies are based on simple correlations between income and health expenditure across individuals, across countries and over time. Their study provides causal estimates of the effect of income on aggregate health spending in US regions. Their strategy is to instrument local area income with the variation of oil prices weighted by oil reserves. Their central estimate for the income elasticity is 0.7, with a maximum bound at 95% interval of 1.1. This result is robust to different specifications with the elasticity being almost always below one (see Table A2.2).

76. Using a dataset of health care expenditures and disposable personal income for the states in the United States over the years 1986-1998, Freeman (2003) finds that health care expenditures and incomes at state level are non-stationary and co-integrated and estimated income elasticity of health care at 0.817 to 0.844. These findings are close to the estimates of Di Matteo and Di Matteo (1998) for Canadian provincial data.

77. Moscone and Tosetti (2010) investigated the long-run economic relationship between health care expenditure and income in the United States at state level. Their estimation controls for cross-section dependence and unobserved heterogeneity. As others in the literature they find health expenditure and income to be non-stationary and co-integrated. Their elasticity estimates across states vary widely. However in the majority of them, the elasticity is lower than one. Their result suggests that health is a necessity rather than a luxury.

78. According to Atella and Marini (2004), the disagreement about income elasticity comes from two sources: the inclusion of specific regressors and functional specification used to estimate the parameter. Their survey does not find a single answer to the question of the value of the elasticity. When assuming homoskedasticity and no-correlation in errors, the authors find elasticities always greater than unity. Under the assumption of heteroskedastic and autocorrelated errors and of cross-country correlation, income elasticities are found to be lower than one.

79. Using panel co-integration techniques, Dreger and Reimers (2005) incorporate medical progress in their model, proxied by variables such as life expectancy or infant mortality. They find that the income elasticity should not be too different from one. This result confirms that the income elasticity may be biased upward if the role of technology is not taken into account.

80. According to Baltagi and Moscone (2010), while income has been recognised as an important determinant of health care spending, there is no consensus on which other factors may influence health expenditure. Using a panel of 20 OECD countries, the authors studied the non-stationarity and co-integration properties of health expenditure and income. Their findings suggest that health care is a necessity rather than a luxury with estimated income elasticities much smaller than in other studies.

81. Using a co-integrated panel data regression approach, Bech *et al.* (2011) derived short-run as well as long-run relationships between health expenditure and explanatory variables in the EU-15 countries. Among those explanatory variables are economic, social, demographic and institutional variables and also variables related to capacity and production technology in the health care sector. They find life expectancy to be a more important driver than ageing. Regarding income, after having checked that both GDP and health expenditure are non-stationary, the authors show that the two variables are co-integrated. They find a unitary income elasticity of health care accounting for the dynamic structure of the relationship between health expenditure and GDP.

82. Narayan *et al.* (2011) examine whether health-care expenditure is a luxury or a necessity for OECD countries within a panel unit root and panel co-integration framework. They first calculate real health expenditure using the GDP deflator, and then they use a specific health-care price index. Based on real expenditure deflated by the GDP deflator, they find that both health expenditure and GDP contain a

panel unit root and are co-integrated when a time trend is included in the model. The authors find that GDP has a positive and statistically significant effect on health but obtain mixed results concerning the income elasticity by country. For the panel as a whole the income elasticity is around one. Based on real expenditure deflated by the health deflator, GDP and health spending are found to be non-stationary and co-integrated with and without a trend. For the panel as a whole the elasticity of health with respect to GDP is less than one. The fact that the coefficients on GDP have changed when the GDP deflator is replaced by an health price index casts doubt on the reliability of the results using the GDP deflator. The authors conclude that there is no support for the proposition that health care is a luxury.

Table A2.2. Selected recent income elasticity estimates of health care expenditures

Papers	Elasticity
Acemoglu <i>et al.</i> (2009)	≈0.7
Baltagi and Moscone (2010)	<1
Bech <i>et al.</i> (2011)	≈1
Dreger and Reimers (2005)	≈1
Dormont <i>et al.</i> (2011)	>1
Freeman (2003) (US States level)	≈0.8
Moscone and Tosetti (2010) (US States level)	<1
Narayan <i>et al.</i> (2011)	
HE deflated by PGDP	≈1
HE deflated by Health price	<1

Source: Secretariat's compilation.

83. This non-exhaustive literature review suggests that the estimation of the income elasticity of health expenditure is not straightforward. Whether health care is a luxury or a necessity remains an unsettled issue. Results partly depend on the other determinants of health spending that are taken into account in the estimation and on the econometric techniques that are used.

APPENDIX 3. ESTIMATIONS TO CALIBRATE THE LTC FRAMEWORK

Table A3.1. Dependency ratio: econometric estimates

Dependent variable			
Ratio of dependents by age group			
	(1)	(2)	(3)
	Pooled	Fixed effects	Random effects
Age	6.072*** (0.16)	5.709*** (0.19)	5.926*** (0.17)
Health expenditure	0.189*** (0.05)	0.449*** (0.10)	0.294*** (0.08)
Life expectancy at birth	-6.270*** (1.37)	.	-7.421*** (1.68)
_cons	2.515 (6.13)	-25.467*** (0.62)	7.330 (7.30)
N	180.000	180.000	180.000
Standard errors in parentheses			
="** p<0.10 ** p<0.05 *** p<0.01"			

Table A3.2. LTC expenditure: econometric estimates

Dependent variable : LTC as a % of GDP

	Pooled	Pooled	Pooled	Pooled	Pooled
Old age dependency ratio (People aged 80 and plus)	2.359*** (0.18)	2.308*** (0.17)	1.553*** (0.18)	1.668*** (0.17)	1.645*** (0.19)
Participation rate of women aged 50-64		0.419** (0.18)	0.704*** (0.17)	0.382** (0.18)	
Productivity (total economy)			2.073*** (0.25)		2.107*** (0.29)
GDP per capita				1.682*** (0.19)	
Exit rate from employment of women aged 50-64					-0.144* (0.08)
_cons	7.243*** (0.59)	7.346*** (0.58)	-17.802*** (3.06)	-12.065*** (2.27)	-18.696*** (3.53)
N	360.000	355.000	340.000	340.000	298.000
Standard errors in parentheses					
="** p<0.10 ** p<0.05 *** p<0.01"					

APPENDIX 4. DETAILED SCENARIO RESULTS FOR HEALTH AND LONG-TERM CARE

Table A4.1. Breakdown of the projections of public health care expenditure for each driver
(Demographic scenario)

	Health expenditure as a % of GDP	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Health expenditure as a % of GDP
	Average 2006-2010	Increase in % points of GDP 2010-2030					Increase in % points of GDP 2010-2060					2060		
Australia	5.6	0.2	0.5	-0.3	0.0	0.0	0.4	0.5	1.0	-0.6	0.0	0.0	0.8	6.4
Austria	6.6	0.2	0.5	-0.3	0.0	0.0	0.4	0.4	1.0	-0.9	0.0	0.0	0.6	7.2
Belgium	5.8	0.2	0.3	-0.3	0.0	0.0	0.2	0.3	0.7	-0.8	0.0	0.0	0.2	6.0
Canada	5.8	0.3	0.6	-0.3	0.0	0.0	0.6	0.5	0.9	-0.7	0.0	0.0	0.7	6.6
Chile	3.1	0.4	0.8	-0.2	0.0	0.0	0.9	0.7	1.8	-0.7	0.0	0.0	1.8	4.9
Czech Republic	5.5	0.3	0.6	-0.4	0.0	0.0	0.4	0.5	1.2	-1.0	0.0	0.0	0.7	6.2
Denmark	6.3	0.2	0.5	-0.3	0.0	0.0	0.4	0.3	0.8	-0.8	0.0	0.0	0.3	6.5
Estonia	4.3	0.2	0.4	-0.4	0.0	0.0	0.2	0.3	1.1	-0.8	0.0	0.0	0.6	4.9
Finland	5.2	0.2	0.5	-0.4	0.0	0.0	0.4	0.3	0.7	-0.7	0.0	0.0	0.3	5.6
France	7.4	0.1	0.5	-0.3	0.0	0.0	0.3	0.3	0.8	-0.8	0.0	0.0	0.3	7.7
Germany	7.3	0.2	0.6	-0.4	0.0	0.0	0.5	0.4	1.0	-0.9	0.0	0.0	0.6	7.8
Greece	5.4	0.2	0.4	-0.3	0.0	0.0	0.3	0.4	1.0	-0.8	0.0	0.0	0.7	6.0
Hungary	4.8	0.2	0.5	-0.5	0.0	0.0	0.2	0.4	1.3	-1.3	0.0	0.0	0.4	5.2
Iceland	5.8	0.0	0.5	-0.3	0.0	0.0	0.3	0.1	0.7	-0.6	0.0	0.0	0.2	6.1
Israel	4.0	0.2	0.4	-0.3	0.0	0.0	0.3	0.5	0.9	-0.7	0.0	0.0	0.7	4.8
Ireland	5.5	0.1	0.5	-0.3	0.0	0.0	0.3	0.3	1.0	-0.8	0.0	0.0	0.5	6.1
Italy	6.1	0.2	0.4	-0.3	0.0	0.0	0.3	0.4	1.0	-0.7	0.0	0.0	0.7	6.8
Japan	6.1	0.3	0.7	-0.3	0.0	0.0	0.6	0.4	1.0	-0.7	0.0	0.0	0.8	6.9
Korea	3.3	0.4	1.1	-0.4	0.0	0.0	1.1	0.8	2.1	-0.8	0.0	0.0	2.0	5.4
Luxembourg	4.4	0.2	0.5	-0.3	0.0	0.0	0.4	0.5	1.1	-0.9	0.0	0.0	0.7	5.1
Mexico	2.5	0.2	0.7	-0.3	0.0	0.0	0.6	0.5	2.0	-0.9	0.0	0.0	1.6	4.2
Netherlands	6.4	0.3	0.6	-0.3	0.0	0.0	0.6	0.4	1.0	-0.8	0.0	0.0	0.7	7.1
New Zealand	6.4	0.3	0.5	-0.3	0.0	0.0	0.5	0.5	1.0	-0.6	0.0	0.0	0.8	7.2
Norway	5.1	0.2	0.4	-0.3	0.0	0.0	0.3	0.4	0.8	-0.7	0.0	0.0	0.5	5.6
Poland	4.1	0.3	0.7	-0.5	0.0	0.0	0.4	0.5	1.7	-1.3	0.0	0.0	1.0	5.1
Portugal	6.5	0.2	0.5	-0.4	0.0	0.0	0.4	0.5	1.2	-0.9	0.0	0.0	0.8	7.3
Slovak Republic	5.4	0.3	0.7	-0.5	0.0	0.0	0.5	0.7	1.8	-1.4	0.0	0.0	1.1	6.5
Slovenia	5.2	0.3	0.6	-0.4	0.0	0.0	0.5	0.5	1.2	-0.7	0.0	0.0	1.0	6.2
Spain	5.6	0.2	0.5	-0.3	0.0	0.0	0.4	0.5	1.3	-0.8	0.0	0.0	1.0	6.6
Sweden	6.6	0.2	0.3	-0.3	0.0	0.0	0.2	0.3	0.6	-0.7	0.0	0.0	0.3	6.8
Switzerland	5.7	0.2	0.5	-0.3	0.0	0.0	0.4	0.5	1.1	-0.8	0.0	0.0	0.9	6.6
Turkey	3.8	0.4	0.7	-0.3	0.0	0.0	0.7	0.8	1.9	-1.0	0.0	0.0	1.8	5.6
United Kingdom	6.5	0.1	0.3	-0.3	0.0	0.0	0.2	0.3	0.7	-0.7	0.0	0.0	0.2	6.8
United States	7.1	0.2	0.5	-0.3	0.0	0.0	0.4	0.3	0.7	-0.6	0.0	0.0	0.5	7.5
OECD average¹	5.5	0.2	0.5	-0.4	0.0	0.0	0.4	0.4	1.1	-0.8	0.0	0.0	0.8	6.2
Brazil	3.7	0.3	0.8	-0.3	0.0	0.0	0.8	0.6	2.1	-1.0	0.0	0.0	1.7	5.4
China	1.9	0.4	0.9	-0.4	0.0	0.0	0.9	0.7	2.0	-1.1	0.0	0.0	1.7	3.6
India	1.2	0.2	0.5	-0.4	0.0	0.0	0.3	0.6	1.5	-1.2	0.0	0.0	0.9	2.1
Indonesia	1.2	0.3	0.7	-0.4	0.0	0.0	0.6	0.7	2.0	-1.3	0.0	0.0	1.3	2.5
Russia	3.1	0.2	0.4	-0.4	0.0	0.0	0.1	0.3	0.9	-1.0	0.0	0.0	0.2	3.3
South Africa	3.2	0.1	0.4	-0.5	0.0	0.0	0.0	0.3	1.1	-1.4	0.0	0.0	0.0	3.2
Non-OECD average¹	2.4	0.2	0.6	-0.4	0.0	0.0	0.5	0.5	1.6	-1.2	0.0	0.0	1.0	3.4
Total average¹	5.0	0.2	0.5	-0.4	0.0	0.0	0.4	0.5	1.2	-0.9	0.0	0.0	0.8	5.8

Table A4.2. Breakdown of the projections of public health care expenditure for each driver

Cost-pressure scenario

	Health expenditure as a % of GDP	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Health expenditure as a % of GDP
	Average 2006-2010	Increase in % points of GDP 2010-2030						Increase in % points of GDP 2010-2060						2060
Australia	5.6	0.2	0.5	-0.3	-0.4	1.9	2.0	0.5	1.0	-0.6	-0.8	6.3	6.3	12.0
Austria	6.6	0.2	0.5	-0.3	-0.2	1.9	2.1	0.4	1.0	-0.9	-0.6	6.3	6.3	12.9
Belgium	5.8	0.2	0.3	-0.3	-0.3	1.9	1.8	0.3	0.7	-0.8	-0.7	6.3	5.8	11.6
Canada	5.8	0.3	0.6	-0.3	-0.3	1.9	2.2	0.5	0.9	-0.7	-0.7	6.3	6.3	12.2
Chile	3.1	0.4	0.8	-0.2	-0.6	1.9	2.3	0.7	1.8	-0.7	-1.1	6.3	7.1	10.2
Czech Republic	5.5	0.3	0.6	-0.4	-0.5	1.9	1.9	0.5	1.2	-1.0	-0.9	6.3	6.1	11.6
Denmark	6.3	0.2	0.5	-0.3	-0.2	1.9	2.1	0.3	0.8	-0.8	-0.7	6.3	5.9	12.2
Estonia	4.3	0.2	0.4	-0.4	-0.5	1.9	1.6	0.3	1.1	-0.8	-1.1	6.3	5.8	10.1
Finland	5.2	0.2	0.5	-0.4	-0.3	1.9	2.0	0.3	0.7	-0.7	-0.7	6.3	5.9	11.2
France	7.4	0.1	0.5	-0.3	-0.3	1.9	1.9	0.3	0.8	-0.8	-0.6	6.3	6.1	13.5
Germany	7.3	0.2	0.6	-0.4	-0.3	1.9	2.1	0.4	1.0	-0.9	-0.7	6.3	6.2	13.5
Greece	5.4	0.2	0.4	-0.3	-0.3	1.9	1.9	0.4	1.0	-0.8	-0.6	6.3	6.4	11.8
Hungary	4.8	0.2	0.5	-0.5	-0.5	1.9	1.6	0.4	1.3	-1.3	-1.0	6.3	5.8	10.6
Iceland	5.8	0.0	0.5	-0.3	-0.2	1.9	2.0	0.1	0.7	-0.6	-0.7	6.3	5.9	11.7
Israel	4.0	0.2	0.4	-0.3	-0.2	1.9	2.0	0.5	0.9	-0.7	-0.7	6.3	6.4	10.4
Ireland	5.5	0.1	0.5	-0.3	-0.2	1.9	2.1	0.3	1.0	-0.8	-0.5	6.3	6.4	11.9
Italy	6.1	0.2	0.4	-0.3	-0.2	1.9	2.1	0.4	1.0	-0.7	-0.6	6.3	6.4	12.6
Japan	6.1	0.3	0.7	-0.3	-0.3	1.9	2.3	0.4	1.0	-0.7	-0.8	6.3	6.3	12.5
Korea	3.3	0.4	1.1	-0.4	-0.5	1.9	2.6	0.8	2.1	-0.8	-0.8	6.3	7.6	10.9
Luxembourg	4.4	0.2	0.5	-0.3	-0.1	1.9	2.2	0.5	1.1	-0.9	-0.2	6.3	6.9	11.3
Mexico	2.5	0.2	0.7	-0.3	-0.5	1.9	2.1	0.5	2.0	-0.9	-1.1	6.3	6.9	9.4
Netherlands	6.4	0.3	0.6	-0.3	-0.3	1.9	2.2	0.4	1.0	-0.8	-0.7	6.3	6.3	12.7
New Zealand	6.4	0.3	0.5	-0.3	-0.3	1.9	2.1	0.5	1.0	-0.6	-0.9	6.3	6.3	12.7
Norway	5.1	0.2	0.4	-0.3	-0.4	1.9	1.9	0.4	0.8	-0.7	-0.7	6.3	6.1	11.2
Poland	4.1	0.3	0.7	-0.5	-0.5	1.9	1.9	0.5	1.7	-1.3	-0.9	6.3	6.4	10.5
Portugal	6.5	0.2	0.5	-0.4	-0.2	1.9	2.0	0.5	1.2	-0.9	-0.7	6.3	6.5	13.0
Slovak Republic	5.4	0.3	0.7	-0.5	-0.5	1.9	1.9	0.7	1.8	-1.4	-0.9	6.3	6.5	11.9
Slovenia	5.2	0.3	0.6	-0.4	-0.3	1.9	2.1	0.5	1.2	-0.7	-0.8	6.3	6.6	11.8
Spain	5.6	0.2	0.5	-0.3	-0.3	1.9	2.0	0.5	1.3	-0.8	-0.6	6.3	6.7	12.3
Sweden	6.6	0.2	0.3	-0.3	-0.3	1.9	1.8	0.3	0.6	-0.7	-0.7	6.3	5.9	12.4
Switzerland	5.7	0.2	0.5	-0.3	-0.3	1.9	2.1	0.5	1.1	-0.8	-0.8	6.3	6.5	12.2
Turkey	3.8	0.4	0.7	-0.3	-0.6	1.9	2.0	0.8	1.9	-1.0	-1.1	6.3	7.0	10.9
United Kingdom	6.5	0.1	0.3	-0.3	-0.2	1.9	1.9	0.3	0.7	-0.7	-0.7	6.3	5.9	12.4
United States	7.1	0.2	0.5	-0.3	-0.3	1.9	2.0	0.3	0.7	-0.6	-0.7	6.3	6.1	13.2
OECD average¹	5.5	0.2	0.5	-0.4	-0.3	1.9	2.0	0.4	1.1	-0.8	-0.8	6.3	6.3	11.8
Brazil	3.7	0.3	0.8	-0.3	-0.6	1.9	2.1	0.6	2.1	-1.0	-1.1	6.3	7.0	10.7
China	1.9	0.4	0.9	-0.4	-1.1	1.9	1.7	0.7	2.0	-1.1	-1.7	6.3	6.4	8.3
India	1.2	0.2	0.5	-0.4	-1.0	1.9	1.3	0.6	1.5	-1.2	-1.7	6.3	5.5	6.7
Indonesia	1.2	0.3	0.7	-0.4	-0.8	1.9	1.7	0.7	2.0	-1.3	-1.5	6.3	6.2	7.3
Russia	3.1	0.2	0.4	-0.4	-0.6	1.9	1.5	0.3	0.9	-1.0	-1.0	6.3	5.5	8.6
South Africa	3.2	0.1	0.4	-0.5	-0.6	1.9	1.4	0.3	1.1	-1.4	-1.2	6.3	5.2	8.4
Non-OECD average¹	2.4	0.2	0.6	-0.4	-0.8	1.9	1.6	0.5	1.6	-1.2	-1.4	6.3	5.9	8.3
Total average¹	5.0	0.2	0.5	-0.4	-0.4	1.9	2.0	0.5	1.2	-0.9	-0.8	6.3	6.3	11.3

Table A4.3. Breakdown of the projections of public health care expenditure for each driver

Cost-containment scenario

	Health expenditure as a % of GDP	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Health expenditure as a % of GDP
	Average 2006-2010	Increase in % points of GDP 2010-2030						Increase in % points of GDP 2010-2060						2060
Australia	5.6	0.2	0.5	-0.3	-0.4	1.5	1.5	0.5	1.0	-0.6	-0.8	2.5	2.5	8.1
Austria	6.6	0.2	0.5	-0.3	-0.2	1.5	1.7	0.4	1.0	-0.9	-0.6	2.5	2.4	9.1
Belgium	5.8	0.2	0.3	-0.3	-0.3	1.5	1.4	0.3	0.7	-0.8	-0.7	2.5	1.9	7.7
Canada	5.8	0.3	0.6	-0.3	-0.3	1.5	1.8	0.5	0.9	-0.7	-0.7	2.5	2.5	8.3
Chile	3.1	0.4	0.8	-0.2	-0.6	1.5	1.8	0.7	1.8	-0.7	-1.1	2.5	3.2	6.3
Czech Republic	5.5	0.3	0.6	-0.4	-0.5	1.5	1.4	0.5	1.2	-1.0	-0.9	2.5	2.2	7.7
Denmark	6.3	0.2	0.5	-0.3	-0.2	1.5	1.6	0.3	0.8	-0.8	-0.7	2.5	2.0	8.3
Estonia	4.3	0.2	0.4	-0.4	-0.5	1.5	1.1	0.3	1.1	-0.8	-1.1	2.5	2.0	6.2
Finland	5.2	0.2	0.5	-0.4	-0.3	1.5	1.5	0.3	0.7	-0.7	-0.7	2.5	2.0	7.3
France	7.4	0.1	0.5	-0.3	-0.3	1.5	1.4	0.3	0.8	-0.8	-0.6	2.5	2.2	9.6
Germany	7.3	0.2	0.6	-0.4	-0.3	1.5	1.6	0.4	1.0	-0.9	-0.7	2.5	2.3	9.6
Greece	5.4	0.2	0.4	-0.3	-0.3	1.5	1.4	0.4	1.0	-0.8	-0.6	2.5	2.5	7.9
Hungary	4.8	0.2	0.5	-0.5	-0.5	1.5	1.2	0.4	1.3	-1.3	-1.0	2.5	1.9	6.7
Iceland	5.8	0.0	0.5	-0.3	-0.2	1.5	1.5	0.1	0.7	-0.6	-0.7	2.5	2.0	7.8
Israel	4.0	0.2	0.4	-0.3	-0.2	1.5	1.5	0.5	0.9	-0.7	-0.7	2.5	2.5	6.6
Ireland	5.5	0.1	0.5	-0.3	-0.2	1.5	1.6	0.3	1.0	-0.8	-0.5	2.5	2.5	8.0
Italy	6.1	0.2	0.4	-0.3	-0.2	1.5	1.6	0.4	1.0	-0.7	-0.6	2.5	2.6	8.7
Japan	6.1	0.3	0.7	-0.3	-0.3	1.5	1.8	0.4	1.0	-0.7	-0.8	2.5	2.5	8.6
Korea	3.3	0.4	1.1	-0.4	-0.5	1.5	2.1	0.8	2.1	-0.8	-0.8	2.5	3.7	7.0
Luxembourg	4.4	0.2	0.5	-0.3	-0.1	1.5	1.7	0.5	1.1	-0.9	-0.2	2.5	3.0	7.4
Mexico	2.5	0.2	0.7	-0.3	-0.5	1.5	1.6	0.5	2.0	-0.9	-1.1	2.5	3.0	5.5
Netherlands	6.4	0.3	0.6	-0.3	-0.3	1.5	1.8	0.4	1.0	-0.8	-0.7	2.5	2.4	8.8
New Zealand	6.4	0.3	0.5	-0.3	-0.3	1.5	1.6	0.5	1.0	-0.6	-0.9	2.5	2.4	8.8
Norway	5.1	0.2	0.4	-0.3	-0.4	1.5	1.4	0.4	0.8	-0.7	-0.7	2.5	2.2	7.3
Poland	4.1	0.3	0.7	-0.5	-0.5	1.5	1.4	0.5	1.7	-1.3	-0.9	2.5	2.6	6.7
Portugal	6.5	0.2	0.5	-0.4	-0.2	1.5	1.6	0.5	1.2	-0.9	-0.7	2.5	2.6	9.1
Slovak Republic	5.4	0.3	0.7	-0.5	-0.5	1.5	1.5	0.7	1.8	-1.4	-0.9	2.5	2.6	8.0
Slovenia	5.2	0.3	0.6	-0.4	-0.3	1.5	1.7	0.5	1.2	-0.7	-0.8	2.5	2.7	7.9
Spain	5.6	0.2	0.5	-0.3	-0.3	1.5	1.6	0.5	1.3	-0.8	-0.6	2.5	2.8	8.5
Sweden	6.6	0.2	0.3	-0.3	-0.3	1.5	1.3	0.3	0.6	-0.7	-0.7	2.5	2.0	8.6
Switzerland	5.7	0.2	0.5	-0.3	-0.3	1.5	1.6	0.5	1.1	-0.8	-0.8	2.5	2.6	8.3
Turkey	3.8	0.4	0.7	-0.3	-0.6	1.5	1.5	0.8	1.9	-1.0	-1.1	2.5	3.1	7.0
United Kingdom	6.5	0.1	0.3	-0.3	-0.2	1.5	1.4	0.3	0.7	-0.7	-0.7	2.5	2.0	8.5
United States	7.1	0.2	0.5	-0.3	-0.3	1.5	1.5	0.3	0.7	-0.6	-0.7	2.5	2.2	9.3
OECD average¹	5.5	0.2	0.5	-0.4	-0.3	1.5	1.6	0.4	1.1	-0.8	-0.8	2.5	2.5	7.9
Brazil	3.7	0.3	0.8	-0.3	-0.6	1.5	1.6	0.6	2.1	-1.0	-1.1	2.5	3.1	6.8
China	1.9	0.4	0.9	-0.4	-1.1	1.5	1.3	0.7	2.0	-1.1	-1.7	2.5	2.5	4.4
India	1.2	0.2	0.5	-0.4	-1.0	1.5	0.8	0.6	1.5	-1.2	-1.7	2.5	1.6	2.8
Indonesia	1.2	0.3	0.7	-0.4	-0.8	1.5	1.3	0.7	2.0	-1.3	-1.5	2.5	2.3	3.5
Russia	3.1	0.2	0.4	-0.4	-0.6	1.5	1.0	0.3	0.9	-1.0	-1.0	2.5	1.6	4.7
South Africa	3.2	0.1	0.4	-0.5	-0.6	1.5	0.9	0.3	1.1	-1.4	-1.2	2.5	1.3	4.5
Non-OECD average¹	2.4	0.2	0.6	-0.4	-0.8	1.5	1.2	0.5	1.6	-1.2	-1.4	2.5	2.1	4.4
Total average¹	5.0	0.2	0.5	-0.4	-0.4	1.5	1.5	0.5	1.2	-0.9	-0.8	2.5	2.4	7.4

Table A4.4. Breakdown of the projections of public health care expenditure for each driver

Sensitivity analysis: income elasticity = 0.6

	Health expenditure as a % of GDP	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Health expenditure as a % of GDP
	Average 2006-2010	Increase in % points of GDP 2010-2030					Increase in % points of GDP 2010-2060					2060		
Australia	5.6	0.2	0.5	-0.3	-0.7	1.5	1.2	0.5	1.0	-0.6	-1.5	2.5	1.8	7.4
Austria	6.6	0.2	0.5	-0.3	-0.5	1.5	1.4	0.4	1.0	-0.9	-1.1	2.5	1.9	8.5
Belgium	5.8	0.2	0.3	-0.3	-0.5	1.5	1.1	0.3	0.7	-0.8	-1.3	2.5	1.3	7.1
Canada	5.8	0.3	0.6	-0.3	-0.5	1.5	1.5	0.5	0.9	-0.7	-1.4	2.5	1.8	7.7
Chile	3.1	0.4	0.8	-0.2	-1.1	1.5	1.3	0.7	1.8	-0.7	-1.9	2.5	2.4	5.4
Czech Republic	5.5	0.3	0.6	-0.4	-0.9	1.5	1.0	0.5	1.2	-1.0	-1.7	2.5	1.5	7.0
Denmark	6.3	0.2	0.5	-0.3	-0.4	1.5	1.5	0.3	0.8	-0.8	-1.3	2.5	1.4	7.7
Estonia	4.3	0.2	0.4	-0.4	-1.0	1.5	0.6	0.3	1.1	-0.8	-2.0	2.5	1.1	5.4
Finland	5.2	0.2	0.5	-0.4	-0.6	1.5	1.2	0.3	0.7	-0.7	-1.3	2.5	1.4	6.7
France	7.4	0.1	0.5	-0.3	-0.6	1.5	1.2	0.3	0.8	-0.8	-1.1	2.5	1.6	9.0
Germany	7.3	0.2	0.6	-0.4	-0.6	1.5	1.4	0.4	1.0	-0.9	-1.3	2.5	1.8	9.0
Greece	5.4	0.2	0.4	-0.3	-0.6	1.5	1.2	0.4	1.0	-0.8	-1.2	2.5	2.0	7.3
Hungary	4.8	0.2	0.5	-0.5	-0.9	1.5	0.7	0.4	1.3	-1.3	-1.8	2.5	1.2	5.9
Iceland	5.8	0.0	0.5	-0.3	-0.4	1.5	1.3	0.1	0.7	-0.6	-1.3	2.5	1.4	7.2
Israel	4.0	0.2	0.4	-0.3	-0.5	1.5	1.3	0.5	0.9	-0.7	-1.2	2.5	2.0	6.0
Ireland	5.5	0.1	0.5	-0.3	-0.4	1.5	1.4	0.3	1.0	-0.8	-0.9	2.5	2.1	7.6
Italy	6.1	0.2	0.4	-0.3	-0.3	1.5	1.4	0.4	1.0	-0.7	-1.1	2.5	2.1	8.2
Japan	6.1	0.3	0.7	-0.3	-0.5	1.5	1.5	0.4	1.0	-0.7	-1.4	2.5	1.8	7.9
Korea	3.3	0.4	1.1	-0.4	-0.9	1.5	1.7	0.8	2.1	-0.8	-1.5	2.5	3.0	6.3
Luxembourg	4.4	0.2	0.5	-0.3	-0.3	1.5	1.6	0.5	1.1	-0.9	-0.3	2.5	2.9	7.3
Mexico	2.5	0.2	0.7	-0.3	-0.9	1.5	1.2	0.5	2.0	-0.9	-1.9	2.5	2.2	4.7
Netherlands	6.4	0.3	0.6	-0.3	-0.6	1.5	1.5	0.4	1.0	-0.8	-1.3	2.5	1.8	8.2
New Zealand	6.4	0.3	0.5	-0.3	-0.6	1.5	1.3	0.5	1.0	-0.6	-1.6	2.5	1.7	8.1
Norway	5.1	0.2	0.4	-0.3	-0.7	1.5	1.1	0.4	0.8	-0.7	-1.4	2.5	1.6	6.7
Poland	4.1	0.3	0.7	-0.5	-0.9	1.5	1.0	0.5	1.7	-1.3	-1.6	2.5	1.9	6.0
Portugal	6.5	0.2	0.5	-0.4	-0.5	1.5	1.3	0.5	1.2	-0.9	-1.2	2.5	2.0	8.5
Slovak Republic	5.4	0.3	0.7	-0.5	-1.0	1.5	1.0	0.7	1.8	-1.4	-1.7	2.5	1.9	7.3
Slovenia	5.2	0.3	0.6	-0.4	-0.6	1.5	1.4	0.5	1.2	-0.7	-1.4	2.5	2.1	7.3
Spain	5.6	0.2	0.5	-0.3	-0.6	1.5	1.3	0.5	1.3	-0.8	-1.2	2.5	2.3	7.9
Sweden	6.6	0.2	0.3	-0.3	-0.7	1.5	1.0	0.3	0.6	-0.7	-1.4	2.5	1.3	7.9
Switzerland	5.7	0.2	0.5	-0.3	-0.5	1.5	1.4	0.5	1.1	-0.8	-1.4	2.5	1.9	7.6
Turkey	3.8	0.4	0.7	-0.3	-1.2	1.5	1.0	0.8	1.9	-1.0	-1.9	2.5	2.3	6.1
United Kingdom	6.5	0.1	0.3	-0.3	-0.5	1.5	1.2	0.3	0.7	-0.7	-1.3	2.5	1.4	7.9
United States	7.1	0.2	0.5	-0.3	-0.5	1.5	1.3	0.3	0.7	-0.6	-1.3	2.5	1.7	8.7
OECD average¹	5.5	0.2	0.5	-0.4	-0.6	1.5	1.2	0.4	1.1	-0.8	-1.4	2.5	1.8	7.3
Brazil	3.7	0.3	0.8	-0.3	-1.2	1.5	1.1	0.6	2.1	-1.0	-2.0	2.5	2.2	5.9
China	1.9	0.4	0.9	-0.4	-2.0	1.5	0.4	0.7	2.0	-1.1	-2.8	2.5	1.4	3.3
India	1.2	0.2	0.5	-0.4	-1.7	1.5	0.1	0.6	1.5	-1.2	-2.8	2.5	0.5	1.7
Indonesia	1.2	0.3	0.7	-0.4	-1.5	1.5	0.6	0.7	2.0	-1.3	-2.6	2.5	1.2	2.4
Russia	3.1	0.2	0.4	-0.4	-1.1	1.5	0.5	0.3	0.9	-1.0	-1.8	2.5	0.8	3.9
South Africa	3.2	0.1	0.4	-0.5	-1.1	1.5	0.4	0.3	1.1	-1.4	-2.0	2.5	0.4	3.6
Non-OECD average¹	2.4	0.2	0.6	-0.4	-1.4	1.5	0.5	0.5	1.6	-1.2	-2.3	2.5	1.1	3.5
Total average¹	5.0	0.2	0.5	-0.4	-0.8	1.5	1.1	0.5	1.2	-0.9	-1.5	2.5	1.7	6.7

Table A4.5. Breakdown of the projections of public health care expenditure for each driver

Sensitivity analysis: income elasticity = 1

	Health expenditure as a % of GDP	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Health expenditure as a % of GDP
	Average 2006-2010	Increase in % points of GDP 2010-2030					Increase in % points of GDP 2010-2060					2060		
Australia	5.6	0.2	0.5	-0.3	0.0	1.5	1.9	0.5	1.0	-0.6	0.0	2.5	3.2	8.9
Austria	6.6	0.2	0.5	-0.3	0.0	1.5	1.9	0.4	1.0	-0.9	0.0	2.5	3.0	9.6
Belgium	5.8	0.2	0.3	-0.3	0.0	1.5	1.6	0.3	0.7	-0.8	0.0	2.5	2.7	8.4
Canada	5.8	0.3	0.6	-0.3	0.0	1.5	2.0	0.5	0.9	-0.7	0.0	2.5	3.2	9.0
Chile	3.1	0.4	0.8	-0.2	0.0	1.5	2.4	0.7	1.8	-0.7	0.0	2.5	4.3	7.4
Czech Republic	5.5	0.3	0.6	-0.4	0.0	1.5	1.9	0.5	1.2	-1.0	0.0	2.5	3.2	8.7
Denmark	6.3	0.2	0.5	-0.3	0.0	1.5	1.8	0.3	0.8	-0.8	0.0	2.5	2.7	9.0
Estonia	4.3	0.2	0.4	-0.4	0.0	1.5	1.7	0.3	1.1	-0.8	0.0	2.5	3.1	7.3
Finland	5.2	0.2	0.5	-0.4	0.0	1.5	1.8	0.3	0.7	-0.7	0.0	2.5	2.8	8.0
France	7.4	0.1	0.5	-0.3	0.0	1.5	1.7	0.3	0.8	-0.8	0.0	2.5	2.8	10.2
Germany	7.3	0.2	0.6	-0.4	0.0	1.5	1.9	0.4	1.0	-0.9	0.0	2.5	3.0	10.3
Greece	5.4	0.2	0.4	-0.3	0.0	1.5	1.7	0.4	1.0	-0.8	0.0	2.5	3.1	8.5
Hungary	4.8	0.2	0.5	-0.5	0.0	1.5	1.7	0.4	1.3	-1.3	0.0	2.5	2.9	7.7
Iceland	5.8	0.0	0.5	-0.3	0.0	1.5	1.7	0.1	0.7	-0.6	0.0	2.5	2.7	8.5
Israel	4.0	0.2	0.4	-0.3	0.0	1.5	1.8	0.5	0.9	-0.7	0.0	2.5	3.2	7.2
Ireland	5.5	0.1	0.5	-0.3	0.0	1.5	1.8	0.3	1.0	-0.8	0.0	2.5	3.0	8.5
Italy	6.1	0.2	0.4	-0.3	0.0	1.5	1.8	0.4	1.0	-0.7	0.0	2.5	3.1	9.3
Japan	6.1	0.3	0.7	-0.3	0.0	1.5	2.1	0.4	1.0	-0.7	0.0	2.5	3.2	9.3
Korea	3.3	0.4	1.1	-0.4	0.0	1.5	2.6	0.8	2.1	-0.8	0.0	2.5	4.5	7.8
Luxembourg	4.4	0.2	0.5	-0.3	0.0	1.5	1.8	0.5	1.1	-0.9	0.0	2.5	3.2	7.6
Mexico	2.5	0.2	0.7	-0.3	0.0	1.5	2.1	0.5	2.0	-0.9	0.0	2.5	4.1	6.6
Netherlands	6.4	0.3	0.6	-0.3	0.0	1.5	2.0	0.4	1.0	-0.8	0.0	2.5	3.1	9.5
New Zealand	6.4	0.3	0.5	-0.3	0.0	1.5	2.0	0.5	1.0	-0.6	0.0	2.5	3.3	9.7
Norway	5.1	0.2	0.4	-0.3	0.0	1.5	1.8	0.4	0.8	-0.7	0.0	2.5	3.0	8.0
Poland	4.1	0.3	0.7	-0.5	0.0	1.5	1.9	0.5	1.7	-1.3	0.0	2.5	3.4	7.5
Portugal	6.5	0.2	0.5	-0.4	0.0	1.5	1.8	0.5	1.2	-0.9	0.0	2.5	3.3	9.7
Slovak Republic	5.4	0.3	0.7	-0.5	0.0	1.5	2.0	0.7	1.8	-1.4	0.0	2.5	3.6	9.0
Slovenia	5.2	0.3	0.6	-0.4	0.0	1.5	2.0	0.5	1.2	-0.7	0.0	2.5	3.5	8.7
Spain	5.6	0.2	0.5	-0.3	0.0	1.5	1.9	0.5	1.3	-0.8	0.0	2.5	3.5	9.1
Sweden	6.6	0.2	0.3	-0.3	0.0	1.5	1.6	0.3	0.6	-0.7	0.0	2.5	2.7	9.3
Switzerland	5.7	0.2	0.5	-0.3	0.0	1.5	1.9	0.5	1.1	-0.8	0.0	2.5	3.3	9.0
Turkey	3.8	0.4	0.7	-0.3	0.0	1.5	2.2	0.8	1.9	-1.0	0.0	2.5	4.2	8.0
United Kingdom	6.5	0.1	0.3	-0.3	0.0	1.5	1.7	0.3	0.7	-0.7	0.0	2.5	2.7	9.2
United States	7.1	0.2	0.5	-0.3	0.0	1.5	1.8	0.3	0.7	-0.6	0.0	2.5	2.9	10.0
OECD average¹	5.5	0.2	0.5	-0.4	0.0	1.5	1.9	0.4	1.1	-0.8	0.0	2.5	3.2	8.7
Brazil	3.7	0.3	0.8	-0.3	0.0	1.5	2.2	0.6	2.1	-1.0	0.0	2.5	4.2	7.9
China	1.9	0.4	0.9	-0.4	0.0	1.5	2.4	0.7	2.0	-1.1	0.0	2.5	4.2	6.1
India	1.2	0.2	0.5	-0.4	0.0	1.5	1.8	0.6	1.5	-1.2	0.0	2.5	3.3	4.5
Indonesia	1.2	0.3	0.7	-0.4	0.0	1.5	2.1	0.7	2.0	-1.3	0.0	2.5	3.8	5.0
Russia	3.1	0.2	0.4	-0.4	0.0	1.5	1.6	0.3	0.9	-1.0	0.0	2.5	2.6	5.8
South Africa	3.2	0.1	0.4	-0.5	0.0	1.5	1.5	0.3	1.1	-1.4	0.0	2.5	2.4	5.6
Non-OECD average¹	2.4	0.2	0.6	-0.4	0.0	1.5	1.9	0.5	1.6	-1.2	0.0	2.5	3.4	5.8
Total average¹	5.0	0.2	0.5	-0.4	0.0	1.5	1.9	0.5	1.2	-0.9	0.0	2.5	3.3	8.2

Table A4.6. Breakdown of the projections of public health care expenditure for each driver

Country-specific residuals converging to zero

	Health expenditure as a % of GDP	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Health expenditure as a % of GDP
	Average 2006-2010	Increase in % points of GDP 2010-2030						Increase in % points of GDP 2010-2060						2060
Australia	5.6	0.2	0.5	-0.3	-0.4	6.2	6.2	0.5	1.0	-0.6	-0.8	12.4	12.4	18.0
Austria	6.6	0.2	0.5	-0.3	-0.2	4.6	4.8	0.4	1.0	-0.9	-0.6	8.8	8.8	15.4
Belgium	5.8	0.2	0.3	-0.3	-0.3	1.6	1.5	0.3	0.7	-0.8	-0.7	2.6	2.1	7.9
Canada	5.8	0.3	0.6	-0.3	-0.3	2.0	2.3	0.5	0.9	-0.7	-0.7	3.4	3.4	9.3
Chile	3.1	0.4	0.8	-0.2	-0.6	1.5	1.8	0.7	1.8	-0.7	-1.1	2.5	3.2	6.3
Czech Republic	5.5	0.3	0.6	-0.4	-0.5	-1.0	-1.1	0.5	1.2	-1.0	-0.9	-1.5	-1.7	3.8
Denmark	6.3	0.2	0.5	-0.3	-0.2	4.2	4.3	0.3	0.8	-0.8	-0.7	7.8	7.4	13.7
Estonia	4.3	0.2	0.4	-0.4	-0.5	1.5	1.1	0.3	1.1	-0.8	-1.1	2.5	2.0	6.2
Finland	5.2	0.2	0.5	-0.4	-0.3	3.5	3.5	0.3	0.7	-0.7	-0.7	6.4	6.0	11.3
France	7.4	0.1	0.5	-0.3	-0.3	0.1	0.0	0.3	0.8	-0.8	-0.6	0.1	-0.2	7.2
Germany	7.3	0.2	0.6	-0.4	-0.3	1.1	1.3	0.4	1.0	-0.9	-0.7	1.8	1.7	8.9
Greece	5.4	0.2	0.4	-0.3	-0.3	3.0	3.0	0.4	1.0	-0.8	-0.6	5.4	5.4	10.8
Hungary	4.8	0.2	0.5	-0.5	-0.5	0.4	0.1	0.4	1.3	-1.3	-1.0	0.6	0.0	4.8
Iceland	5.8	0.0	0.5	-0.3	-0.2	8.4	8.5	0.1	0.7	-0.6	-0.7	18.2	17.7	23.5
Israel	4.0	0.2	0.4	-0.3	-0.2	1.5	1.5	0.5	0.9	-0.7	-0.7	2.5	2.5	6.6
Ireland	5.5	0.1	0.5	-0.3	-0.2	1.5	1.6	0.3	1.0	-0.8	-0.5	2.5	2.5	8.0
Italy	6.1	0.2	0.4	-0.3	-0.2	0.4	0.6	0.4	1.0	-0.7	-0.6	0.7	0.8	6.9
Japan	6.1	0.3	0.7	-0.3	-0.3	1.5	1.8	0.4	1.0	-0.7	-0.8	2.5	2.5	8.6
Korea	3.3	0.4	1.1	-0.4	-0.5	1.7	2.4	0.8	2.1	-0.8	-0.8	2.9	4.1	7.5
Luxembourg	4.4	0.2	0.5	-0.3	-0.1	0.9	1.2	0.5	1.1	-0.9	-0.2	1.5	2.1	6.5
Mexico	2.5	0.2	0.7	-0.3	-0.5	1.5	1.6	0.5	2.0	-0.9	-1.1	2.5	3.0	5.5
Netherlands	6.4	0.3	0.6	-0.3	-0.3	-0.2	0.1	0.4	1.0	-0.8	-0.7	-0.2	-0.3	6.1
New Zealand	6.4	0.3	0.5	-0.3	-0.3	2.6	2.7	0.5	1.0	-0.6	-0.9	4.5	4.4	10.9
Norway	5.1	0.2	0.4	-0.3	-0.4	0.6	0.5	0.4	0.8	-0.7	-0.7	0.9	0.7	5.7
Poland	4.1	0.3	0.7	-0.5	-0.5	-2.1	-2.2	0.5	1.7	-1.3	-0.9	-2.9	-2.8	1.3
Portugal	6.5	0.2	0.5	-0.4	-0.2	5.6	5.7	0.5	1.2	-0.9	-0.7	11.2	11.3	17.8
Slovak Republic	5.4	0.3	0.7	-0.5	-0.5	-3.3	-3.3	0.7	1.8	-1.4	-0.9	-4.0	-3.8	1.6
Slovenia	5.2	0.3	0.6	-0.4	-0.3	1.5	1.7	0.5	1.2	-0.7	-0.8	2.5	2.7	7.9
Spain	5.6	0.2	0.5	-0.3	-0.3	4.4	4.5	0.5	1.3	-0.8	-0.6	8.3	8.7	14.3
Sweden	6.6	0.2	0.3	-0.3	-0.3	1.2	1.1	0.3	0.6	-0.7	-0.7	2.1	1.6	8.2
Switzerland	5.7	0.2	0.5	-0.3	-0.3	2.1	2.2	0.5	1.1	-0.8	-0.8	3.6	3.7	9.4
Turkey	3.8	0.4	0.7	-0.3	-0.6	1.5	1.5	0.8	1.9	-1.0	-1.1	2.5	3.1	7.0
United Kingdom	6.5	0.1	0.3	-0.3	-0.2	0.1	0.1	0.3	0.7	-0.7	-0.7	0.2	-0.3	6.3
United States	7.1	0.2	0.5	-0.3	-0.3	0.5	0.6	0.3	0.7	-0.6	-0.7	0.8	0.6	7.7
OECD average¹	5.5	0.2	0.5	-0.4	-0.3	1.8	1.9	0.4	1.1	-0.8	-0.8	3.4	3.4	8.8
Brazil	3.7	0.3	0.8	-0.3	-0.6	1.5	1.6	0.6	2.1	-1.0	-1.1	2.5	3.1	6.8
China	1.9	0.4	0.9	-0.4	-1.1	1.5	1.3	0.7	2.0	-1.1	-1.7	2.5	2.5	4.4
India	1.2	0.2	0.5	-0.4	-1.0	1.5	0.8	0.6	1.5	-1.2	-1.7	2.5	1.6	2.8
Indonesia	1.2	0.3	0.7	-0.4	-0.8	1.5	1.3	0.7	2.0	-1.3	-1.5	2.5	2.3	3.5
Russia	3.1	0.2	0.4	-0.4	-0.6	1.5	1.0	0.3	0.9	-1.0	-1.0	2.5	1.6	4.7
South Africa	3.2	0.1	0.4	-0.5	-0.6	1.5	0.9	0.3	1.1	-1.4	-1.2	2.5	1.3	4.5
Non-OECD average¹	2.4	0.2	0.6	-0.4	-0.8	1.5	1.2	0.5	1.6	-1.2	-1.4	2.5	2.1	4.4
Total average¹	5.0	0.2	0.5	-0.4	-0.4	1.7	1.8	0.5	1.2	-0.9	-0.8	3.3	3.2	8.2

Table A4.7. Breakdown of the projections of public health care expenditure for each driver

Compression of morbidity

	Health expenditure as a % of GDP	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Health expenditure as a % of GDP
	Average 2006-2010	Increase in % points of GDP 2010-2030						Increase in % points of GDP 2010-2060						2060
Australia	5.6	0.2	0.5	-0.5	-0.4	1.5	1.3	0.5	1.0	-1.2	-0.8	2.5	1.9	7.5
Austria	6.6	0.2	0.5	-0.6	-0.2	1.5	1.4	0.4	1.0	-1.5	-0.6	2.5	1.8	8.4
Belgium	5.8	0.2	0.3	-0.6	-0.3	1.5	1.1	0.3	0.7	-1.4	-0.7	2.5	1.3	7.1
Canada	5.8	0.3	0.6	-0.6	-0.3	1.5	1.6	0.5	0.9	-1.2	-0.7	2.5	1.9	7.8
Chile	3.1	0.4	0.8	-0.4	-0.6	1.5	1.6	0.7	1.8	-1.3	-1.1	2.5	2.6	5.7
Czech Republic	5.5	0.3	0.6	-0.8	-0.5	1.5	1.0	0.5	1.2	-1.9	-0.9	2.5	1.4	6.9
Denmark	6.3	0.2	0.5	-0.6	-0.2	1.5	1.3	0.3	0.8	-1.5	-0.7	2.5	1.4	7.6
Estonia	4.3	0.2	0.4	-0.6	-0.5	1.5	0.9	0.3	1.1	-1.5	-1.1	2.5	1.3	5.5
Finland	5.2	0.2	0.5	-0.6	-0.3	1.5	1.2	0.3	0.7	-1.4	-0.7	2.5	1.4	6.6
France	7.4	0.1	0.5	-0.6	-0.3	1.5	1.2	0.3	0.8	-1.3	-0.6	2.5	1.6	9.0
Germany	7.3	0.2	0.6	-0.6	-0.3	1.5	1.4	0.4	1.0	-1.6	-0.7	2.5	1.6	8.9
Greece	5.4	0.2	0.4	-0.6	-0.3	1.5	1.2	0.4	1.0	-1.5	-0.6	2.5	1.9	7.2
Hungary	4.8	0.2	0.5	-0.9	-0.5	1.5	0.7	0.4	1.3	-2.2	-1.0	2.5	1.0	5.8
Iceland	5.8	0.0	0.5	-0.5	-0.2	1.5	1.3	0.1	0.7	-1.1	-0.7	2.5	1.4	7.3
Israel	4.0	0.2	0.4	-0.4	-0.2	1.5	1.4	0.5	0.9	-1.2	-0.7	2.5	2.0	6.0
Ireland	5.5	0.1	0.5	-0.6	-0.2	1.5	1.3	0.3	1.0	-1.5	-0.5	2.5	1.8	7.4
Italy	6.1	0.2	0.4	-0.6	-0.2	1.5	1.3	0.4	1.0	-1.4	-0.6	2.5	1.9	8.0
Japan	6.1	0.3	0.7	-0.6	-0.3	1.5	1.6	0.4	1.0	-1.2	-0.8	2.5	1.9	8.0
Korea	3.3	0.4	1.1	-0.6	-0.5	1.5	1.9	0.8	2.1	-1.5	-0.8	2.5	3.0	6.3
Luxembourg	4.4	0.2	0.5	-0.6	-0.1	1.5	1.4	0.5	1.1	-1.6	-0.2	2.5	2.3	6.7
Mexico	2.5	0.2	0.7	-0.5	-0.5	1.5	1.4	0.5	2.0	-1.6	-1.1	2.5	2.3	4.8
Netherlands	6.4	0.3	0.6	-0.7	-0.3	1.5	1.4	0.4	1.0	-1.4	-0.7	2.5	1.8	8.2
New Zealand	6.4	0.3	0.5	-0.5	-0.3	1.5	1.4	0.5	1.0	-1.2	-0.9	2.5	1.8	8.2
Norway	5.1	0.2	0.4	-0.6	-0.4	1.5	1.1	0.4	0.8	-1.3	-0.7	2.5	1.6	6.7
Poland	4.1	0.3	0.7	-0.9	-0.5	1.5	1.0	0.5	1.7	-2.3	-0.9	2.5	1.5	5.6
Portugal	6.5	0.2	0.5	-0.7	-0.2	1.5	1.3	0.5	1.2	-1.7	-0.7	2.5	1.8	8.3
Slovak Republic	5.4	0.3	0.7	-0.9	-0.5	1.5	1.1	0.7	1.8	-2.4	-0.9	2.5	1.6	7.0
Slovenia	5.2	0.3	0.6	-0.6	-0.3	1.5	1.5	0.5	1.2	-1.4	-0.8	2.5	2.0	7.2
Spain	5.6	0.2	0.5	-0.6	-0.3	1.5	1.3	0.5	1.3	-1.5	-0.6	2.5	2.2	7.8
Sweden	6.6	0.2	0.3	-0.5	-0.3	1.5	1.1	0.3	0.6	-1.3	-0.7	2.5	1.4	8.0
Switzerland	5.7	0.2	0.5	-0.6	-0.3	1.5	1.4	0.5	1.1	-1.4	-0.8	2.5	2.0	7.7
Turkey	3.8	0.4	0.7	-0.6	-0.6	1.5	1.3	0.8	1.9	-1.7	-1.1	2.5	2.4	6.2
United Kingdom	6.5	0.1	0.3	-0.6	-0.2	1.5	1.1	0.3	0.7	-1.4	-0.7	2.5	1.3	7.9
United States	7.1	0.2	0.5	-0.5	-0.3	1.5	1.4	0.3	0.7	-1.2	-0.7	2.5	1.7	8.8
OECD average¹	5.5	0.2	0.5	-0.6	-0.3	1.5	1.3	0.4	1.1	-1.5	-0.8	2.5	1.8	7.2
Brazil	3.7	0.3	0.8	-0.6	-0.6	1.5	1.3	0.6	2.1	-1.8	-1.1	2.5	2.3	6.0
China	1.9	0.4	0.9	-0.7	-1.1	1.5	0.9	0.7	2.0	-1.9	-1.7	2.5	1.6	3.6
India	1.2	0.2	0.5	-0.7	-1.0	1.5	0.6	0.6	1.5	-2.0	-1.7	2.5	0.9	2.1
Indonesia	1.2	0.3	0.7	-0.7	-0.8	1.5	0.9	0.7	2.0	-2.2	-1.5	2.5	1.4	2.5
Russia	3.1	0.2	0.4	-0.8	-0.6	1.5	0.7	0.3	0.9	-1.7	-1.0	2.5	0.9	4.1
South Africa	3.2	0.1	0.4	-0.9	-0.6	1.5	0.5	0.3	1.1	-2.0	-1.2	2.5	0.7	3.9
Non-OECD average¹	2.4	0.2	0.6	-0.7	-0.8	1.5	0.8	0.5	1.6	-1.9	-1.4	2.5	1.3	3.7
Total average¹	5.0	0.2	0.5	-0.6	-0.4	1.5	1.2	0.5	1.2	-1.6	-0.8	2.5	1.7	6.7

Table A4.8. Breakdown of the projections of public health care expenditure for each driver

Expansion of morbidity

	Health expenditure as a % of GDP	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Death-related costs	Pure age effect (survivors)	Adjustment for healthy ageing	Income effect	Non-ageing residual effect	Total	Health expenditure as a % of GDP
Average 2006-2010	Increase in % points of GDP 2010-2030						Increase in % points of GDP 2010-2060						2060	
Australia	5.6	0.2	0.5	0.0	-0.4	1.5	1.8	0.5	1.0	0.0	-0.8	2.5	3.1	8.7
Austria	6.6	0.2	0.5	0.0	-0.2	1.5	2.0	0.4	1.0	0.0	-0.6	2.5	3.3	9.9
Belgium	5.8	0.2	0.3	0.0	-0.3	1.5	1.7	0.3	0.7	0.0	-0.7	2.5	2.7	8.5
Canada	5.8	0.3	0.6	0.0	-0.3	1.5	2.1	0.5	0.9	0.0	-0.7	2.5	3.1	9.0
Chile	3.1	0.4	0.8	0.0	-0.6	1.5	2.0	0.7	1.8	0.0	-1.1	2.5	3.9	6.9
Czech Republic	5.5	0.3	0.6	0.0	-0.5	1.5	1.8	0.5	1.2	0.0	-0.9	2.5	3.2	8.8
Denmark	6.3	0.2	0.5	0.0	-0.2	1.5	2.0	0.3	0.8	0.0	-0.7	2.5	2.9	9.1
Estonia	4.3	0.2	0.4	0.0	-0.5	1.5	1.5	0.3	1.1	0.0	-1.1	2.5	2.8	7.1
Finland	5.2	0.2	0.5	0.0	-0.3	1.5	1.9	0.3	0.7	0.0	-0.7	2.5	2.8	8.0
France	7.4	0.1	0.5	0.0	-0.3	1.5	1.8	0.3	0.8	0.0	-0.6	2.5	2.9	10.3
Germany	7.3	0.2	0.6	0.0	-0.3	1.5	2.0	0.4	1.0	0.0	-0.7	2.5	3.2	10.5
Greece	5.4	0.2	0.4	0.0	-0.3	1.5	1.8	0.4	1.0	0.0	-0.6	2.5	3.3	8.7
Hungary	4.8	0.2	0.5	0.0	-0.5	1.5	1.7	0.4	1.3	0.0	-1.0	2.5	3.2	8.0
Iceland	5.8	0.0	0.5	0.0	-0.2	1.5	1.8	0.1	0.7	0.0	-0.7	2.5	2.6	8.4
Israel	4.0	0.2	0.4	0.0	-0.2	1.5	1.8	0.5	0.9	0.0	-0.7	2.5	3.2	7.2
Ireland	5.5	0.1	0.5	0.0	-0.2	1.5	1.9	0.3	1.0	0.0	-0.5	2.5	3.3	8.8
Italy	6.1	0.2	0.4	0.0	-0.2	1.5	1.9	0.4	1.0	0.0	-0.6	2.5	3.3	9.4
Japan	6.1	0.3	0.7	0.0	-0.3	1.5	2.1	0.4	1.0	0.0	-0.8	2.5	3.1	9.2
Korea	3.3	0.4	1.1	0.0	-0.5	1.5	2.5	0.8	2.1	0.0	-0.8	2.5	4.5	7.8
Luxembourg	4.4	0.2	0.5	0.0	-0.1	1.5	2.0	0.5	1.1	0.0	-0.2	2.5	3.9	8.3
Mexico	2.5	0.2	0.7	0.0	-0.5	1.5	1.9	0.5	2.0	0.0	-1.1	2.5	3.9	6.4
Netherlands	6.4	0.3	0.6	0.0	-0.3	1.5	2.1	0.4	1.0	0.0	-0.7	2.5	3.2	9.6
New Zealand	6.4	0.3	0.5	0.0	-0.3	1.5	2.0	0.5	1.0	0.0	-0.9	2.5	3.0	9.5
Norway	5.1	0.2	0.4	0.0	-0.4	1.5	1.7	0.4	0.8	0.0	-0.7	2.5	3.0	8.1
Poland	4.1	0.3	0.7	0.0	-0.5	1.5	1.9	0.5	1.7	0.0	-0.9	2.5	3.9	8.0
Portugal	6.5	0.2	0.5	0.0	-0.2	1.5	2.0	0.5	1.2	0.0	-0.7	2.5	3.5	10.0
Slovak Republic	5.4	0.3	0.7	0.0	-0.5	1.5	2.0	0.7	1.8	0.0	-0.9	2.5	4.0	9.4
Slovenia	5.2	0.3	0.6	0.0	-0.3	1.5	2.0	0.5	1.2	0.0	-0.8	2.5	3.5	8.6
Spain	5.6	0.2	0.5	0.0	-0.3	1.5	1.9	0.5	1.3	0.0	-0.6	2.5	3.6	9.2
Sweden	6.6	0.2	0.3	0.0	-0.3	1.5	1.6	0.3	0.6	0.0	-0.7	2.5	2.7	9.2
Switzerland	5.7	0.2	0.5	0.0	-0.3	1.5	2.0	0.5	1.1	0.0	-0.8	2.5	3.3	9.0
Turkey	3.8	0.4	0.7	0.0	-0.6	1.5	1.9	0.8	1.9	0.0	-1.1	2.5	4.1	7.9
United Kingdom	6.5	0.1	0.3	0.0	-0.2	1.5	1.7	0.3	0.7	0.0	-0.7	2.5	2.7	9.2
United States	7.1	0.2	0.5	0.0	-0.3	1.5	1.9	0.3	0.7	0.0	-0.7	2.5	2.9	9.9
OECD average¹	5.5	0.2	0.5	0.0	-0.3	1.5	1.9	0.4	1.1	0.0	-0.8	2.5	3.3	8.7
Brazil	3.7	0.3	0.8	0.0	-0.6	1.5	1.9	0.6	2.1	0.0	-1.1	2.5	4.1	7.8
China	1.9	0.4	0.9	0.0	-1.1	1.5	1.6	0.7	2.0	0.0	-1.7	2.5	3.5	5.5
India	1.2	0.2	0.5	0.0	-1.0	1.5	1.2	0.6	1.5	0.0	-1.7	2.5	2.8	4.0
Indonesia	1.2	0.3	0.7	0.0	-0.8	1.5	1.7	0.7	2.0	0.0	-1.5	2.5	3.6	4.8
Russia	3.1	0.2	0.4	0.0	-0.6	1.5	1.4	0.3	0.9	0.0	-1.0	2.5	2.6	5.7
South Africa	3.2	0.1	0.4	0.0	-0.6	1.5	1.4	0.3	1.1	0.0	-1.2	2.5	2.7	5.9
Non-OECD average¹	2.4	0.2	0.6	0.0	-0.8	1.5	1.5	0.5	1.6	0.0	-1.4	2.5	3.2	5.6
Total average¹	5.0	0.2	0.5	0.0	-0.4	1.5	1.9	0.5	1.2	0.0	-0.8	2.5	3.3	8.3

Table A4.9. Breakdown of the projections of total long-term care expenditure for each driver

Demographic scenario

	Long-term care expenditure as a % of GDP	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Level as a % of GDP
	(0)	(1)	(2)	(3)	(4)	(5)	(6)=Sum (1) to (5)	(7)	(8)	(9)	(10)	(11)	(12)=Sum (7) to (11)	(13)=(0)+(12)
	2006-2010	Increase in % points of GDP 2010-2030					Increase in % points of GDP 2010-2060					2060		
Australia	0.0	0.2	-0.1	0.0	0.0	0.0	0.1	0.5	-0.2	0.0	0.0	0.0	0.3	0.3
Austria	1.1	0.2	-0.1	0.0	0.0	0.0	0.1	0.4	-0.2	0.0	0.0	0.0	0.2	1.4
Belgium	1.7	0.1	-0.1	0.0	0.0	0.0	0.1	0.3	-0.2	0.0	0.0	0.0	0.1	1.9
Canada	1.2	0.2	-0.1	0.0	0.0	0.0	0.2	0.4	-0.2	0.0	0.0	0.0	0.2	1.5
Chile	0.0	0.3	-0.1	0.0	0.0	0.0	0.2	0.8	-0.3	0.0	0.0	0.0	0.6	0.6
Czech Republic	0.3	0.2	-0.1	0.0	0.0	0.0	0.2	0.6	-0.2	0.0	0.0	0.0	0.4	0.6
Denmark	2.2	0.2	-0.1	0.0	0.0	0.0	0.1	0.4	-0.2	0.0	0.0	0.0	0.2	2.4
Estonia	0.2	0.2	-0.1	0.0	0.0	0.0	0.1	0.5	-0.2	0.0	0.0	0.0	0.3	0.5
Finland	0.8	0.2	-0.1	0.0	0.0	0.0	0.2	0.4	-0.2	0.0	0.0	0.0	0.2	1.0
France	1.1	0.2	-0.1	0.0	0.0	0.0	0.1	0.4	-0.2	0.0	0.0	0.0	0.2	1.3
Germany	0.9	0.2	-0.1	0.0	0.0	0.0	0.2	0.5	-0.2	0.0	0.0	0.0	0.3	1.2
Greece	0.5	0.2	-0.1	0.0	0.0	0.0	0.1	0.5	-0.2	0.0	0.0	0.0	0.3	0.8
Hungary	0.3	0.2	-0.1	0.0	0.0	0.0	0.1	0.6	-0.2	0.0	0.0	0.0	0.3	0.6
Iceland	1.7	0.2	-0.1	0.0	0.0	0.0	0.2	0.4	-0.2	0.0	0.0	0.0	0.2	1.9
Ireland	0.5	0.2	-0.1	0.0	0.0	0.0	0.2	0.5	-0.2	0.0	0.0	0.0	0.3	0.8
Israel	0.4	0.2	0.0	0.0	0.0	0.0	0.1	0.4	-0.2	0.0	0.0	0.0	0.2	0.6
Italy	0.7	0.2	-0.1	0.0	0.0	0.0	0.1	0.4	-0.2	0.0	0.0	0.0	0.2	1.0
Japan	0.7	0.3	-0.1	0.0	0.0	0.0	0.2	0.5	-0.2	0.0	0.0	0.0	0.3	0.9
Korea	0.3	0.4	-0.1	0.0	0.0	0.0	0.4	1.1	-0.3	0.0	0.0	0.0	0.8	1.1
Luxembourg	0.9	0.2	-0.1	0.0	0.0	0.0	0.1	0.5	-0.2	0.0	0.0	0.0	0.3	1.2
Mexico	0.0	0.2	-0.1	0.0	0.0	0.0	0.2	0.9	-0.3	0.0	0.0	0.0	0.6	0.7
Netherlands	2.3	0.3	-0.1	0.0	0.0	0.0	0.2	0.5	-0.2	0.0	0.0	0.0	0.3	2.6
New Zealand	1.3	0.2	-0.1	0.0	0.0	0.0	0.2	0.5	-0.2	0.0	0.0	0.0	0.3	1.5
Norway	2.1	0.1	-0.1	0.0	0.0	0.0	0.1	0.4	-0.2	0.0	0.0	0.0	0.2	2.3
Poland	0.4	0.3	-0.1	0.0	0.0	0.0	0.2	0.8	-0.3	0.0	0.0	0.0	0.5	0.9
Portugal	0.1	0.2	-0.1	0.0	0.0	0.0	0.1	0.5	-0.2	0.0	0.0	0.0	0.3	0.4
Slovak Republic	0.0	0.3	-0.1	0.0	0.0	0.0	0.2	0.8	-0.3	0.0	0.0	0.0	0.6	0.6
Slovenia	0.7	0.2	-0.1	0.0	0.0	0.0	0.2	0.6	-0.2	0.0	0.0	0.0	0.4	1.0
Spain	0.5	0.2	-0.1	0.0	0.0	0.0	0.1	0.6	-0.2	0.0	0.0	0.0	0.3	0.9
Sweden	0.7	0.1	-0.1	0.0	0.0	0.0	0.1	0.3	-0.2	0.0	0.0	0.0	0.1	0.8
Switzerland	1.2	0.2	-0.1	0.0	0.0	0.0	0.1	0.5	-0.2	0.0	0.0	0.0	0.3	1.5
Turkey	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.9	-0.3	0.0	0.0	0.0	0.6	0.6
United Kingdom	0.9	0.1	-0.1	0.0	0.0	0.0	0.1	0.3	-0.2	0.0	0.0	0.0	0.1	1.0
United States	0.6	0.2	-0.1	0.0	0.0	0.0	0.1	0.3	-0.2	0.0	0.0	0.0	0.2	0.7
OECD average¹	0.8	0.2	-0.1	0.0	0.0	0.0	0.1	0.5	-0.2	0.0	0.0	0.0	0.3	1.1
Brazil	0.0	0.3	-0.1	0.0	0.0	0.0	0.2	1.0	-0.3	0.0	0.0	0.0	0.7	0.7
China	0.1	0.3	-0.1	0.0	0.0	0.0	0.3	1.0	-0.3	0.0	0.0	0.0	0.7	0.8
India	0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.6	-0.2	0.0	0.0	0.0	0.4	0.5
Indonesia	0.1	0.2	0.0	0.0	0.0	0.0	0.2	0.9	-0.3	0.0	0.0	0.0	0.7	0.7
Russia	0.2	0.2	-0.1	0.0	0.0	0.0	0.1	0.4	-0.2	0.0	0.0	0.0	0.2	0.5
South Africa	0.2	0.2	0.0	0.0	0.0	0.0	0.1	0.4	-0.2	0.0	0.0	0.0	0.3	0.4
Non-OECD average¹	0.1	0.2	0.0	0.0	0.0	0.0	0.2	0.7	-0.2	0.0	0.0	0.0	0.5	0.6
Total average¹	0.7	0.2	-0.1	0.0	0.0	0.0	0.2	0.6	-0.2	0.0	0.0	0.0	0.3	1.0

Table A4.10. Breakdown of the projections of total long-term care expenditure for each driver

Cost-pressure scenario

	Long-term care expenditure as a % of GDP	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Level as a % of GDP
	(0)	(1)	(2)	(3)	(4)	(5)	(6)=Sum (1) to (5)	(7)	(8)	(9)	(10)	(11)	(12)=Sum (7) to (11)	(13)=(0)+(12)
	2006-2010	Increase in % points of GDP 2010-2030					Increase in % points of GDP 2010-2060					2060		
Australia	0.0	0.2	-0.1	0.0	0.3	0.1	0.6	0.5	-0.2	0.0	0.9	0.1	1.3	1.4
Austria	1.1	0.2	-0.1	0.0	0.2	0.1	0.5	0.4	-0.2	0.0	0.6	0.2	1.0	2.2
Belgium	1.7	0.1	-0.1	0.0	0.2	0.2	0.5	0.3	-0.2	0.0	0.9	0.3	1.2	3.0
Canada	1.2	0.2	-0.1	0.0	0.3	0.1	0.5	0.4	-0.2	0.0	0.9	0.1	1.2	2.5
Chile	0.0	0.3	-0.1	0.0	0.4	0.3	0.9	0.8	-0.3	0.0	1.3	0.4	2.3	2.3
Czech Republic	0.3	0.2	-0.1	0.0	0.4	0.1	0.7	0.6	-0.2	0.0	1.2	0.0	1.6	1.9
Denmark	2.2	0.2	-0.1	0.0	0.2	0.1	0.4	0.4	-0.2	0.0	0.8	0.1	1.0	3.3
Estonia	0.2	0.2	-0.1	0.0	0.5	0.1	0.7	0.5	-0.2	0.0	1.6	0.1	2.0	2.2
Finland	0.8	0.2	-0.1	0.0	0.3	0.0	0.5	0.4	-0.2	0.0	0.8	0.0	1.0	1.8
France	1.1	0.2	-0.1	0.0	0.3	0.1	0.5	0.4	-0.2	0.0	0.7	0.1	1.0	2.1
Germany	0.9	0.2	-0.1	0.0	0.2	0.1	0.5	0.5	-0.2	0.0	0.7	0.1	1.1	2.1
Greece	0.5	0.2	-0.1	0.0	0.2	0.3	0.6	0.5	-0.2	0.0	0.7	0.4	1.4	1.9
Hungary	0.3	0.2	-0.1	0.0	0.3	0.2	0.6	0.6	-0.2	0.0	1.3	0.2	1.8	2.0
Iceland	1.7	0.2	-0.1	0.0	0.2	-0.1	0.3	0.4	-0.2	0.0	0.8	0.0	1.0	2.7
Ireland	0.5	0.2	-0.1	0.0	0.1	0.1	0.4	0.5	-0.2	0.0	0.5	0.1	0.9	1.5
Israel	0.4	0.2	0.0	0.0	0.2	0.2	0.5	0.4	-0.2	0.0	0.5	0.3	1.0	1.3
Italy	0.7	0.2	-0.1	0.0	0.1	0.2	0.5	0.4	-0.2	0.0	0.7	0.3	1.2	1.9
Japan	0.7	0.3	-0.1	0.0	0.2	0.1	0.5	0.5	-0.2	0.0	1.0	0.1	1.4	2.0
Korea	0.3	0.4	-0.1	0.0	0.4	0.0	0.8	1.1	-0.3	0.0	1.1	0.1	2.0	2.3
Luxembourg	0.9	0.2	-0.1	0.0	0.1	0.3	0.5	0.5	-0.2	0.0	0.2	0.3	0.8	1.7
Mexico	0.0	0.2	-0.1	0.0	0.2	0.3	0.7	0.9	-0.3	0.0	1.2	0.4	2.2	2.2
Netherlands	2.3	0.3	-0.1	0.0	0.3	0.2	0.6	0.5	-0.2	0.0	0.9	0.2	1.4	3.7
New Zealand	1.3	0.2	-0.1	0.0	0.3	0.1	0.5	0.5	-0.2	0.0	1.0	0.1	1.4	2.6
Norway	2.1	0.1	-0.1	0.0	0.3	0.0	0.4	0.4	-0.2	0.0	0.8	0.0	1.0	3.1
Poland	0.4	0.3	-0.1	0.0	0.5	0.0	0.7	0.8	-0.3	0.0	1.3	0.0	1.8	2.2
Portugal	0.1	0.2	-0.1	0.0	0.2	0.1	0.4	0.5	-0.2	0.0	0.8	0.1	1.3	1.4
Slovak Republic	0.0	0.3	-0.1	0.0	0.5	0.1	0.8	0.8	-0.3	0.0	1.3	0.1	1.9	1.9
Slovenia	0.7	0.2	-0.1	0.0	0.3	0.1	0.6	0.6	-0.2	0.0	1.1	0.1	1.5	2.2
Spain	0.5	0.2	-0.1	0.0	0.2	0.3	0.6	0.6	-0.2	0.0	0.7	0.4	1.5	2.0
Sweden	0.7	0.1	-0.1	0.0	0.3	0.0	0.4	0.3	-0.2	0.0	0.7	0.0	0.9	1.6
Switzerland	1.2	0.2	-0.1	0.0	0.2	0.1	0.5	0.5	-0.2	0.0	0.9	0.1	1.3	2.5
Turkey	0.0	0.2	0.0	0.0	0.4	0.1	0.7	0.9	-0.3	0.0	1.1	0.6	2.3	2.3
United Kingdom	0.9	0.1	-0.1	0.0	0.2	0.1	0.3	0.3	-0.2	0.0	0.7	0.1	0.9	1.8
United States	0.6	0.2	-0.1	0.0	0.2	0.0	0.4	0.3	-0.2	0.0	0.6	0.0	0.8	1.3
OECD average¹	0.8	0.2	-0.1	0.0	0.3	0.1	0.5	0.5	-0.2	0.0	0.9	0.2	1.4	2.1
Brazil	0.0	0.3	-0.1	0.0	0.1	0.0	0.3	1.0	-0.3	0.0	0.6	-0.1	1.2	1.3
China	0.1	0.3	-0.1	0.0	0.2	0.0	0.4	1.0	-0.3	0.0	1.4	-0.1	2.0	2.1
India	0.1	0.2	0.0	0.0	0.1	0.0	0.3	0.6	-0.2	0.0	1.1	0.0	1.5	1.6
Indonesia	0.1	0.2	0.0	0.0	0.1	0.0	0.3	0.9	-0.3	0.0	1.0	-0.1	1.6	1.7
Russia	0.2	0.2	-0.1	0.0	0.1	-0.1	0.2	0.4	-0.2	0.0	0.6	-0.1	0.8	1.0
South Africa	0.2	0.2	0.0	0.0	0.0	0.0	0.2	0.4	-0.2	0.0	0.4	0.0	0.7	0.9
Non-OECD average¹	0.1	0.2	0.0	0.0	0.1	0.0	0.3	0.7	-0.2	0.0	0.9	-0.1	1.3	1.4
Average¹	0.7	0.2	-0.1	0.0	0.3	0.1	0.5	0.6	-0.2	0.0	0.9	0.1	1.4	2.0

Table A4.11. Breakdown of the projections of total long-term care expenditure for each driver

Cost-containment

	Long-term care expenditure as a % of GDP	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Level as a % of GDP
	(0)	(1)	(2)	(3)	(4)	(5)	(6)=Sum (1) to (5)	(7)	(8)	(9)	(10)	(11)	(12)=Sum (7) to (11)	(13)=(0)+(12)
	2006-2010	Increase in % points of GDP 2010-2030					Increase in % points of GDP 2010-2060					2060		
Australia	0.0	0.2	-0.1	0.0	0.1	0.1	0.3	0.5	-0.2	0.0	0.4	0.1	0.8	0.8
Austria	1.1	0.2	-0.1	0.0	0.0	0.1	0.3	0.4	-0.2	0.0	0.3	0.2	0.7	1.8
Belgium	1.7	0.1	-0.1	0.0	0.0	0.2	0.3	0.3	-0.2	0.0	0.3	0.3	0.7	2.5
Canada	1.2	0.2	-0.1	0.0	0.0	0.1	0.3	0.4	-0.2	0.0	0.4	0.1	0.7	1.9
Chile	0.0	0.3	-0.1	0.0	0.1	0.3	0.6	0.8	-0.3	0.0	0.5	0.4	1.5	1.5
Czech Republic	0.3	0.2	-0.1	0.0	0.1	0.1	0.3	0.6	-0.2	0.0	0.5	0.0	0.9	1.1
Denmark	2.2	0.2	-0.1	0.0	0.0	0.1	0.2	0.4	-0.2	0.0	0.3	0.1	0.6	2.8
Estonia	0.2	0.2	-0.1	0.0	0.1	0.1	0.3	0.5	-0.2	0.0	0.6	0.1	0.9	1.1
Finland	0.8	0.2	-0.1	0.0	0.1	0.0	0.3	0.4	-0.2	0.0	0.3	0.0	0.5	1.3
France	1.1	0.2	-0.1	0.0	0.0	0.1	0.2	0.4	-0.2	0.0	0.3	0.1	0.6	1.7
Germany	0.9	0.2	-0.1	0.0	0.0	0.1	0.3	0.5	-0.2	0.0	0.3	0.1	0.7	1.6
Greece	0.5	0.2	-0.1	0.0	0.0	0.3	0.4	0.5	-0.2	0.0	0.3	0.4	0.9	1.5
Hungary	0.3	0.2	-0.1	0.0	0.1	0.2	0.3	0.6	-0.2	0.0	0.5	0.2	1.0	1.2
Iceland	1.7	0.2	-0.1	0.0	0.0	-0.1	0.1	0.4	-0.2	0.0	0.3	0.0	0.5	2.2
Ireland	0.5	0.2	-0.1	0.0	0.0	0.1	0.3	0.5	-0.2	0.0	0.2	0.1	0.6	1.2
Israel	0.4	0.2	0.0	0.0	0.0	0.2	0.4	0.4	-0.2	0.0	0.2	0.3	0.7	1.1
Italy	0.7	0.2	-0.1	0.0	0.0	0.2	0.3	0.4	-0.2	0.0	0.3	0.3	0.8	1.5
Japan	0.7	0.3	-0.1	0.0	0.0	0.1	0.3	0.5	-0.2	0.0	0.4	0.1	0.8	1.4
Korea	0.3	0.4	-0.1	0.0	0.1	0.0	0.5	1.1	-0.3	0.0	0.4	0.1	1.3	1.6
Luxembourg	0.9	0.2	-0.1	0.0	0.0	0.3	0.4	0.5	-0.2	0.0	0.1	0.3	0.7	1.7
Mexico	0.0	0.2	-0.1	0.0	0.0	0.3	0.5	0.9	-0.3	0.0	0.4	0.4	1.5	1.5
Netherlands	2.3	0.3	-0.1	0.0	0.0	0.2	0.4	0.5	-0.2	0.0	0.3	0.2	0.8	3.1
New Zealand	1.3	0.2	-0.1	0.0	0.0	0.1	0.3	0.5	-0.2	0.0	0.4	0.1	0.8	2.0
Norway	2.1	0.1	-0.1	0.0	0.1	0.0	0.2	0.4	-0.2	0.0	0.3	0.0	0.5	2.7
Poland	0.4	0.3	-0.1	0.0	0.1	0.0	0.3	0.8	-0.3	0.0	0.5	0.0	1.0	1.4
Portugal	0.1	0.2	-0.1	0.0	0.0	0.1	0.2	0.5	-0.2	0.0	0.3	0.1	0.8	0.9
Slovak Republic	0.0	0.3	-0.1	0.0	0.1	0.1	0.4	0.8	-0.3	0.0	0.5	0.1	1.1	1.1
Slovenia	0.7	0.2	-0.1	0.0	0.1	0.1	0.4	0.6	-0.2	0.0	0.4	0.1	0.9	1.5
Spain	0.5	0.2	-0.1	0.0	0.0	0.3	0.5	0.6	-0.2	0.0	0.3	0.4	1.0	1.6
Sweden	0.7	0.1	-0.1	0.0	0.1	0.0	0.1	0.3	-0.2	0.0	0.3	0.0	0.5	1.1
Switzerland	1.2	0.2	-0.1	0.0	0.0	0.1	0.3	0.5	-0.2	0.0	0.4	0.1	0.7	1.9
Turkey	0.0	0.2	0.0	0.0	0.1	0.1	0.3	0.9	-0.3	0.0	0.4	0.6	1.6	1.6
United Kingdom	0.9	0.1	-0.1	0.0	0.0	0.1	0.2	0.3	-0.2	0.0	0.3	0.1	0.5	1.4
United States	0.6	0.2	-0.1	0.0	0.0	0.0	0.2	0.3	-0.2	0.0	0.3	0.0	0.4	1.0
OECD average¹	0.8	0.2	-0.1	0.0	0.0	0.1	0.3	0.5	-0.2	0.0	0.3	0.2	0.8	1.6
Brazil	0.0	0.3	-0.1	0.0	0.0	0.0	0.3	1.0	-0.3	0.0	0.3	-0.1	0.9	0.9
China	0.1	0.3	-0.1	0.0	0.1	0.0	0.3	1.0	-0.3	0.0	0.5	-0.1	1.1	1.2
India	0.1	0.2	0.0	0.0	0.1	0.0	0.2	0.6	-0.2	0.0	0.4	0.0	0.8	0.9
Indonesia	0.1	0.2	0.0	0.0	0.1	0.0	0.2	0.9	-0.3	0.0	0.4	-0.1	1.0	1.0
Russia	0.2	0.2	-0.1	0.0	0.1	-0.1	0.1	0.4	-0.2	0.0	0.3	-0.1	0.4	0.7
South Africa	0.2	0.2	0.0	0.0	0.0	0.0	0.2	0.4	-0.2	0.0	0.2	0.0	0.5	0.6
Non-OECD average¹	0.1	0.2	0.0	0.0	0.1	0.0	0.2	0.7	-0.2	0.0	0.3	-0.1	0.8	0.9
Total average¹	0.7	0.2	-0.1	0.0	0.0	0.1	0.3	0.6	-0.2	0.0	0.3	0.1	0.8	1.5

Table A4.12. Breakdown of the projections of total long-term care expenditure for each driver

Income elasticity = 2 (1.5 for non-OECD countries)

	Long-term care expenditure as a % of GDP	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Level as a % of GDP
	(0)	(1)	(2)	(3)	(4)	(5)	(6)=Sum (1) to (5)	(7)	(8)	(9)	(10)	(11)	(12)=Sum (7) to (11)	(13)=(0)+(12)
	2006-2010	Increase in % points of GDP 2010-2030					Increase in % points of GDP 2010-2060					2060		
Australia	0.0	0.2	-0.1	0.3	0.1	0.1	0.6	0.5	-0.2	1.0	0.4	0.1	1.7	1.7
Austria	1.1	0.2	-0.1	0.2	0.0	0.1	0.5	0.4	-0.2	0.6	0.3	0.2	1.3	2.4
Belgium	1.7	0.1	-0.1	0.2	0.0	0.2	0.5	0.3	-0.2	0.8	0.3	0.3	1.5	3.3
Canada	1.2	0.2	-0.1	0.2	0.0	0.1	0.5	0.4	-0.2	0.8	0.4	0.1	1.6	2.8
Chile	0.0	0.3	-0.1	0.6	0.1	0.3	1.2	0.8	-0.3	1.7	0.5	0.4	3.2	3.2
Czech Republic	0.3	0.2	-0.1	0.4	0.1	0.1	0.7	0.6	-0.2	1.3	0.5	0.0	2.1	2.4
Denmark	2.2	0.2	-0.1	0.1	0.0	0.1	0.4	0.4	-0.2	0.8	0.3	0.1	1.4	3.6
Estonia	0.2	0.2	-0.1	0.5	0.1	0.1	0.8	0.5	-0.2	1.8	0.6	0.1	2.7	2.9
Finland	0.8	0.2	-0.1	0.3	0.1	0.0	0.5	0.4	-0.2	0.8	0.3	0.0	1.4	2.2
France	1.1	0.2	-0.1	0.2	0.0	0.1	0.5	0.4	-0.2	0.6	0.3	0.1	1.2	2.3
Germany	0.9	0.2	-0.1	0.2	0.0	0.1	0.6	0.5	-0.2	0.8	0.3	0.1	1.4	2.4
Greece	0.5	0.2	-0.1	0.2	0.0	0.3	0.7	0.5	-0.2	0.6	0.3	0.4	1.6	2.1
Hungary	0.3	0.2	-0.1	0.5	0.1	0.2	0.8	0.6	-0.2	1.4	0.5	0.2	2.3	2.6
Iceland	1.7	0.2	-0.1	0.2	0.0	-0.1	0.3	0.4	-0.2	0.8	0.3	0.0	1.3	3.0
Ireland	0.5	0.2	-0.1	0.2	0.0	0.1	0.5	0.5	-0.2	0.7	0.2	0.1	1.4	1.9
Israel	0.4	0.2	0.0	0.2	0.0	0.2	0.5	0.4	-0.2	0.5	0.2	0.3	1.2	1.5
Italy	0.7	0.2	-0.1	0.1	0.0	0.2	0.5	0.4	-0.2	0.6	0.3	0.3	1.4	2.1
Japan	0.7	0.3	-0.1	0.2	0.0	0.1	0.5	0.5	-0.2	0.9	0.4	0.1	1.7	2.3
Korea	0.3	0.4	-0.1	0.4	0.1	0.0	0.9	1.1	-0.3	1.0	0.4	0.1	2.3	2.6
Luxembourg	0.9	0.2	-0.1	0.1	0.0	0.3	0.5	0.5	-0.2	0.1	0.1	0.3	0.8	1.8
Mexico	0.0	0.2	-0.1	0.4	0.0	0.3	0.9	0.9	-0.3	1.7	0.4	0.4	3.2	3.2
Netherlands	2.3	0.3	-0.1	0.2	0.0	0.2	0.7	0.5	-0.2	0.8	0.3	0.2	1.7	4.0
New Zealand	1.3	0.2	-0.1	0.3	0.0	0.1	0.5	0.5	-0.2	1.2	0.4	0.1	1.9	3.2
Norway	2.1	0.1	-0.1	0.3	0.1	0.0	0.5	0.4	-0.2	0.8	0.3	0.0	1.4	3.5
Poland	0.4	0.3	-0.1	0.5	0.1	0.0	0.8	0.8	-0.3	1.1	0.5	0.0	2.1	2.5
Portugal	0.1	0.2	-0.1	0.2	0.0	0.1	0.4	0.5	-0.2	0.7	0.3	0.1	1.5	1.6
Slovak Republic	0.0	0.3	-0.1	0.5	0.1	0.1	0.9	0.8	-0.3	1.3	0.5	0.1	2.4	2.4
Slovenia	0.7	0.2	-0.1	0.3	0.1	0.1	0.6	0.6	-0.2	0.9	0.4	0.1	1.8	2.4
Spain	0.5	0.2	-0.1	0.2	0.0	0.3	0.7	0.6	-0.2	0.7	0.3	0.4	1.7	2.2
Sweden	0.7	0.1	-0.1	0.3	0.1	0.0	0.4	0.3	-0.2	0.9	0.3	0.0	1.3	2.0
Switzerland	1.2	0.2	-0.1	0.2	0.0	0.1	0.5	0.5	-0.2	0.9	0.4	0.1	1.6	2.8
Turkey	0.0	0.2	0.0	0.7	0.1	0.1	1.0	0.9	-0.3	1.7	0.4	0.6	3.2	3.3
United Kingdom	0.9	0.1	-0.1	0.2	0.0	0.1	0.4	0.3	-0.2	0.8	0.3	0.1	1.3	2.2
United States	0.6	0.2	-0.1	0.2	0.0	0.0	0.4	0.3	-0.2	0.7	0.3	0.0	1.2	1.7
OECD average¹	0.8	0.2	-0.1	0.3	0.0	0.1	0.6	0.5	-0.2	0.9	0.3	0.2	1.8	2.5
Brazil	0.0	0.3	-0.1	0.3	0.0	0.0	0.5	1.0	-0.3	0.6	0.3	-0.1	1.5	1.5
China	0.1	0.3	-0.1	0.6	0.1	0.0	0.9	1.0	-0.3	1.2	0.5	-0.1	2.4	2.5
India	0.1	0.2	0.0	0.5	0.1	0.0	0.7	0.6	-0.2	1.3	0.4	0.0	2.1	2.2
Indonesia	0.1	0.2	0.0	0.4	0.1	0.0	0.6	0.9	-0.3	1.0	0.4	-0.1	2.0	2.1
Russia	0.2	0.2	-0.1	0.3	0.1	-0.1	0.4	0.4	-0.2	0.5	0.3	-0.1	0.9	1.2
South Africa	0.2	0.2	0.0	0.3	0.0	0.0	0.4	0.4	-0.2	0.7	0.2	0.0	1.1	1.3
Non-OECD average¹	0.1	0.2	0.0	0.4	0.1	0.0	0.6	0.7	-0.2	0.9	0.3	-0.1	1.7	1.8
Total average¹	0.7	0.2	-0.1	0.3	0.0	0.1	0.6	0.6	-0.2	0.9	0.3	0.1	1.7	2.4

Table A4.13. Breakdown of the projections of total long-term care expenditure for each driver

Sensitivity analysis: life expectancy – 2 standard deviation

	Long-term care expenditure as a % of GDP	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Level as a % of GDP
	(0)	(1)	(2)	(3)	(4)	(5)	(6)=Sum (1) to (5)	(7)	(8)	(9)	(10)	(11)	(12)=Sum (7) to (11)	(13)=(0)+(12)
	2006-2010	Increase in % points of GDP 2010-2030					Increase in % points of GDP 2010-2060					2060		
Australia	0.0	0.2	-0.1	0.0	0.1	0.1	0.3	0.5	-0.4	0.0	0.4	0.1	0.6	0.6
Austria	1.1	0.2	-0.1	0.0	0.0	0.1	0.2	0.4	-0.4	0.0	0.3	0.2	0.5	1.6
Belgium	1.7	0.1	-0.1	0.0	0.0	0.2	0.3	0.3	-0.3	0.0	0.3	0.3	0.6	2.3
Canada	1.2	0.2	-0.1	0.0	0.0	0.1	0.3	0.4	-0.4	0.0	0.4	0.1	0.5	1.7
Chile	0.0	0.3	-0.1	0.0	0.1	0.3	0.5	0.8	-0.5	0.0	0.5	0.4	1.2	1.2
Czech Republic	0.3	0.2	-0.1	0.0	0.1	0.1	0.2	0.6	-0.4	0.0	0.5	0.0	0.6	0.9
Denmark	2.2	0.2	-0.1	0.0	0.0	0.1	0.2	0.4	-0.4	0.0	0.3	0.1	0.4	2.6
Estonia	0.2	0.2	-0.1	0.0	0.1	0.1	0.2	0.5	-0.4	0.0	0.6	0.1	0.7	0.9
Finland	0.8	0.2	-0.1	0.0	0.1	0.0	0.2	0.4	-0.4	0.0	0.3	0.0	0.4	1.2
France	1.1	0.2	-0.1	0.0	0.0	0.1	0.2	0.4	-0.4	0.0	0.3	0.1	0.4	1.5
Germany	0.9	0.2	-0.1	0.0	0.0	0.1	0.3	0.5	-0.4	0.0	0.3	0.1	0.5	1.4
Greece	0.5	0.2	-0.1	0.0	0.0	0.3	0.4	0.5	-0.4	0.0	0.3	0.4	0.7	1.3
Hungary	0.3	0.2	-0.1	0.0	0.1	0.2	0.3	0.6	-0.4	0.0	0.5	0.2	0.8	1.0
Iceland	1.7	0.2	-0.1	0.0	0.0	-0.1	0.1	0.4	-0.3	0.0	0.3	0.0	0.3	2.1
Ireland	0.5	0.2	-0.1	0.0	0.0	0.1	0.2	0.5	-0.4	0.0	0.2	0.1	0.4	1.0
Israel	0.4	0.2	-0.1	0.0	0.0	0.2	0.3	0.4	-0.3	0.0	0.2	0.3	0.5	0.9
Italy	0.7	0.2	-0.1	0.0	0.0	0.2	0.3	0.4	-0.4	0.0	0.3	0.3	0.6	1.3
Japan	0.7	0.3	-0.1	0.0	0.0	0.1	0.3	0.5	-0.4	0.0	0.4	0.1	0.6	1.2
Korea	0.3	0.4	-0.1	0.0	0.1	0.0	0.4	1.1	-0.6	0.0	0.4	0.1	1.0	1.3
Luxembourg	0.9	0.2	-0.1	0.0	0.0	0.3	0.3	0.5	-0.4	0.0	0.1	0.3	0.5	1.5
Mexico	0.0	0.2	-0.1	0.0	0.0	0.3	0.4	0.9	-0.5	0.0	0.4	0.4	1.2	1.2
Netherlands	2.3	0.3	-0.1	0.0	0.0	0.2	0.4	0.5	-0.4	0.0	0.3	0.2	0.7	2.9
New Zealand	1.3	0.2	-0.1	0.0	0.0	0.1	0.2	0.5	-0.4	0.0	0.4	0.1	0.6	1.8
Norway	2.1	0.1	-0.1	0.0	0.1	0.0	0.1	0.4	-0.4	0.0	0.3	0.0	0.4	2.5
Poland	0.4	0.3	-0.1	0.0	0.1	0.0	0.2	0.8	-0.5	0.0	0.5	0.0	0.8	1.1
Portugal	0.1	0.2	-0.1	0.0	0.0	0.1	0.2	0.5	-0.4	0.0	0.3	0.1	0.6	0.7
Slovak Republic	0.0	0.3	-0.1	0.0	0.1	0.1	0.3	0.8	-0.5	0.0	0.5	0.1	0.8	0.9
Slovenia	0.7	0.2	-0.1	0.0	0.1	0.1	0.3	0.6	-0.4	0.0	0.4	0.1	0.7	1.3
Spain	0.5	0.2	-0.1	0.0	0.0	0.3	0.4	0.6	-0.4	0.0	0.3	0.4	0.8	1.4
Sweden	0.7	0.1	-0.1	0.0	0.1	0.0	0.1	0.3	-0.3	0.0	0.3	0.0	0.3	1.0
Switzerland	1.2	0.2	-0.1	0.0	0.0	0.1	0.2	0.5	-0.4	0.0	0.4	0.1	0.5	1.7
Turkey	0.0	0.2	-0.1	0.0	0.1	0.1	0.3	0.9	-0.5	0.0	0.4	0.6	1.3	1.4
United Kingdom	0.9	0.1	-0.1	0.0	0.0	0.1	0.1	0.3	-0.3	0.0	0.3	0.1	0.4	1.2
United States	0.6	0.2	-0.1	0.0	0.0	0.0	0.1	0.3	-0.3	0.0	0.3	0.0	0.3	0.8
OECD average¹	0.8	0.2	-0.1	0.0	0.0	0.1	0.3	0.5	-0.4	0.0	0.3	0.2	0.6	1.4
Brazil	0.0	0.3	-0.1	0.0	0.0	0.0	0.2	1.0	-0.6	0.0	0.3	-0.1	0.6	0.6
China	0.1	0.3	-0.1	0.0	0.1	0.0	0.2	1.0	-0.6	0.0	0.5	-0.1	0.8	0.9
India	0.1	0.2	-0.1	0.0	0.1	0.0	0.2	0.6	-0.4	0.0	0.4	0.0	0.7	0.7
Indonesia	0.1	0.2	-0.1	0.0	0.1	0.0	0.2	0.9	-0.5	0.0	0.4	-0.1	0.7	0.8
Russia	0.2	0.2	-0.1	0.0	0.1	-0.1	0.1	0.4	-0.4	0.0	0.3	-0.1	0.3	0.5
South Africa	0.2	0.2	-0.1	0.0	0.0	0.0	0.1	0.4	-0.3	0.0	0.2	0.0	0.3	0.5
Non-OECD average¹	0.1	0.2	-0.1	0.0	0.1	0.0	0.2	0.7	-0.5	0.0	0.3	-0.1	0.6	0.7
Total average¹	0.7	0.2	-0.1	0.0	0.0	0.1	0.2	0.6	-0.4	0.0	0.3	0.1	0.6	1.3

Table A4.14. Breakdown of the projections of total long-term care expenditure for each driver

Sensitivity analysis: life expectancy + 2 standard deviations

	Long-term care expenditure as a % of GDP	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Level as a % of GDP
	(0)	(1)	(2)	(3)	(4)	(5)	(6)=Sum (1) to (5)	(7)	(8)	(9)	(10)	(11)	(12)=Sum (7) to (11)	(13)=(0)+(12)
	2006-2010	Increase in % points of GDP 2010-2030						Increase in % points of GDP 2010-2060						2060
Australia	0.0	0.2	0.0	0.0	0.1	0.1	0.4	0.5	0.0	0.0	0.4	0.1	1.0	1.0
Austria	1.1	0.2	0.0	0.0	0.0	0.1	0.4	0.4	0.0	0.0	0.3	0.2	0.9	2.0
Belgium	1.7	0.1	0.0	0.0	0.0	0.2	0.4	0.3	0.0	0.0	0.3	0.3	0.9	2.7
Canada	1.2	0.2	0.0	0.0	0.0	0.1	0.4	0.4	0.0	0.0	0.4	0.1	1.0	2.2
Chile	0.0	0.3	0.0	0.0	0.1	0.3	0.7	0.8	0.1	0.0	0.5	0.4	1.8	1.8
Czech Republic	0.3	0.2	0.0	0.0	0.1	0.1	0.4	0.6	0.0	0.0	0.5	0.0	1.1	1.4
Denmark	2.2	0.2	0.0	0.0	0.0	0.1	0.3	0.4	0.0	0.0	0.3	0.1	0.8	3.0
Estonia	0.2	0.2	0.0	0.0	0.1	0.1	0.4	0.5	0.0	0.0	0.6	0.1	1.2	1.4
Finland	0.8	0.2	0.0	0.0	0.1	0.0	0.3	0.4	0.0	0.0	0.3	0.0	0.8	1.6
France	1.1	0.2	0.0	0.0	0.0	0.1	0.3	0.4	0.0	0.0	0.3	0.1	0.8	1.9
Germany	0.9	0.2	0.0	0.0	0.0	0.1	0.4	0.5	0.0	0.0	0.3	0.1	0.9	1.9
Greece	0.5	0.2	0.0	0.0	0.0	0.3	0.5	0.5	0.0	0.0	0.3	0.4	1.2	1.7
Hungary	0.3	0.2	0.0	0.0	0.1	0.2	0.4	0.6	0.0	0.0	0.5	0.2	1.2	1.5
Iceland	1.7	0.2	0.0	0.0	0.0	-0.1	0.2	0.4	0.0	0.0	0.3	0.0	0.7	2.4
Ireland	0.5	0.2	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.0	0.2	0.1	0.9	1.4
Israel	0.4	0.2	0.0	0.0	0.0	0.2	0.4	0.4	0.0	0.0	0.2	0.3	0.9	1.3
Italy	0.7	0.2	0.0	0.0	0.0	0.2	0.4	0.4	0.0	0.0	0.3	0.3	1.0	1.8
Japan	0.7	0.3	0.0	0.0	0.0	0.1	0.4	0.5	0.0	0.0	0.4	0.1	1.0	1.7
Korea	0.3	0.4	0.0	0.0	0.1	0.0	0.5	1.1	0.1	0.0	0.4	0.1	1.7	2.0
Luxembourg	0.9	0.2	0.0	0.0	0.0	0.3	0.5	0.5	0.0	0.0	0.1	0.3	1.0	1.9
Mexico	0.0	0.2	0.0	0.0	0.0	0.3	0.5	0.9	0.1	0.0	0.4	0.4	1.8	1.8
Netherlands	2.3	0.3	0.0	0.0	0.0	0.2	0.5	0.5	0.0	0.0	0.3	0.2	1.1	3.4
New Zealand	1.3	0.2	0.0	0.0	0.0	0.1	0.3	0.5	0.0	0.0	0.4	0.1	1.0	2.3
Norway	2.1	0.1	0.0	0.0	0.1	0.0	0.2	0.4	0.0	0.0	0.3	0.0	0.8	2.9
Poland	0.4	0.3	0.0	0.0	0.1	0.0	0.4	0.8	0.1	0.0	0.5	0.0	1.3	1.7
Portugal	0.1	0.2	0.0	0.0	0.0	0.1	0.3	0.5	0.0	0.0	0.3	0.1	1.0	1.1
Slovak Republic	0.0	0.3	0.0	0.0	0.1	0.1	0.5	0.8	0.1	0.0	0.5	0.1	1.4	1.5
Slovenia	0.7	0.2	0.0	0.0	0.1	0.1	0.4	0.6	0.0	0.0	0.4	0.1	1.2	1.8
Spain	0.5	0.2	0.0	0.0	0.0	0.3	0.5	0.6	0.0	0.0	0.3	0.4	1.3	1.8
Sweden	0.7	0.1	0.0	0.0	0.1	0.0	0.2	0.3	0.0	0.0	0.3	0.0	0.7	1.3
Switzerland	1.2	0.2	0.0	0.0	0.0	0.1	0.3	0.5	0.0	0.0	0.4	0.1	1.0	2.2
Turkey	0.0	0.2	0.0	0.0	0.1	0.1	0.4	0.9	0.1	0.0	0.4	0.6	1.9	1.9
United Kingdom	0.9	0.1	0.0	0.0	0.0	0.1	0.3	0.3	0.0	0.0	0.3	0.1	0.7	1.6
United States	0.6	0.2	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.3	0.0	0.6	1.2
OECD average¹	0.8	0.2	0.0	0.0	0.0	0.1	0.4	0.5	0.0	0.0	0.3	0.2	1.1	1.9
Brazil	0.0	0.3	0.0	0.0	0.0	0.0	0.3	1.0	0.1	0.0	0.3	-0.1	1.2	1.2
China	0.1	0.3	0.0	0.0	0.1	0.0	0.4	1.0	0.1	0.0	0.5	-0.1	1.5	1.6
India	0.1	0.2	0.0	0.0	0.1	0.0	0.3	0.6	0.0	0.0	0.4	0.0	1.1	1.1
Indonesia	0.1	0.2	0.0	0.0	0.1	0.0	0.3	0.9	0.1	0.0	0.4	-0.1	1.3	1.4
Russia	0.2	0.2	0.0	0.0	0.1	-0.1	0.2	0.4	0.0	0.0	0.3	-0.1	0.7	0.9
South Africa	0.2	0.2	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.0	0.2	0.0	0.6	0.8
Non-OECD average¹	0.1	0.2	0.0	0.0	0.1	0.0	0.3	0.7	0.0	0.0	0.3	-0.1	1.1	1.2
Total average¹	0.7	0.2	0.0	0.0	0.0	0.1	0.4	0.6	0.0	0.0	0.3	0.1	1.1	1.8

Table A4.15. Breakdown of the projections of total long-term care expenditure for each driver

Sensitivity analysis: health expenditure cost-pressure scenario

	Long-term care expenditure as a % of GDP	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Pure ageing effect	Adjustment for healthy ageing	Income effect	Cost disease effect	Effect of the participation rate of people aged 50-64	Total increase	Level as a % of GDP
	(0)	(1)	(2)	(3)	(4)	(5)	(6)=Sum (1) to (5)	(7)	(8)	(9)	(10)	(11)	(12)=Sum (7) to (11)	(13)=(0)+(12)
	2006-2010	Increase in % points of GDP 2010-2030					Increase in % points of GDP 2010-2060					2060		
Australia	0.0	0.2	0.0	0.0	0.1	0.1	0.3	0.5	-0.1	0.0	0.4	0.1	0.9	0.9
Austria	1.1	0.2	0.0	0.0	0.0	0.1	0.3	0.4	-0.1	0.0	0.3	0.2	0.8	1.9
Belgium	1.7	0.1	0.0	0.0	0.0	0.2	0.4	0.3	-0.1	0.0	0.3	0.3	0.8	2.6
Canada	1.2	0.2	0.0	0.0	0.0	0.1	0.3	0.4	-0.1	0.0	0.4	0.1	0.8	2.0
Chile	0.0	0.3	0.0	0.0	0.1	0.3	0.6	0.8	-0.1	0.0	0.5	0.4	1.6	1.6
Czech Republic	0.3	0.2	0.0	0.0	0.1	0.1	0.3	0.6	-0.1	0.0	0.5	0.0	1.0	1.2
Denmark	2.2	0.2	0.0	0.0	0.0	0.1	0.2	0.4	-0.1	0.0	0.3	0.1	0.7	2.9
Estonia	0.2	0.2	0.0	0.0	0.1	0.1	0.3	0.5	-0.1	0.0	0.6	0.1	1.0	1.2
Finland	0.8	0.2	0.0	0.0	0.1	0.0	0.3	0.4	-0.1	0.0	0.3	0.0	0.6	1.4
France	1.1	0.2	0.0	0.0	0.0	0.1	0.3	0.4	-0.1	0.0	0.3	0.1	0.7	1.8
Germany	0.9	0.2	0.0	0.0	0.0	0.1	0.4	0.5	-0.1	0.0	0.3	0.1	0.8	1.7
Greece	0.5	0.2	0.0	0.0	0.0	0.3	0.5	0.5	-0.1	0.0	0.3	0.4	1.0	1.6
Hungary	0.3	0.2	0.0	0.0	0.1	0.2	0.4	0.6	-0.1	0.0	0.5	0.2	1.1	1.3
Iceland	1.7	0.2	0.0	0.0	0.0	-0.1	0.2	0.4	-0.1	0.0	0.3	0.0	0.6	2.3
Ireland	0.5	0.2	0.0	0.0	0.0	0.1	0.3	0.5	-0.1	0.0	0.2	0.1	0.7	1.3
Israel	0.4	0.2	0.0	0.0	0.0	0.2	0.4	0.4	-0.1	0.0	0.2	0.3	0.8	1.2
Italy	0.7	0.2	0.0	0.0	0.0	0.2	0.4	0.4	-0.1	0.0	0.3	0.3	0.9	1.6
Japan	0.7	0.3	0.0	0.0	0.0	0.1	0.4	0.5	-0.1	0.0	0.4	0.1	0.9	1.5
Korea	0.3	0.4	0.0	0.0	0.1	0.0	0.5	1.1	-0.2	0.0	0.4	0.1	1.5	1.8
Luxembourg	0.9	0.2	0.0	0.0	0.0	0.3	0.4	0.5	-0.1	0.0	0.1	0.3	0.8	1.8
Mexico	0.0	0.2	0.0	0.0	0.0	0.3	0.5	0.9	-0.1	0.0	0.4	0.4	1.6	1.6
Netherlands	2.3	0.3	0.0	0.0	0.0	0.2	0.5	0.5	-0.1	0.0	0.3	0.2	0.9	3.2
New Zealand	1.3	0.2	0.0	0.0	0.0	0.1	0.3	0.5	-0.1	0.0	0.4	0.1	0.9	2.1
Norway	2.1	0.1	0.0	0.0	0.1	0.0	0.2	0.4	-0.1	0.0	0.3	0.0	0.6	2.8
Poland	0.4	0.3	0.0	0.0	0.1	0.0	0.3	0.8	-0.1	0.0	0.5	0.0	1.2	1.5
Portugal	0.1	0.2	0.0	0.0	0.0	0.1	0.3	0.5	-0.1	0.0	0.3	0.1	0.9	1.0
Slovak Republic	0.0	0.3	0.0	0.0	0.1	0.1	0.4	0.8	-0.1	0.0	0.5	0.1	1.2	1.3
Slovenia	0.7	0.2	0.0	0.0	0.1	0.1	0.4	0.6	-0.1	0.0	0.4	0.1	1.0	1.6
Spain	0.5	0.2	0.0	0.0	0.0	0.3	0.5	0.6	-0.1	0.0	0.3	0.4	1.1	1.7
Sweden	0.7	0.1	0.0	0.0	0.1	0.0	0.2	0.3	-0.1	0.0	0.3	0.0	0.5	1.2
Switzerland	1.2	0.2	0.0	0.0	0.0	0.1	0.3	0.5	-0.1	0.0	0.4	0.1	0.8	2.0
Turkey	0.0	0.2	0.0	0.0	0.1	0.1	0.4	0.9	-0.1	0.0	0.4	0.6	1.7	1.7
United Kingdom	0.9	0.1	0.0	0.0	0.0	0.1	0.2	0.3	-0.1	0.0	0.3	0.1	0.6	1.5
United States	0.6	0.2	0.0	0.0	0.0	0.0	0.2	0.3	-0.1	0.0	0.3	0.0	0.5	1.1
OECD average¹	0.8	0.2	0.0	0.0	0.0	0.1	0.3	0.5	-0.1	0.0	0.3	0.2	0.9	1.7
Brazil	0.0	0.3	0.0	0.0	0.0	0.0	0.3	1.0	-0.1	0.0	0.3	-0.1	1.0	1.0
China	0.1	0.3	0.0	0.0	0.1	0.0	0.3	1.0	-0.2	0.0	0.5	-0.1	1.3	1.4
India	0.1	0.2	0.0	0.0	0.1	0.0	0.2	0.6	-0.1	0.0	0.4	0.0	0.9	1.0
Indonesia	0.1	0.2	0.0	0.0	0.1	0.0	0.3	0.9	-0.1	0.0	0.4	-0.1	1.1	1.2
Russia	0.2	0.2	0.0	0.0	0.1	-0.1	0.1	0.4	-0.1	0.0	0.3	-0.1	0.5	0.7
South Africa	0.2	0.2	0.0	0.0	0.0	0.0	0.2	0.4	-0.1	0.0	0.2	0.0	0.5	0.7
Non-OECD average¹	0.1	0.2	0.0	0.0	0.1	0.0	0.2	0.7	-0.1	0.0	0.3	-0.1	0.9	1.0
Total average¹	0.7	0.2	0.0	0.0	0.0	0.1	0.3	0.6	-0.1	0.0	0.3	0.1	0.9	1.6

REFERENCES

- Acemoglu, D., A. Finkelstein and M. Notowidigdo (2009), "Income and Health Spending: Evidence from Oil Shocks", *CEPR Discussion Papers* No. 7255.
- Alzheimer Europe (2006), *Dementia in Europe Yearbook 2006*, Luxembourg
- Aprile, R. (2004), "How to Take Account of Death-Related Costs in Projecting Health Care Expenditure – Updated Version", *Ragioneria Generale Dello Stato*.
- Atella V. and Marini G. (2004), "The determinants of health care expenditure: a never ending story?", SSRN Working Paper No 607162.
- Baltagi B.H. and Moscone F (2010), "Health care expenditure and income in the OECD reconsidered : Evidence from panel data", Institute for the Study of Labor (IZA).
- Baumol, W.J. (1967), "Macroeconomics of Unbalanced Growth: The Anatomy of Urban Crisis", *American Economic Review* 57: 415-426.
- Baumol, W.J. (1993), "Health Care, Education and the Cost of Disease: A Looming Crisis for Public Choice," *Public Choice* 77:17-28.
- Bech M., T. Christiansen, E. Khoman, J. Lauridsen and M. Weale (2011), "Ageing and health care expenditure in EU-15", *European Journal of Health Economics* 12, 469-478.
- Bessen J. and Grid T. (2012), "Which Patent Systems Are Better For Inventors?", forthcoming.
- Blomqvist, A.G. and R.A.L. Carter (1997), "Is health care really a luxury?", *Journal of Health Economics* 16 2, pp.207–230.
- Breyer F. and S. Felder (2006), "Life expectancy and health care expenditures: A new calculation for Germany using the costs of dying", *Health Policy* 75, 178–186.
- Breyer F, Costa-i-Font J and S. Felder (2011), "Does ageing really affect health expenditures? If so, why?", Vox EU, May.
- Colombo, F., A. Llana-Nozal, J. Mercier and F. Tjadens (2011), "Help Wanted? Providing and Paying for Long-Term Care", *OECD Health Policy Studies*, OECD Publishing.
- Comas-Herrera and R. Wittenberg, eds., (2003), *European study of Long-Term Care Expenditure: Investigating the Sensitivity of Projections of Future Long-Term Care Expenditure in Germany, Spain, Italy and the United Kingdom to Changes in Assumptions About Demography, Dependency, Informal Care, Formal Care and Unit Costs*, PSSRU, LSE Health and Social Care, London School of Economics.

- Culyer, A.J. (1990), "Cost Containment in Europe", *Health Care Systems in Transition*, OECD, Paris.
- Cutler, D. (2001), "The Reduction in Disability among the Elderly", *Proceedings of the National Academy of Science*, Vol. 98, No. 12, June.
- Di Matteo, L. and R. Di Matteo (1998), "Evidence on the determinants of Canadian provincial government health expenditures: 1965–1991", *Journal of Health Economics* 17(2), pp. 211–228
- Dormont, B. and H. Huber (2005), "Ageing and Changes in medical practices: reassessing the influence of demography", *mimeo*, THEMA University of Paris X, Paris.
- Dormont, B., M. Grignon and H. Huber (2006), "Health Expenditure Growth: Reassessing the Threat of Ageing", *Health Economics*, 15 (9), pp. 947-63.
- Dormont B., Oliveira Martins J., Pelgrin F and Suhrcke M. (2011), "Health Expenditures, Longevity and Growth", in *Ageing, Health and Productivity*, Oxford University Press.
- Dreger, C. and H.-E. Reimers (2005), "Health Care Expenditures in OECD Countries: A panel Unit Root and Cointegration Analysis", *IZA Discussion Paper* 1469, Bonn.
- Duval, R. and C. de la Maisonneuve (2010), "Long-Run Growth Scenarios for the World Economy" *Journal of Policy Modeling*, Elsevier, Vol. 32(1).
- European Commission, 2009 Ageing Report: Economic and budgetary projections for the EU-27 Member States (2008-2060).
- Felder, S., Meier, M. and Schmitt, H. (2000), "Health care expenditure in the last months of life", *Journal of Health Economics*, 19, 679–95.
- Fouré, J., A. Bénassy-Quéré and L. Fontagné (2010), "The World Economy in 2050: A Tentative Picture", CEPII, Working Paper No. 2010-27.
- Freeman, D. G. (2003), Is health care a necessity or a luxury? Pooled estimates of income elasticity from US state-level data, *Applied Economics*, 35(5): 495-502.
- Fuchs, V. (1972), *Essays in the Economics of Health and Medical Care*, National Bureau of Economic Research, New York.
- Fuchs, V. (1984), "Though Much is Taken Reflections on Ageing, Health and Medical Care", *NBER Working Paper* No.1269.
- Fujisawa, R. and F. Colombo (2009), "The Long-term Care Workforce: Overview and Strategies to Adapt Supply to a Growing Demand", *OECD Health Working Paper*, No. 44, OECD Publishing, Paris.
- Gerdtham, U., J. Sogaard., F. Anderson and B. Jonsson (1992), "An Econometric Analysis of Health Care Expenditure: A Cross-Section Study of the OECD Countries", *Journal of Health Economics*, Vol.11, No.1, pp.63-84.
- Getzen, T. (2000), "Health Care is an Individual Necessity and a National Luxury: Applying Multilevel Decision Models to the Analysis of Health Care Expenditure", *Journal of Health Economics* 19, pp.259-270.

- Goldman *et al.* (2005), “Consequences of Health Trends and Medical Innovation for the Future Elderly”, *Health Affairs*, September.
- Gray, A. (2004), *Estimating the impact of ageing populations on future health expenditures*, Public lecture to the National Institute of Economics and Business and the National Institute of Health and Human Science, 4 November, Canberra.
- Hall, R. and C. Jones (2007), “The Value of Life and the Rise in Health Spending”, *The Quarterly Journal of Economics*, February, pp. 39-72.
- Hitiris, T. and J. Posnett (1992), “The determinants and effects of health expenditure in developed countries”, *Journal of Health Economics*, Vol. 11, No. 2, pp.173-81.
- Jacobzone, S. (2003), “Ageing and the Challenges of New Technologies: Can OECD Social and Health Care Systems Provide for the Future? “, *The Geneva Papers on Risk and Insurance*, Vol. 28, No. 2, April, pp.254-74.
- Johansson *et al.* (2012), “Long-Term Growth Scenario”, *OECD Economics Department Working Papers* (forthcoming).
- Jönsson, B. and I. Eckerlund (2003), “Why do different countries spend different amounts on health care?”, *A Disease-based Comparison of Health Systems*, OECD, Paris.
- KPMG Consulting (2001), *Impact of New Technology on Victorian Public Hospital Costs*, Report to the Victorian Department of Human Services, September.
- Moise, P. and S. Jacobzone (2003), “Population Ageing, Health Expenditure and Treatment: an ARD Perspective”, *A Disease-based Comparison of Health Systems*, OECD, Paris.
- Moscone F. And Tosetti E. (2010), “Health expenditure and income in the United States”, *Health Economics* 19: 1385–1403.
- Mushkin, E.P. and J.S. Landefeld (1979), *Biomedical Research: Costs and Benefits*, Ballinger Publishing Company, Cambridge, Massachusetts.
- Narayan P.K., S. Narayan and R. Smyth (2011), “Is health care really a luxury in OECD countries ? Evidence from alternative price deflators”, *Applied Economics* 43, 3631-3643.
- Newhouse, J.P. (1977), "Medical Care Expenditure: A Cross-National Survey", *Journal of Human Resources* 12, pp. 115-125.
- Newhouse (1992), “Medical Care Costs: How Much Welfare Loss?”, *Journal of Economic Perspectives*, Vol. 6, No. 3, pp.3-21.
- OECD (2005b), *Long-term Care for Older People*, Paris.
- OECD (2006), “Projecting OECD Health and Long-Term Care Expenditures: What are the Main Drivers?”, *OECD Economics Department Working Papers* No. 477, OECD, Paris.
- OECD (2010), *Health Care Systems: Efficiency and Policy Settings*, OECD Publishing.

- Okunade, A.A., and V.N.R. Murthy (2002), "Technology as a Major Driver of Health Costs: A Cointegration Analysis of the Newhouse Conjecture", *Journal of Health Economics* 21, pp.147-159.
- Oliveira Martins, J. and C. de la Maisonneuve (2006), "The Drivers of Public Expenditure on Health and Long-Term Care: An Integrated Approach", *OECD Economic Studies* No. 43, 2006/2.
- Productivity Commission (2005a), *Economic Implications of an Ageing Australia*, Research Report, Canberra.
- Productivity Commission (2005b), *Impacts of Medical Technology in Australia*, Progress Report, Melbourne, April.
- Richardson, J. and I. Robertson (1999), "Ageing and the Cost of Health Services", in *Policy Implications of the Ageing of Australia's Population*, Productivity Commission and Melbourne Institute, Canberra.
- Seshamani, M. and Gray, A. (2004), "A longitudinal study of the effects of age and time to death on hospital costs", *Journal of Health Economics*, 23, 217–35.
- Sheehan, P. (2002), "Health Costs, Innovation and Ageing", *Pharmaceutical Industry Working Paper Series* No. 9, Centre for Strategic Economic Studies, Victoria University of Technology, Melbourne.
- Viitanen, T.K. (2005), "Informal Elderly Care and Female Labour Force Participation Across Europe", Center for European Policy Studies, *ENEPRI Research Reports No. 13, 1, July*.
- Wanless, D. (2001), *Securing our Future Health: Taking a Long-Term View*, Interim Report, HM Treasury, London.
- Werblow, A., S. Felder and P. Zweifel (2007), "Population Ageing and Health Care Expenditure: A School of 'Red Herrings'?", *Health Economics*, 16: pp. 1109–26.
- Zweifel P., S. Felder, and M. Meiers (1999), "Ageing Of Population And Health Care Expenditure: A Red Herring?", *Health Economics*, 8: pp. 485–496.